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Summary 
 
Malaria caused by the most lethal Plasmodium species, P. falciparum, remains a major 
global health problem to almost half the world’s population. With the lack of a vaccine and 
the emergence of both drug and insecticide resistance, the identification of novel drug targets 
and the development of rationally effective combination therapies are urgently required. To 
contribute to the efficient control or the elimination of malaria, three approaches to support 
novel drug discovery strategies were explored in this thesis. 
First, the role of the glutathione redox potential (EGSH) in the mechanism of drug 
action and resistance in malaria parasites was systematically studied. The EGSH in P. 
falciparum influences drug action and resistance by detoxification of reactive oxygen and 
nitrogen species. However, real-time determination of the compartmentalization of EGSH has 
been limited so far because conventional approaches disrupt sub-cellular integrity. Using a 
EGSH biosensor, comprising human glutaredoxin-1 linked to a redox sensitive green 
fluorescent protein (hGrx1-roGFP2), the basal cytosolic EGSH as well as the antimalarial drug-
induced changes in EGSH were determined in drug-sensitive (3D7) and resistant (Dd2) strains 
of P. falciparum. By confocal microscopy, the ability of hGrx1-roGFP2 to rapidly react to 
changes in EGSH due to oxidative and nitrosative stress was demonstrated. Importantly, the 
cytosolic basal EGSH of 3D7 and Dd2 strains was found to be -314.2 ± 3.1 mV and -313.9 ± 
3.4 mV, respectively, which is suggestive of a highly reducing cytosol. Among the tested 
antimalarial drugs, only methylene blue (MB) rapidly, on scale of minutes, oxidized 
glutathione (GSH). In contrast, quinoline and artemisinin based drugs required 24 h to 
significantly change the EGSH thus suggesting downstream effects on GSH metabolism. 
Notably, following 24 h incubation at 4-fold IC50, artemisinin derivatives exerted, by far, the 
strongest impact on EGSH. In accordance with the higher levels of reduced GSH in Dd2 than 
3D7 parasites, the effects on EGSH were more pronounced in the 3D7 than in the Dd2 strain 
which indicates a role of GSH in drug action and resistance. In conclusion, for the first time, 
the applicability of a highly specific EGSH biosensor for spatiotemporal measurement of the 
intracellular EGSH, in real time, in P. falciparum was established, illustrating its feasibility for 
the use in other parasites and pathogens (Kasozi et al., 2012 submitted). 
Secondly, the mechanism of uptake of host human peroxiredoxin 2 (hPrx2) into P. 
falciparum and its inhibition were investigated in order to identify new drug targets. During 
its erythrocytic cycle, P. falciparum imports several host proteins to play crucial roles in 
specific processes of parasite biochemistry, physiology, and antioxidant defense. However, 
the molecular mechanism of the uptake of host erythrocytic proteins remains elusive. By 
bioinformatic analysis of host proteins (~ 30) significantly abundant in parasite protein lysates 
that exhibited specific abundance profiles across the intraerythrocytic cycle, 4 endocytic 
vesicle associated motifs were identified including: the sorting and internalization signal 
(SIS), the tyrosine-based sorting signal (TSS), the clathrin box motif (Clat) and the 
WXXXY|F motif. Surprisingly, TSS was found 3-5 times and in contrast SIS and Clat 
occurred on average 1-2 times in nearly all proteins with the exception of superoxide 
dismutase. Additionally, the WXXXY|F motif was identified in the β-subunit of hemoglobin, 
biliverdin reductase B, and carbonic anhydrase I. Notably, hPrx2 had all three endocytic 
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vesicle associated motifs namely SIS (154VDEALRL159), TSS (37YVVL40; 
115YGVL118;126YRGL129), and Clat (129 LFIID133). To validate the role of endocytic vesicle 
associated motifs in uptake of proteins to different compartments/organelles, several mutants 
of hPrx2 were generated. By deletion mutagenesis, SIS and Clat mutants of hPrx2 were 
constructed. By site directed mutagenesis, active site mutants as well as N- and C-terminal 
deletion mutants of hPrx2 were generated. Next all hPrx2 mutants were heterologously over-
expressed in E. coli and added to cultures of P. falciparum. Notably, these endocytic vesicle 
associated motifs may have differential effects on the uptake of hPrx2. Furthermore, by 
Western blot analysis of parasite lysates after 24 h incubation at a concentration of 4 x IC50, 
actin inhibitors [cytochalasin D (CTD) and jasplakinolide (JAS)], alkalizing agents [monensin 
(MNS) and ammonium chloride (NH4Cl)], brefeldin A (BFA), paraquat (PQT), and the ATP 
depleting agent sodium azide (NaN3), were found to differentially inhibit the uptake of hPrx2 
into P. falciparum. The IC50 values of CTD, JAS, MNS, NH4Cl, NaN3, BFA, and PQT 
against the 3D7 strain were determined to be 13.1 nM, 73.5 nM, 1.01 nM, 2050 nM, 209 nM, 
1310 nM and 45 µM, respectively. After 24 h of incubation MQ, ART, CTD, JAS, DYN, 
PQT MNS, CQ and NaN3 inhibited uptake and digestion of host hPrx2. By constrast, NH4Cl 
increased uptake of hPrx2 while BFA had no effect on inhibition of hPrx2 uptake. Together 
the evaluation of endocytic vesicle associated motifs may lead to the development of novel 
drugs that inhibit uptake of proteins into P. falciparum. 
Thirdly, the in vitro gametocytocidal activity of MB was evaluated. To eliminate 
malaria, clinical studies and mathematical models predict that artemisinin combination 
therapies (ACT) must incorporate a drug with gametocytocidal activity to block the 
transmission of P. falciparum. Until now, ACTs have efficacy against young but induce no or 
only moderate inhibition of mature gametocytes. Notably, the IC50 (95% confidence interval) of 
MB against young (stage II-III) and mature (stage IV-V) gametocytes was found to be 33.8 
(32.1-35.7) nM and 59.5 (37.3-94.8) nM, respectively, indicating that MB has significant 
activity against all stages of gametocyte development. To eliminate malaria, incorporation of 
MB into currently used ACTs would reduce transmission of P. falciparum (Kasozi et al., 
2011). In addition, a simple, rapid SYBR green-1 fluorescence-based gametocytocidal assay 
was developed which should speed up the characterization of transmission blocking drugs or 
drug candidates.  
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ZUSAMMENFASSUNG 
Malaria stellt eine Gefahr für fast die Hälfte der Weltbevölkerung dar. Die schwerste 
Form der Malaria, Malaria tropica, wird durch Plasmodium falciparum verursacht. Da 
Malariaparasiten zunehmend Resistenzen gegen verfügbare Medikamente entwickeln und 
bisher keine effektive Vakzine zur Verfügung steht, werden neue Medikamente dringend 
benötigt. Im Rahmen dieser Arbeit wurden drei Fragestellungen untersucht, die für die 
Entwicklung von neuen Therapieansätzen von grundlegender Bedeutung sind. 
Der erste Schwerpunkt dieser Arbeit beschäftigt sich mit der systematischen 
Untersuchung der Rolle des Redoxpotentials von Glutathion (EGSH) für die Wirkung von und 
der Resistenz gegenüber Antimalariamedikamenten. In P. falciparum beeinflusst das 
Redoxpotential von Glutathion die Effektivität von Medikamenten sowie Resistenzen durch 
die Detoxifikation von reaktiven Sauerstoff- und Stickstoffspezies. Bisher war es nicht 
möglich, EGSH in verschiedenen Kompartimenten des Malariaerregers in Echtzeit zu 
untersuchen, da konventionelle Experimente mit einer Zerstörung der subzellulären Integrität 
einhergehen. Durch den Einsatz eines EGSH-Biosensors bestehend aus humanem Glutaredoxin 
1 und einem redox-sensitiven green fluorescent protein (hGrx1-roGFP2) konnten wir das 
basale zytosolische EGSH untersuchen. Außerdem haben wir die Änderungen des EGSH nach 
der Behandlung von sensitiven (3D7) und resistenten (Dd2) Malariaparasiten mit 
Antimalariamedikamenten analysiert. Mittels konfokaler Lasermikroskopie konnten wir 
zeigen, dass hGrx1-roGFP2 Änderungen des EGSH als Antwort auf oxidativen und nitrosativen 
Stress schnell detektiert. Das basale EGSH im Cytosol der Plasmodium-Stämme 3D7 und Dd2 
beträgt -314.2 ± 3.1 mV und -313.9 ± 3.4 mV, was auf stark reduzierende Bedingungen im 
Cytosol hinweist. Von den getesteten Antimalariamedikamenten induzierte nur Methylenblau 
innerhalb weniger Minute eine Oxidation von Glutathion. Quinolin und Artemisinin führten 
nach 24 Stunden zu einer Änderungen des EGSH, was auf Downstream-Effekte auf den 
Glutathionmetabolismus zurückzuführen sein könnte. Interessanterweise zeigten sich die 
stärksten Effekte auf das EGSH nach einer 24-stündigen Inkubation mit Artemisinin. In 
Übereinstimmung mit höheren Konzentrationen an reduziertem Glutathion in dem P. 
falciparum Stamm Dd2 im Vergleich zu 3D7 waren auch die Auswirkungen der 
Medikamente auf das EGSH im Stamm 3D7 stärker ausgeprägt als im Stamm Dd2, was auf 
eine Rolle von Glutathion für die Wirkung der Medikamente hinweist. Im Rahmen dieser 
Arbeit konnten wir zum ersten Mal die Anwendbarkeit eines hochspezifischen EGSH-
Biosensors zur Messung des intrazellulären Redoxpotentials in P. falciparum aufzeigen 
(Kasozi et al., 2012, eingereicht). 
Im zweiten Schwerpunkt dieser Arbeit wurde der Aufnahmemechanismus sowie 
dessen Hemmung von humanem Peroxiredoxin 2 (hPrx2) in P. falciparum untersucht. 
Während der intraerythrozytären Phase importiert P. falciparum verschiedene Wirtsproteine, 
die spezifische Funktionen für die Biochemie, Physiologie, und die antioxidative Abwehr des 
Parasiten haben. Allerdings ist bisher nicht bekannt, wie diese humanen Proteine durch den 
Malariaparasiten aus dem Erythrozyten aufgenommen werden. Durch bioinformatische 
Analysen der importierten Wirtsproteine wurden vier Motive identifiziert, die mit 
endozytischen Vesikeln assoziiert sind: das Sortier- und Internalisierungssignal (SIS), das 
Tyrosinbasierte Sortierungssignal (TSS), das Clathrinbox-Motiv (Clat) und das WXXXV/F-
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Motiv. Interessanterweise enthält hPrx2 drei der mit endozytischen Vesikeln assoziierten 
Motive: SIS (154VDEALRL159), TSS (37YVVL40, 115YGVL118, 126YRGL129) und Clat (129 
LFIID133). Um die Funktion dieser Motive für die Aufnahme von Proteinen in verschiedenen 
Kompartimente zu untersuchen, wurden hPrx2 Mutanten ohne SIS bzw. Clat-Motiv, sowie 
Mutanten mit verändertem aktiven Zentrum oder N- und C-terminalen Deletionen erstellt, in 
E.coli heterolog überexprimiert, und zu den P. falciparum Kulturen dazugegeben. So konnte 
die Funktion der Motive auf die Aufnahme von hPrx2 in die Parasiten untersucht werden. 
Außerdem wurde gezeigt, dass Inhibitoren von Actin (Cytochalasin D, Jasplakinolide), 
alkylierende Verbindungen (Monensin, Ammoniumchlorid), Brefeldin A, Paraquat, und 
Natriumazid die Aufnahme von hPrx2 in P. falciparum hemmen. Die Untersuchung der mit 
endozytischen Vesikeln assoziierten Motive ist für die Entwicklung von Medikamenten, 
welche die Aufnahme von Wirtsproteinen durch Plasmodium hemmen, von großem Interesse. 
Der dritte Schwerpunkt dieser Arbeit beschäftigt sich mit der Wirkung von 
Methylenblau auf Gametozyten. Klinische Studien und mathematische Modelle schlagen vor, 
dass Artemisinin in Kombination mit einem auf Gametozyten wirkenden Medikament die 
Transmission von P. falciparum blockieren könnte. Methylenblau hemmt junge (Stadium II-
III) und reife (Stadium IV-V) Gametozyten mit einem IC50 von 33.8 nM und 59.5 nM. 
Methylenblau zeigt daher eine signifikante Aktivität gegen alle Entwicklungsstadien der 
Gametozyten. Die Verwendung von Artemisinin in Kombination mit Methylenblau könnte 
daher die Transmission von P. falciparum effektiv reduzieren (Kasozi et al., 2011). 
Außerdem wurde ein schneller SYBR green-1 Fluoreszenz-basierter Assay entwickelt, der die 
Untersuchung von Wirkstoffen zur Hemmung der Transmission vereinfacht. 
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1 INTRODUCTION 
1.1 Malaria 
1.1.1 The burden of malaria 
Malaria is currently a major disease burden in 106 countries, causing an estimated 225 
million cases and 781,000 deaths each year in tropical and sub-tropical regions (WHO, 2010). 
Globally, 90% of the burden occurs in Africa, affecting mainly children (<5 years) and 
pregnant women (Snow et al., 2005; Prudhomme et al., 2010). Yet malaria is an ancient, 
preventable, and treatable disease. Historically, ancient records indicate that malaria-like 
illnesses have been reported since Hippocrates as fevers associated with swamps and marshes 
(Meshnick and Dobson 2001). Indeed, the term “malaria” is derived from the Italian words 
“mal’ aria” meaning “bad air.” Subsequently, between 1880 and 1890, Alphonse Laveran, 
Ronald Ross, Bassitista Grassi and others identified the malaria parasite and its transmission 
through mosquitoes. For thousands of years, two herbal treatments namely, cinchona bark and 
qinghao, the sources of quinine (QN) and artemisinin (ART), respectively, were used to treat 
malaria-like illnesses. Malaria was also widespread in temperate regions until the middle of 
the 20th century but was wiped out after the global malaria eradication program between 1955 
and 1969 (Hay et al., 2004). Despite successes in temperate regions and failure in tropical 
regions, global eradication was abandoned in 1972 due to the emergence of Plasmodium 
parasites resistant to chloroquine (CQ) and DDT-resistant Anopheles mosquitoes (Brito, 
2001). Since then, the burden of malaria increased 2-3 fold in the 1980s (Trape, 2001), due to 
rapid emergence of P. falciparum parasites resistant to CQ (CQR) and its first-line 
replacement sulfadoxine-pyrimethamine (SP, Fansidar). 
 
 
Figure 1.1: World malaria map (WHO 2009) 
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In response to this dreadful situation, in 1998 and 1999 three programs were set up 
namely the Roll Back Malaria, the Malaria Vaccine Initiative and the Medicines for Malaria 
Venture to coordinate efforts to control malaria. Notably, the Roll Back Malaria initiative was 
launched in order to deliver more effective interventions such as artemisinin drug 
combinations (ACTs) and anti-vector control tools. As a result, remarkable progress (Figure 
1.1) has been reported throughout tropical areas including Africa, raising a new call for global 
eradication (Bhattarai et al., 2007; WHO, 2009; Kappe et al., 2011). Nevertheless, despite 
advances in understanding the biology, many challenges remain; strains of P. falciparum 
virtually resistant to all antimalarial drugs have been reported while the, mechanisms of action 
and resistance remain incompletely understood, and a vaccine remains elusive. 
 
1.1.2 Life cycle of Plasmodium falciparum 
Malaria is caused by protozoan parasites of the genus Plasmodium from the phylum 
Apicomplexa. Although the five species including P. vivax, P. ovale, P. malariae and P. 
knowlesii (Singh et al., 2004) cause human malaria, P. falciparum is the most lethal. P. 
falciparum has a complex life cycle with different stages inhabiting multiple cell types not 
only in the vertebrate host (human) but also in its invertebrate (Anopheles mosquito) vector 
(Figure 1.2). Infection with malaria begins following a bite by an anopheline mosquito 
containing sporozoites. Thereafter the sporozoites circulate and invade the hepatocytes, 
initiating liver stage development (the pre-erythrocytic phase). After a few weeks, merozoites 
are released into circulation, rapidly invading red blood cells and thus beginning the asexual 
blood stage development (erythrocytic phase), which is responsible for all the clinical 
manifestations of malaria. In order to transmit malaria, parasites develop into 
macrogametocytes (female) and microgametocytes (male) which are ingested by mosquitoes. 
 
Figure 1.2:  Life cycle of P. falciparum. Adapted from Kappe et al. (2011) 
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In the mosquito midgut, gametocytes form gametes that further develop into ookinetes. The 
ookinetes undergo oocyst development, maturing and releasing sporozoites into the salivary 
gland. Subsequently, a bite by mosquitoes delivers sporozoites into the circulatory system, 
thus completing the life cycle. 
1.1.1 Control of malaria 
Malaria control strategies face several challenges. Besides the lack of a vaccine, drug 
resistance by the malaria parasite P. falciparum and insecticide resistance by the mosquito 
vectors make sustainable control let alone eradication an elusive goal. 
 
1.1.3.1 Progress towards a malaria vaccine 
A safe, effective and an affordable malaria vaccine would play a leading role in 
malaria control. The clinical development of candidate malaria vaccines has been reviewed 
(Ballou et al., 2004; The malERA Consultative Group on Vaccines, 2011). Recently, progress 
into vaccine development has accelerated with the identification of candidates targeting 
different life cycle stages (Figure 1.3). Pre-erythrocytic vaccines targeting sporozoites or 
schizont-infected liver cells would prevent the release of primary merozoites from infected 
hepatocytes. Initial protection in rodents by radiation-attenuated sporozoites (Hoffman et al., 
2010; Pinder et al., 2010) lead to optimism that candidates such as circumsporozoite (CSP) 
and thrombospondin-related adhesive proteins would prevent infection altogether. 
Furthermore, the exported antigen 1 and liver stage antigens would act on hepatocyte stages. 
Indeed RTS, a promising vaccine candidate, is a single polypeptide chain corresponding to 
amino acids 207–395 of the CSP fused to the amino terminus of the hepatitis B surface 
antigen (Bojang et al., 2001). 
 
 
Figure 1.3: Vaccine candidates targeting different life cycle stages. Candidates include circum-
sporozoite protein (CSP), serine repeat antigen 5 (SERA5), merozoite stage protein 3 (MSP-3), 
glutamate-rich protein (GLURP) and apical membrane antigen 1 (AMA-1). Adapted from Palacpac et 
al. (2011). 
Introduction   
 4 
Alternatively, the development of a malaria vaccine against the asexual stage (blood 
stage) of the parasite has raised profound promise. Blood stage vaccine candidates have 
included merozoite surface protein 1 (MSP-1), MSP-2, MSP-3, and apical membrane antigen 
1 (AMA-1). Recently, antibodies to MSP-3 were reported to offer protection in a new mouse 
model of P. falciparum malaria. Furthermore, transmission-blocking vaccines including Pfs25 
would be antigens capable of preventing the development of infectious sporozoites in the 
salivary glands of Anopheles mosquitoes. Notably, several vaccine candidates namely RTS, 
S/AS02A (Bojang et al., 2001; Alonso et al., 2004) RTS,S/AS02D (Aponte et al., 2007; 
Abdulla et al., 2008), RTS S/AS01E (Bejon et al., 2008) MVA-ME TRAP (Bejon et al., 
2007), and MSP-1/AS02A), SERA5 (Palacpac et al., 2011) have been studied in clinical 
settings. Despite recent progress, malaria vaccine development remains as complex as ever, 
and thus chemotherapy remains the only tool in the fight against malaria. 
 
1.1.3.2 Chemotherapeutic control of malaria  
Despite the identification of several drug targets (Kappe et al., 2011) and lead 
compounds, antimalarial chemotherapy is limited to a few classes of drugs: artemisinins, 
quinolines, antifolates, methylene blue (MB), and its derivatives. Despite advances, the 
mechanisms of action (Figure 1.4) are yet to be fully understood. 
 
 
Figure 1.4: Sites of antimalarial drug action. After decades of research, our understanding of the 
site of action of antimalarial drugs has increased remarkably. However, how drugs interact with a few 
identified target(s) in one or multiple organelles and how parasite death occurs remains elusive 
Adapted from Fidock et al. (2004). 
 
To date ACTs are the mainstay of malaria control (WHO, 2010). Currently, the ACTs widely 
used include artemether (ATM)-lumefantrine, artesunate-amodiaquine (ATS-AQ), artesunate-
mefloquine (ATS-MQ) and artesunate-sulfadoxine-pyrimethamine (ATS-SP). To a large 
extent ACTs have over 90% clinical efficacy (WHO, 2010) despite emergence of strains of P. 
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falciparum resistant to artemisinins in southeast Asia (Dondorp et al., 2009; Anderson et al., 
2010). Although characterized by rapid action and broad spectrum, the mechanism of action 
of ART and its derivates including ATS, ATM, arteether, and dihyro-artemisinin (Figure 1.5) 
remain incompletely understood. Current evidence suggests that the endoperoxide bridge is 
cleaved, leading to the formation of reactive carbon radicals that subsequently alkylate 
essential biomolecules (O’Neil and Posner, 2004). 
 
Figure 1.5: Artemisinin is isolated from Artemisia annua – a sweet wormwood. Due to a short 
plasma half-life, limited bioavailability, and poor solubility, several derivatives including 
dihydroartemisinin, artemether, arteether, and sodium artesunate have been synthesized. 8 and 9 are 
trifluoromethyl - and phenoxy- derivatives of artesunate and artemether respectively. Adapted from 
Magueur et al. (2004). 
 
Before adoption of ACT, quinoline antimalarial drugs (Figure 1.6) including CQ, AQ, QN, 
MQ, lumefantrine (LF) and halofantrine (HF) played a key role in antimalarial chemotherapy. 
Although mechanisms of action remain unclear, quinoline antimalarial drugs have been 
reported bind to heme and inhibit heme detoxification in the food vacuole (Foley and Tilley, 
1998; Fitch, 2004). 
  
Figure 1.6:  Quinoline antimalarial drugs.  
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Despite differences in chemical structure, the same transporters namely pfcrt (Fidock et al., 
2000), pfmdr1 (Reed et al., 2000) and pfmrp (Raj et al., 2009) have been reported to mediate 
resistance to multiple antimalarial drugs in P. falciparum including drugs to which the 
parasite has never been exposed (Sanchez et al., 2010). The role of transporters (Figure 1.7) in 
drug resistance of P. falciparum was reviewed recently (Sanchez et al., 2010). Fidock et al. 
(2000) identified PfCRT by analysis of a genetic cross between a CQR Dd2 and CQS HB3 
strains of P. falciparum. PfCRT is a protein of 424 amino acids and is localized at the 
membrane of the parasite’s food vacuole (Figure 1.7).  
 
Table 1.1: Polymorphisms in PfCRT and PfMDR1 
 
 
 
Since then, several mutations (Table 1.1) have been reported but only the key codon mutation, 
replacing a lysine at position 76 by a threonine, is conserved amongst the different mutant 
pfcrt alleles (Fidock et al., 2000). Although the function of PfCRT remains unknown, 
evidence suggests that it may transport drugs including CQ, AQ, QN, quinidine, MQ, 
primaquine, amantadine, and quinacrine (QC) out of the digestive vacuole where these drugs 
accumulate (Sanchez et al., 2010). Verapamil (Ver) blocks PfCRT-mediated drug transport. 
Recently, PfCRT homologs were identified in chloroplast membranes in a model plant 
Arabidopsis thaliana (Maughan et al., 2010). A. thaliana strains lacking these PfCRT 
homologs were glutathione (GSH)-deficient and probably unable to export the γ-
glutamylcysteine, which is exclusively produced in the plastid, into the cytoplasm where it is 
converted to GSH. 
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Figure 1.7:  Structure and function of major transporters involved in drug resistance. 
Plasmodium falciparum chloroquine resistance transporter (PfCRT, A,B), Plasmodium falciparum 
multi-drug resistance transporter 1 (PfMDR1, C,D), Plasmodium falciparum multi-drug resistance-
associated protein (PfMRP1, E,F). PfCRT may transport drugs out of the digestive vacuole where 
these drugs accumulate while PfMDR1 pumps compounds, including fluorochromes (Fluo-4, Fluo-4 
AM), into the digestive vacuole and PfMRP1 seems to pump glutathione (GSH), glutathione 
conjugates and the antimalarial drugs. Chloroquine (CQ), quinine (QN), and artemisinin (ART) out of 
the parasite’s cytoplasm. AQ is amodiaquine; QD, quinidine; MQ, mefloquine; PQ, primaquine; AM, 
amantadine; and QC, quinacrine. Verapamil (Ver) blocks PfCRT-mediated drug transport. HF, 
halofantrine; ONT-093 and XR-9576 block PfMDR1-mediated transport. Adapted from Sanchez et al. 
(2010). 
 
 
Introduction   
 8 
Indeed, heterologous expression in Xenopus laevis oocytes confirmed that the PfCRT 
homologs facilitate thiol transport (Maughan et al., 2010). Notably, the P. falciparum genome 
encodes at least 16 ATP-binding cassette (ABC) proteins (Kavishe et al., 2009), including 
PfMDR1 and PfMRP which are located on food vacuole (Reed et al., 2000) and parasite 
plasma membrane (Raj et al., 2009) respectively. Interestingly, polymorphisms at amino acids 
86, 184, 1034, 1042, and 1246 of PfMDR1 (Table 1.1) can also influence in vitro 
susceptibility to antimalarial drugs including QN, HF, MQ, and ART ( Reed et al., 2000; 
Sidhu et al., 2005), probably by pumping compounds, including fluorochromes (Rohrbach et 
al., 2006), into the digestive vacuole. Remarkably, the PfMDR1 86N, 184F, and 1246D 
alleles were selected after treatment with ATM-LF but not after ATS-AQ or AQ-SP 
(Baliraine and Rosenthal 2011). Although the exact function remains unknown, PfMRP1 
seems to pump GSH, GSH conjugates, and antimalarial drugs such as CQ, QN, and ART out 
of the parasite’s cytoplasm (Raj et al., 2009; Sanchez et al., 2010). Remarkably, the transport 
of antimalarial drugs between different sub-cellular compartments by PfCRT, PfMDR1, and 
PfMRP1 may have significant implications on GSH metabolism in P. falciparum.  
 
Figure 1.8: Antifolate antimalarial drugs. Pyrimethamine, trimethoprim, cycloguanil, and 
WR99210 inhibit dihydrofolate reductase. Sulfadoxine and dapsone inhibit dihydropteroate.  
 
Mutations in the dhfr and dhps genes of P. falciparum parasites have been associated 
with decreased parasite sensitivity to SP both in vivo and in vitro. Nevertheless, several new 
antifolate drugs that are in development including lapdap and WR99210 are active against P. 
falciparum strains with mutations in dhfr and dhps genes. Thus understanding the mechanism 
of action and resistance to this class of drugs may open up avenues for development of 
antifolate compounds that circumvent resistance. 
MB (Guttamann and Ehrlich, 1891; Yayon et al., 1984; Schirmer et al., 2011) is the 
oldest known synthetic antimalarial drug. MB and its analogs (Figure 1.9), including azure A 
(AZA) and B (AZB), thionin (TH), celestine blue (CB), phenosaphranin and pyocyanin 
(PYO) (Kasozi et al., 2011) show antimalarial activity by inducing oxidative stress (Färber et 
al., 1998) and inhibiting hemozoin formation. 
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Figure 1.9: Methylene blue and its analogs. 
  
Due to antifolate and quinoline drug resistance, there is renewed interest in MB as a 
combination therapy (Zoungrana et al., 2008) supported by its gametocytocidal activity in 
vivo (Coulibaly et al., 2009) and in vitro (Kasozi et al., 2011). However, the mechanism of 
action and possible resistance remain incompletely understood. Recently, Panstrana-Mena et 
al. (2010) and Buchholz et al. (2010) found that wild type and glutathione reductase (GR) null 
P. berghei had the same susceptibility to MB, suggesting that GR may not be the major target 
for MB.  
 
1.2 Rationale of the study 
The challenges encountered to sustainable control or containment and ultimately 
eradication of malaria strongly suggest that a novel multifactorial approach is urgently 
required. With the lack of a vaccine and the emergence of both drug and insecticide 
resistance, never before has the identification of promising targets been more greatly needed. 
Beginning with CQ (Trape, 2001), then SP (WHO, 2006), and now delayed clinical and 
parasitological response to ART (Noedl et al., 2008; Dondrop et al., 2009) strains resistant to 
almost all antimalarial drugs have been reported. As a response to this dire situation and in 
order to contribute to the fight against malaria, three novel projects were explored. First the 
role of the GSH redox system in the mechanism of action and resistance to antimalarial drugs 
was characterized by real time imaging of the EGSH using hGrx1-roGFP2. Secondly, the 
mechanism of uptake and inhibition of host human peroxiredoxin 2 (hPrx2) into P. 
falciparum was investigated to identify new targets for chemotherapy. Thirdly, the 
gametocytocidal activity of MB was characterized and a novel, rapid microfluorimetric 
(SYBR green 1 based) method to evaluate drug activity against gametocyte stages of P. 
falciparum was developed in order to aid drug discovery. An introduction to the 
aforementioned projects is given below. 
 
1.2.1 Redox and antioxidant systems of P. falciparum 
Cells have several redox systems including the GSH and thioredoxin systems that 
maintain normal redox homeostasis. However, these redox systems are subject to independent 
regulation and perform distinct regulatory and only partially overlapping functions (Jones, 
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2006). Notably, intracellular redox changes may be short or long-lived and unique to different 
sub-cellular compartments or organelles. Generally, in eukaryotic cells, the cytosol, 
mitochondria and nucleus have reducing milieu, but in contrast the endoplasmic reticulum is 
oxidizing. Yet, these organelles are embedded in an aqueous phase, the cytosol. Interestingly, 
the cytosol is not just a reducing compartment surrounding organelles with high oxidative 
activity but also a milieu for regulation of the redox status of more than one compartment.  
Despite advances in redox biology, the lack of non-invasive tools with high specificity 
to defined redox couples in different sub-cellular compartments remains a major limitation to 
understanding redox metabolism in the malarial parasite P. falciparum. Moreover, P. 
falciparum is exposed exogenously and endogenously to oxidative and nitrosative stress 
(Müller et al., 2003; Becker et al., 2004). Notably, the stress arises from reactive oxygen 
species (ROS) including hydrogen peroxide (H2O2), superoxide radicals, hydroxyl radicals, 
and reactive nitrogen species (RNS) comprising nitric oxide and peroxynitrite. Indeed, H2O2 
and superoxide radicals were detected in erythrocytes infected with P. berghei (Etkin and 
Eaton, 1975) and P. falciparum (Hunt and Stocker, 1990) respectively. Besides the host 
immune system, stress also arises from spontaneous oxidation and degradation (Figure 1.10) 
of ingested hemoglobin in the food vacuole (Atamna and Ginsburg, 1993; Muller, 2004). 
 
Figure 1.10: Sources of reactive oxygen species in P. falciparum. 
Following the digestion of host hemoglobin in the food vacuole, most of the released free heme (FP 
IX) is biomineralized to hemozoin. However, some free FP IX exits the food vacuole to the cytosol, 
causing membrane damage and redox reactions that generate superoxide anions. Superoxide anions 
either are detoxified by superoxide dismutase (SOD), yielding H2O2, or they spontaneously react with 
H2O2 or iron via the Fenton reaction, forming hydroxyl radicals. These radicals are highly reactive and 
cause lipid peroxidation. The H2O2 generated by the SOD reaction is detoxified to water by 
thioredoxin peroxidases. Adapted from Mueller (2004). 
 
To counteract oxidative stress, P. falciparum possesses its own defense (Becker et al., 2004) 
comprising a GSH redox system, thioredoxin system, superoxide dismutases, and 
thioredoxin-dependent peroxidases (Figure 1.11). Surprisingly, P. falciparum lacks a catalase 
and glutathione peroxidases (Sztajer et al., 2001). 
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Figure 1.11: A schematic representation of the antioxidant defense in a Plasmodium-infected 
erythrocyte. Adapted from Becker et al. (2004). 
 
1.2.1.1 The glutathione redox system in P. falciparum 
P. falciparum has a fully functional antioxidative GSH system comprising NADPH, 
GSSG/2GSH, and GR, (Färber et al., 1996; Meierjohann et al., 2002). Furthermore, other 
GSH-dependent proteins including glyoxalase, glutathione-dependent peroxidase (GPx), 
glutaredoxin, and glutathione S-transferase contribute to essential functions. The major 
sources of NADPH are glucose-6-phosphate dehydrogenase and glutamate dehydrogenase 
(Werner et al., 2005). 
In Plasmodium parasites, GSH is synthesized in the cytoplasm by γ-glutamylcysteine 
synthetase (γ-GCS) and GSH synthetase (GS), the two enzymes that respectively catalyze the 
ligation of glutamate and cysteine followed by the addition of glycine (Lüersen et al., 1999; 
Meierjohann et al., 2002). In principle as a drug target, inhibition of γ-GCS by D,L-
buthionine-S,R-sulfoximine (BSO) kills P. falciparum due to the depletion of GSH (Lüersen 
et al., 2000). Surprisingly, Vega-Rodriguez et al. (2009) showed that γ-GCS was essential for 
the oocyte rather than blood stages of P. berghei, suggesting that de novo GSH synthesis may 
not be limiting for erythrocytic malaria parasites. 
  Additionally, P. falciparum has PfGR that reduces GSSG (oxidized) to GSH 
(reduced). The primary structure of PfGR (Sarma et al., 2003) contains parasite-specific 
insertions in the FAD domain (residues 123–134), the central domain (residues 314–347), and 
the interface domain (residues 496–499). As a drug target (Schirmer et al., 1995), PfGR may 
Introduction   
 12 
be one of the molecular targets of MB (Färber et al., 1998), the first synthetic antimalarial 
compound (Guttmann and Ehrlich, 1891) and PYO (an analog of MB) (Kasozi et al., 2011). 
GSH is a major low-molecular-weight, thiol redox buffer in almost all aerobic cells 
(Schafer and Buettner, 2001). As a result of its high concentrations (1-11 mM), GSH is not 
only considered a major indicator of the cellular redox status but also an indicator of oxidative 
stress (Schafer and Buettner 2001). In the cytosol, the ratio of GSH to GSSG is maintained 
between 30:1 and 300:1, suggesting a highly reducing compartment (Miguel et al., 2007). In 
the trophozoite stage of P. falciparum, total estimates of 2.39 mM GSH and 8.4 µM GSSG 
were reported (Atamna and Ginsburg, 1997). Notably, the GSH responsible for this highly 
reducing cytosolic compartment is maintained by de novo synthesis (Griffith, 1999), action of 
PfGR and efflux of GSSG (Raj et al., 2009). The glutathione redox potential (EGSH) of the 
GSSG/2GSH system at pH 7.0, physiologic ionic strength, and 25°C was reported to be - 240 
mV (Schafer and Buettner, 2001). The redox potential depends not only on the ratio [reduced 
form]/[oxidized form], as it is in the case of redox couples such as NADPH/NADP or 
Trx(SH)2/TrxS2, but also on the absolute concentration of GSH. Of note, changes in EGSH 
appear to correlate with the biological status of the cell (Schafer and Buettner 2001) 
including: proliferation (EGSH = -240 mV); differentiation (EGSH = -220 mV) and apoptosis 
(EGSH = -170 mV). 
Despite accompanying several vital cellular processes, EGSH changes have rarely been 
measured accurately in real time and at the site of their occurrence in organelles or 
compartments of P. falciparum. Using data from Atamna and Ginsburg (1997), the EGSH  for 
the cytosol in the trophozoite stage of P. falciparum at pH 7.2 and 37°C has been estimated to 
be -265 mV (Becker et al., 2003). However, these EGSH estimates are inaccurate, because cell 
disruption methods were used in measurements of GSH and GSSG. Notably, disruption of 
cellular integrity leads to mixing of GSH and GSSG from different compartments including 
those that are reducing such as cytosol, mitochondria and nucleus, and oxidizing such as the 
endoplasmic reticulum. Furthermore, cell disruption methods inherently involve oxidative 
stress. By far, the major source of error is the determination of GSSG concentration, because 
this species is at low abundance yet is measured only after complete removal of GSH, which 
is highly susceptible to oxidation. 
 
1.2.1.1.2 Glutathione metabolism and antimalarial drug resistance 
Despite difficulties in accurate quantification, GSH has been shown to influence 
mechanisms of action or resistance to some antimalarial drugs. Besides MB, an inhibitor of 
PfGR, the role of GSH in the mechanism of action or resistance to quinoline and ART drugs 
remains incompletely understood. With regard to the quinolines only CQ and AQ but not QN 
nor MQ were reported to interfere with the GSH-dependent degradation of 
ferriprotoporphyrin (Famin et al., 1999). Furthermore, a possible role for oxidative stress as 
part of the mechanism of action of CQ suggested by Loria et al. (1999) and Graves et al. 
(2002) has been question (Monti et al., 2002). Hence, the role of ROS in the GSH-mediated 
destruction of FP remains unclear. Apart from CQ, the mechanisms of resistance to other 
quinoline drugs remain elusive. Evidence suggests a primary role for mutations in pfcrt 
(Fidock et al., 2000) and to a less extent those in pfmdr1 (Reed et al., 2000). Additionally, 
Ginsburg et al. (1998) suggested increased GSH levels may contribute to CQR. 
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Figure 1.12 : The GSH-dependent mechanism of heme detoxification 
Following uptake [1] and digestion [2] of hemoglobin, non-polymerized heme exits the food vacuole 
into the cytosol, were it is degraded by GSH. The released iron (Fe3+) enters into redox cycling 
producing a superoxide that dismutates to H2O2 [4]. H2O2 is reduced by catalase and glutathione 
peroxidases (GPx) while oxidizing GSH to GSSG [5]. GSSG is reduced back to GSH by glutathione 
reductase (GR) using NADPH as a reducing cofactor [6]. Then NADP is reduced back to NADPH by 
the hexose monophosphate shunt (HMS) [7]. GSH can also be synthesized de novo from Glu, Cys and 
Gly [8]. CQ or AQ accumulate in the food vacuole and forma complex with heme (FP) inhibitibg its 
polymerization [9]. Heme is degraded by GSH in the cytosol a process inhibited by CQ and AQ [10]. 
Heme then accumulates in the membrane and permeablises them to cations disturbing hemoestastis 
[11] leading to parasite death. Adapted from Ginsburg et al. (1998). 
 
Consistent with Ginsburg et al. (1998) CQR in P. falciparum (Meierjohann et al., 
2002) and P. berghei (Dubois et al., 1995) was found to correlate with increased GSH levels. 
Interestingly, the regulation of GSH in CQS (3D7 strain) and CQR (Dd2 strain) were reported 
to differ depending on PfGR and de novo synthesis, respectively (Meierjohann et al., 2002). 
In contrast to quinolines, especially CQ, the role of GSH in the mode of action of ART-based 
drugs is less characterized. Although the molecular mechanism of action remains debatable 
(O’Neill and Posner, 2004; Stocks et al., 2007), current evidence suggests that ART 
derivatives act through a free radical mediated mechanism (Meshnick and Dobson, 2002). 
ART derivatives accumulate in the cytosol, a highly reducing environment, and are activated 
via reductive cleavage of the peroxide bond by intracellular Fe(II) iron or heme generating, 
oxygen-centered radicals and subsequently carbon centered free radicals (Figure 1.13) The 
free radicals may alkylate vital cellular components including GSH (Wang and Wu, 2000) 
leading to parasite death. 
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Figure 1.13: Mechanism of action of artemisinin derivatives. Adapted from Muraleedharan and 
Avery (2009). 
 
Notably, consistent with this finding, ART activity is potentiated by oxygen and 
oxidizing agents and attenuated by reducing agents (Krungkrai and Yuthavong 1987). 
However, Ittarat et al. (2003) reported no change in the GSSG level in the presence of 
dihydroartemisinin, the active metabolite of ART, but with significant reduction in GSH 
which could be due to export of GSSG (Atamma and Ginsburg, 1997) or formation of GSH 
ART adducts (Mukanganyama et al, 2001). Recently, reduction in susceptibility of P. 
falciparum to ART-based drugs or ACTs has been reported (Noedl et al., 2008; Dondorp et 
al., 2009). Moreover stable and transmittable ART resistance was induced in a related species, 
P. chabaudi chabaudi, yet no association with SNPs or copy numbers in the candidate genes 
atp6 (encoding the SERCA-type Ca2+-ATPase), tctp (encoding a translationally controlled 
tumor protein, TCTP), mdr1, crt, and pfubp-1 (ubiquitin-specific protease-1) was found (Hunt 
et al., 2007). Despite intensive research efforts, unraveling the role of GSH redox systems in 
antimalarial drug action or resistance remains elusive. 
 
1.2.1.1.3 Redox-sensitive green fluorescent protein 
 Although highly specific and reproducible, GSH assays including enzymatic or 
HPLC-based assays suffer a major disadvantage as a result of cell disruption that 
inadvertently creates oxidation artifacts, limits dynamic measurements, and hence the 
computed redox potentials lack defined sub-cellular relevance. This is critically vital for P. 
falciparum-infected erythrocytes, since both the parasite compartments and the host cell have 
GSH. Alternatively, redox-sensitive fluorescent dyes have been used; however, these interact 
with multiple oxidants, are not dynamic, and cannot be targeted to specific compartments or 
organelles. Genetically encoded biosensors, especially redox-sensitive green fluorescent 
proteins (roGFPs) overcome limitations of conventional redox measurements. Similarly, 
pHluorin (Kuhn et al., 2007) and Ca2+-sensitive GFP-derivative (Billker et al., 2004) were 
used to measure sub-cellular pH and calcium concentrations, respectively in P. falciparum. 
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These genetically encoded biosensors are dynamic and can be targeted to specific 
compartments or organelles of cells. Redox-sensitive green fluorescent proteins were created 
starting from either wild type GFP or Enhanced GFP (EGFP), respectively, where two 
cysteines were engineered into the positions S147 and Q204, which are located on β-strands 7 
and 10. The resulting redox probes were called roGFP1, which is based on wild type GFP, 
and roGFP2, which is derived from EGFP (Figure 1.14). Due to the diversity in redox 
environments, several probes with different mid-point potentials have been engineered 
(Dooley et al., 2004). In physiologically reducing compartments such as the cytosol and 
mitochondria, roGFP1 (GFP with mutations C48S, S147C, and Q204C) and roGFP2 (the 
same plus S65T) have been used in HeLa cells (Hanson et al., 2004), Arabidopsis (Jiang et 
al., 2006; Meyer et al., 2007) and mammalian cells (Dooley et al., 2004) to determine redox 
potentials. However, the S65T mutation in roGFP2 renders its fluorescence pH-sensitive 
(Elsliger et al., 1999) and thus is suitable for pH values from 5.8 to 8.0. Nevertheless, roGFP2 
is brighter and offers a larger dynamic ratio between fully oxidized and fully reduced probes 
than roGFP1 for excitation wavelengths 405 and 488 nm frequently used on confocal 
microscopes (Meyer, 2007). Additionally, roGFP3 and roGFP4 differ from roGFP1 and 
roGFP2, respectively, by the presence of a disulfide bridge in position C149/C204. 
Furthermore, roGFP5 and roGFP6 contain all four cysteines and thus can potentially form two 
internal disulfide bridges (Meyer and Dick, 2010). Despite their prospective potential, roGFPs 
(3-6) have not been investigated in detail. To suit oxidizing environments such as the 
endoplasmic reticulum, Lohman and Remington (2008) developed a new subfamily of 
roGFP1-iX, (where ‘X’ denominates the insertion of different single amino acids into β-strand 
7, adjacent to C147) including roGFP1_iE and roGFP1_iL. The mid-point potential of roGFP 
1 and 2 are shown in Table 1.2. 
 
 
 
Figure 1.14: Genetically engineered redox-sensitive fluorescent proteins. 
The redox-sensitive, yellow fluorescent proteins (rxYFP) were created by introducing the T203Y 
mutation converting EGFP to YFP, resulting in a red-shifted GFP variant with an excitation maximum 
at 513 nm and emission at 527 nm (Ostergaard et al., 2001). However, rxYFPs are not ratiometric, 
which limits their use as effective redox biosensors. Adapted from Meyer and Dick (2010). 
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Typically, the dynamic reversibility of the cytosolic or mitochondrial roGFP response 
was demonstrated by sequential incubation with the oxidizing agents such as diamide, H2O2 
or aldrithiol (2,2-dipyridyl disulfide) and reduction with DTT (Dooley et al., 2004). 
Formation of a disulfide bridge between C204 and C147 shifts one β-strand relative to the 
other, causing a slight relocation of H148 (neighbour of C147 on strand 7) and S205 
(neighbor of C204 on strand 10); the resulting influence changes the Y66 protonation state 
(Figure 1.15, Wolf et al., 2008). These changes explain the ratiometric shift in the excitation 
spectrum. 
 
Table 1.2: Properties of roGFP1 and roGFP2 
 
Data from Schwarzländer et al. (2009),** Hanson et al. (2004), Dooley et al. (2004)* and Meyer and 
Dick (2010). 
 
 
 
Figure 1.15: Reduced and oxidized forms of roGFP. Adapated from Wolf et al. (2008). 
 
These roGFPs have two excitation maxima at 400 nm for the A-band (main peak in roGFP1) 
and 475–490 nm for the B-band (main peak in roGFP2). Correspondingly, oxidation results in 
an increase in the ~400 nm peak and a decrease in the 475–490 nm peak and an inverse 
behavior under reducing conditions (Figure 1.16) with an isosbestic point at 425 nm (Meyer 
and Dick, 2010). 
 
Redox probe 
 
Engineered amino 
acids 
Disulfide 
bond 
Standard Midpoint 
potential E°' (mV)  
 
Dynamic 
range 
roGFP1 C48S Q80R S147C 
Q204C 
C147-C204 -288 (DTTred/DTTox) 
-294 (BMESred/BMESox) 
-291 (consensus) 
2.58 
(405/488)* 
6.1 
(400/475)** 
roGFP2 C48S S65T Q80R 
S147C Q204C 
C147-C204 -272 (DTTred/DTTox) 
-287 (BMESred/BMESox) 
-280 (consensus) 
9.23 
(405/488)* 
5.8 
(400/490)** 
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Figure 1.16:  Excitation spectrum of roGFP2. Oxidation increases the excitation peak at 405 nm 
and decreases the peak  at 488 nm, and vice versa under reducing conditions. Adapted from Meyer and 
Dick (2010). 
 
1.2.1.1.4 hGrx1-roGFP2 as a biosensor for the glutathione redox potential 
Although roGFP2 interacts with the GSH system, its response was slow due to limited 
availability of endogenous glutaredoxin for enforcing rapid equilibration. Consequently, 
Gutscher et al. (2008) fused human glutaredoxin-1 to roGFP2 (hGrx1-roGFP2), resulting in a 
catalytically self-sufficient biosensor capable of securing rapid and efficient equilibration 
under all circumstances. Interestingly, hGrx1-roGFP2 was reported to detect nanomolar 
changes in GSSG against a backdrop of millimolar concentrations of reduced GSH on a scale 
of seconds to minutes (Gutscher et al., 2008). Importantly, hGrx1-roGFP2 was used for 
dynamic live imaging of the EGSH in different cellular compartments with high sensitivity and 
temporal resolution. The response properties of Grx1-roGFP2 are based on the well-
established monothiol mechanism of glutaredoxins (Figure 1.17).  
 
 
Figure 1.17: Molecular mechanism of the hGrx1–roGFP2 biosensor. Each individual step of the 
three-step thiol-disulfide exchange cascade is fully reversible. Adapted from Meyer and Dick (2010). 
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In the oxidative response, the nucleophilic cysteine C23 of Grx1 specifically reacts 
with GSSG to form a mixed Grx1-GSSG intermediate. The latter reacts with one of the two 
thiols on roGFP2, which, as a consequence, becomes S-glutathionylated. 
In this thesis, hGrx1-roGFP2 was used to detect changes in the EGSH not only in 
presence of classical redox agents such as H2O2, diamide, and DTT, but more importantly 
following treatment with antimalarial drugs including GSH biosynthetic inhibitors, quinolines 
and ART derivatives. 
 
1.2.1.2 Thioredoxin system in P. falciparum 
P. falciparum has a fully functional thioredoxin system comprising thioredoxin 
reductase, thioredoxins (Rahlfs et al., 2002) and thioredoxin-dependent peroxidases (Rahlfs 
and Becker, 2001). The P. falciparum thioredoxin reductase (PfTrxR) is a 55 kDa 
homodimeric FAD-dependent oxidoreductase (Muller et al., 1995), which as demonstrated by 
knockout studies is essential for erythrocytic stages (Krnajski et al., 2002). Interestingly, the 
C-terminal active site motif (CGGGKC) of PfTrxR differs from human TrxR (Cys-Sec), and 
hence it was suggested as a suitable drug target (Becker et al., 2000). Davioud-Charvet et al. 
(1999) synthesized and evaluated 5, 5-dithiobis (2-nitrobenzamides) as inhibitors against 
PfTrxR. However, recently it was demonstrated that PfTrxR is not essential for the various 
developmental stages of Plasmodium parasites (Bucholz et al., 2008) 
P. falciparum has a 13 kDa typical thioredoxin (PfTrx1) with a classical active site 
motif WCGPCK (Kanzok et al., 2000) that provides reducing equivalents to peroxidases and 
ribonucleotide reductase and is reduced by PfTrxR (Rahlfs et al., 2002). Furthermore, a non-
enzymatic reduction of GSSG (Kanzok et al., 2000), H2O2, t-butylhydroperoxide (TBHP), 
and cumene hydroperoxide (Rahlfs et al., 2003) has been reported by PfTrx1. Besides PfTrx1, 
three other thioredoxin-like proteins have been detected in P. falciparum. Additionally, 
plasmoredoxin, a member of the thioredoxin superfamily exclusively found in malaria 
parasites that is reduced faster by thioredoxin and glutaredoxin than by GSH, has been 
reported (Becker et al., 2003). However, Bucholz et al. (2008) reported that plasmoredoxin in 
P. berghei played a non-essential role for life cycle progression. The redox potential of 
thioredoxin/thioredoxin disulfide [Trx(SH)/Trx(S)2] couples in the cytosol of P. falciparum 
remains unknown. Previously, the standard potential (Eo) of the active site dithiol/disulfide 
couple of human Trx1 was estimated to be -230 mV (Watson et al., 2003). Moreover, the 
human Trx1 and GSH/GSSG redox couples in the cytoplasm were reported not to be in 
equilibrium. Nevertheless in thioredoxin and GSH, redox systems in P. falciparum may be 
linked by the reduction of GSSG via thioredoxin (Kanzok et al., 2000). Indeed, the human 
Trx1 and GSH/GSSG couples were found to vary independently during growth transitions 
(Nkabyo et al., 2002), redox signaling (Halvey et al., 2005), and metal-induced toxicity 
(Hansen et al., 2006). Thus, studies suggest that the major redox systems consisting of Trx1 
and GSH are distinct both between and within compartments however this remains to be 
elucidated in P. falciparum. 
 
1.2.1.3 Peroxiredoxin system in P. falciparum 
Peroxiredoxins (Prx) contribute significantly to the peroxide-detoxifying capacity of 
cells (Wood et al., 2003). This protein family comprises different subfamilies (Figure 1.18): 
the typical 2-Cys peroxiredoxins, the atypical 2-Cys peroxiredoxins and the 1-Cys 
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peroxiredoxins (Wood et al., 2003). Recently, Prx in parasites have been reviewed (Gretes et 
al., 2011) and an informative systematic nomenclature proposed. For clarity, the new 
nomenclature has been adopted and the old names are in brackets. P. falciparum has five 
Prxs: two from the Prx1 subfamily (Prx1a and Prx1m), and one from each of PrxQ, Prx5, and 
Prx6 subfamilies (Gretes et al., 2011). P. falciparum Prx1a (Prx-1, Px2, TPx1, TPx-2, Trx-
Px1) and Prx6 (1-Cys-Prx, Prx2, TPx-1) are located to the cytosol (Kehr et al., 2010), Prx1m 
(TPx2) to the mitochondrion (Yano et al., 2005), and Prx5 (Antioxidant protein, AOP) to the 
apicoplast (Sarma et al., 2005) and PrxQ (MCO1, nPrx) is exclusively localized to the 
nucleus.  
 
 
Figure 1.18: The mechanisms of peroxiredoxin classes. 
In the case-typical 2-Cys Prxs, the peroxidatic cysteine (black SP) and resolving cysteine (pink SR) 
originate from different subunits and condense to form an inter-subunit disulfide bond (black and pink 
striped bar). Reduction of typical and atypical 2-Cys Prxs involves one flavoprotein disulfide 
reductase and at least one additional protein or domain containing a CXXC motif, which is oxidized 
from a dithiol (2 RSH) to a disulfide (RSSR) state during Prx reduction. Reductants of 1-Cys Prxs 
include low molecular weight thiols, but physiological partners are as yet unidentified (adapted from 
Wood et al., 2003). 
 
The PfPrx1a is thioredoxin-dependent and efficiently reduces H2O2 in vitro and 
probably in vivo (Akerman and Müller, 2003). Importantly, PfPrx1a is transcribed not only in 
the erythrocytic stages but also to a lesser extent in gametocyte and sporozoite stages of P. 
falciparum (Le Roch et al., 2003). However, despite transcription of PfPrx1a, knockout of 
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this gene resulted in only a slight increase in susceptibility to oxidative and nitrosative stress 
compared to wild-type parasites (Komaki-Yasuda et al., 2003). Furthermore, although PfPrx6 
is transcribed (Roch et al., 2003) and expressed in erythrocytic stages, its role in antioxidant 
defense is still uncertain. Interestingly, P. falciparum has been reported to import the human 
redox-active protein peroxiredoxin 2 (hPrx2) for peroxide-detoxifying functions (Koncarevic 
et al., 2009). However, the inhibition and mechanism of uptake of hPrx2 remains to be 
elucidated.  
 
1.2.2 Trafficking in a P. falciparum-infected red blood cell 
1.2.2.1 Trafficking pathways within and from P. falciparum 
During the asexual stage of its life cycle, the malaria parasite P. falciparum invades 
and grows within the RBC of its host (Figure 1.19). To develop, merozoites import and export 
a wide range of host substances for different purposes. However, the host RBC has no 
trafficking pathways for the transport of solutes and macromolecules for the rapidly 
developing parasite P. falciparum. As a result the parasite remodels its host cell, establishing 
routes not only to import but also to export macromolecules crossing the parasitophorous 
vacuole (PV), the parasite membrane (PPM), and the RBC membrane destined to different 
organelles in order to perform different functions. Notably, proteins may be imported not only 
from the external medium but also from the host erythrocyte. 
 
Figure 1.19: Development of P. falciparum in host human red blood cells. 
The merozoites invade host red blood cells during the asexual stage. To develop, merozoites import 
and export a wide range of host substances crossing not only the parasitophorous vacuole but also the 
parasite membrane destined to different organelles in order to perform different functions (Maier et 
al., 2009). 
 
Comparatively, proteins are exported not only to organelles but also into the host erythrocyte 
cytosol and the erythrocyte membrane. Since publication of the P. falciparum genome 
sequence, signal sequences responsible for targeting parasite-synthesized proteins to 
organelles and to host erythrocytes have been predicted and intensely investigated. 
Nevertheless, import and export trafficking pathways remain incompletely understood. 
P. falciparum synthesizes nuclear encoded proteins and targets them to the organelles 
and the host cell compartment (Figure 1.20). Initially, most secreted proteins require a signal 
peptide (SP) that is later cleaved off in order to enter the endoplasmic reticulum (ER). Some 
proteins such as the Pf BIP (binding immunoglobin protein) and Pf ERC (endoplasmic 
reticulum resident protein) that possess the KDEL sequence are retained in the endoplasmic 
reticulum (Külzer et al., 2009). The apicoplast has four membranes and nuclear encoded 
proteins require a signal and a transit peptide for correct targeting to the apicoplast (Waller et 
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al., 2000). Protein traffic to the apicoplast occurs through the secretory pathway but it is likely 
that they do not pass through the Golgi.  
 
 
Figure 1.20 Trafficking pathways within and from P. falciparum. 
P. falciparum synthesizes several proteins that are targeted not only to different organelles but also to 
the host cell compartment. Adapted from Przyborski and Lanzer (2005). 
 
After entry into the secretory pathway, the transit peptide mediates the remaining steps 
to the apicoplast. Transit peptides are identifiable by a predominance of hydrophilic and basic 
amino acids and a corresponding lack of acidic residues (Ralph et al., 2004). Traffic to the 
food vacuole is achieved by a variety of mechanisms, as proteins may be nuclear-encoded or 
imported from the host cytosol or even the medium. Indeed, two nuclear encoded proteases 
have an N-terminal signal but are targeted to the food vacuole but via different routes (Tonkin 
et al., 2006). Plasmepsin II, an aspartic protease, travels through the ER and is delivered 
initially to the cytostome and from there to the food vacuole via an unknown mechanism 
(Klemba et al., 2004a). In contrast, the protease dipeptide aminopeptidase 1 accumulates in 
the PV before transport to the food vacuole (Klemba et al., 2004b). Trafficking of nuclear-
encoded proteins has been extensively reviewed (Lingelbach and Przyborski et al., 2006). To 
traffic proteins to the host cell compartment across the PVM, a pentapeptide at the N-terminus 
of the protein, referred to as the Plasmodium Export Element (PEXEL) (Marti et al., 2004) or 
vacuolar translocation signal (VTS) (Hiller et al., 2004) is required. However, it is not clear at 
which point of the pathway PEXEL/VTS acts in order to determine the fate of the protein. 
Subsequently, some proteins translocate across the erythrocyte cytoplasm, 
accumulating in the Maurers clefts (MC), and some are then trafficked to the erythrocyte 
membrane independently of PEXEL (Charpian and Przyborski, 2008). It is still unclear what 
sequences are required to export proteins beyond the MC to the erythrocyte membrane. 
Different export pathways have been proposed for five different integral membrane proteins. 
Two of the proteins, STEVOR and PfEMP1, have a PEXEL sequence, while the others 
including REX2 and SBP1 do not. Sam-Yellowe (2009) recently reviewed the role of MC in 
targeting proteins. It remains to be elucidated whether the MC not only play a role in the 
export but also import of proteins into P. falciparum. 
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1.2.2.2 Transport of solutes into P. falciparum 
Due to the increased permeability of the host cell membrane, early studies suggested 
the presence of new permeation pathways (Baumeister et al., 2010). Although still 
controversial, several models have been put forward (Figure 1.21). Pouvelle et al. (1991) 
suggested the parasitophorous duct model, in which the PV is permanently fused with the 
erythrocyte membrane, thereby allowing access of large molecules directly to the parasite. 
Furthermore, Lauer et al. (1997) suggested the metabolic window model a modification of the 
parasitophorous duct model by hypothesizing that it is a temporal rather than permanent 
contact of PVM with the erythrocyte membrane. Additionally, Kirk (2001) suggested the 
sequential uptake model. By the sequential uptake model, solutes gain access to the parasite 
first through transport proteins in the erythrocyte membrane and then followed by passage via 
non-selective pores in the PVM. Subsequently, several transport proteins and selective pores 
have been identified in the erythrocyte membrane and PVM (Nyalwidhe et al., 2002). 
 
 
Figure 1.21: Import trafficking pathways. 
(A) P. falciparum is surrounded by the parasitophorous vacuole (PV) between its parasite plasma 
membrane (PPM) and the parasitophorous vacuole membrane (PVM). (B) Several models including a 
the sequential uptake model (Kirk, 2001), b the parasitophorous duct model (Pouvelle et al., 1991), 
and c the metabolic window model (Lauer et al., 1997) have been put forward to explain how P. 
falciparum acquires macromolecules. Adapted from Baumeister et al. (2010). 
 
1.2.2.3 Transport of host proteins into P. falciparum 
To develop, merozoites import a wide range of host substances crossing not only the 
PV but also the PPM destined to different organelles to perform different functions. Indeed, 
the uptake of low molecular weight substances including glucose, amino acids, vitamins, 
nucleosides, and drugs through anion-selective channels, non-specific ion pores, and an 
interconnected network of tubovesicular membranes (Hibb et al., 1997; Lauer et al., 1997; 
Kirk, 2001; Haldar et al., 2003) has been recognized. However, trafficking pathways between 
the host red blood cell and P. falciparum remain complex and poorly understood. Moreover, 
macromolecular import of host proteins into different organelles remains controversial (Dive 
et al., 2003) partly due to limitations in organelle separation techniques. Even with 
fluorescence labeling, it is very difficult to establish whether the macromolecular proteins or 
A 
 
B 
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released dye is responsible for the level of fluorescence in the parasite (Hibbs et al., 1997). 
Furthermore, import of proteins from medium has been reported. Using fluorescent 
macromolecules, Pouvelle et al. (1991) reported the import of dextran, protein A, and an IgG2 
antibody into P. falciparum. Additionally, Tahir et al. (2003) showed the uptake of 
polypeptides ranging from 45 to 206 kDa into P. falciparum. Bonday et al. (2000) showed the 
uptake of different recombinant fragments of δ – aminonlevulinate dehydratase into P. 
falciparum. Interestingly, several host proteins including human superoxide (Fairfield et al., 
1981), aminolevulinic acid dehydratase (Bonday et al., 2000), ferrochelatase (Varadharajan et 
al., 2004), and human peroxiredoxin (Koncarevic et al., 2009) have been reported to be 
imported into the cytosol while others such as hemoglobin (Lazarus et al., 2008; Elliott et al., 
2008) and catalase (Clarebout et al., 1998) are imported into the food vacuole. Recently, Foth 
et al. (2011) identified 24 human proteins which were significantly abundant in parasite 
protein lysates and exhibited specific abundance profiles across the intra erythrocytic cycle. 
Except for hemoglobin, neither the mechanisms of uptake nor the inhibition of other host 
proteins have been thoroughly investigated. Although not entirely clear, current models 
(Lazarus et al., 2008) and evidence suggests that hemoglobin may be imported by four 
distinct pathways (Figure 1.22) including the “Big Gulp” that occurs between 6 to 30 h, small 
hemoglobin vacuoles (throughout the life cycle), and at 30 h by both endocytosis via 
cytostomal tubes and phagotrophy (Elliott et al., 2008). 
 
Figure 1.22: Hemoglobin uptake. 
(A) A model of hemoglobin uptake (Lazarus et al., 2008) and (B) the four distinct but related ways of 
importing hemoglobin into P. falciparum (Elliott et al., 2008). 
 
However, molecular mechanisms that mediate and regulate either endocytosis or 
phagocytosis or pinocytosis in P. falciparum remain unknown. Receptor-mediated 
endocytosis results in the internalization of extracellular ligands bound to specific receptors 
via clathrin-coated pits and vesicles (Kirchhausen, 2000). By contrast, in phagocytosis, 
exogenous particulate substances are encapsulated in membrane vesicles or vacuoles derived 
from the plasma membrane. Additionally, in pinocytosis, soluble extracellular markers are 
internalized in membrane bound pinosomes and eventually delivered either to the lysosomes 
or back to the plasma membrane. P. falciparum is a eukaryote and as a result has similarities 
with trafficking in mammalian cells (Figure 1.23). In mammalian cells this process involves a 
set of proteins, including the coat proteins COPI, COPII, and clathrin, and carries out a 
programmed set of sequential interactions that lead to the budding of vesicles. Despite being 
the best studied, the molecular trafficking mechanisms even in mammalian cells remain 
complex. Several proteins are involved in vesicle coat formation including its initiation, 
A 
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propagation, vesicle budding, and uncoating (Figure 1.24), including Rho family GTPases and 
signaling cascades triggered by external stimuli (Niedergang and Chavrier, 2004). Indeed, 
Kappe et al. (2004) have reported that actin and myosin motors are required for motility by 
merozoites for host cell penetration and are present in other asexual stages. The role of actin 
has been demonstrated in endocytic trafficking of hemoglobin in P. falciparum (Elliott et al., 
2008; Lazarus et al., 2008; Smythe et al., 2008). Furthermore, the role of actin was evaluated 
using two well-characterized actin toxins (Figure 1.25), cytochalasin D (CTD) and 
jasplakinolide (JAS) (Smythe et al., 2008). CTD prevents actin elongation and promotes the 
dispersion of existing actin filaments, and JAS stabilizes actin filaments, thus enhancing 
polymerization (Smythe et al., 2008). Furthermore, latrunculin A is reported to disrupt 
microfilament polymerization due to a one-to-one binding with monomeric G-actin but has no 
effect on microtubular structure. Additionally, P. falciparum expresses three members of the 
Rab5 family (Quevillon, et al. 2003), the prototypic marker associated with early endosome 
formation and transport in other eukaryotes (Seabra and Coudrier, 2004). 
 
 
Figure 1.23: Traffic pathways in eukaryotic cells. In the endocytic pathway, macromolecules are 
internalized at the plasma membrane and forwarded to early endosomes, from where they are either 
recycled to the plasma membrane through recycling endosomes or forwarded towards degradation in 
late endosomes and lysosomes or sorted to different organelles (Kirchhausen, 2000). 
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Figure 1.24: Network of proteins involved in clathrin coat formation. 
Various proteins are involved in clathrin coat formation including actin, clathrin, syndapin, intersectin, 
dynamin, endophilin, and adaptor proteins (AP-180, AP-2), among others. Adapted from Kirchhausen, 
(2000). 
 
 
 
Figure 1.25: Inhibitors of actin and dynamin. Cytochalasin D, jasplakinolide, latrunculin A, 
and dynasore have been shown to influence uptake of hemoglobin. 
 
Dynamin super-family members are conserved GTPase proteins existing in many 
eukaryotic cells from yeast to mammals. Recently, Zhou et al. (2009) reported that the 
genome of the P. falciparum parasite encodes two dynamin-like proteins, namely dynamin-
like protein 1 (PfDYN1) and dynamin-like protein 2 (PfDYN2). By using a dynamin 
inhibitor, dynasore (DYN) the role PfDYN1 in the uptake of hemoglobin was showed. For 
decades, vesicles have been known to have an acidic pH of 4.8-5.2 that can be increased by 
the addition of weak bases including NH4C1 and the antimalarial drugs CQ, QN, and MQ to 
the medium (Krogstad et al., 1985). Previously, both ART and MQ were reported to inhibit 
phagocytosis in immune cells (Wenisch et al., 1997), while the 8-aminoquinoline primaquine 
interferes with the endosome behavior in Hep-G2 cells (Van Weert et al., 2000). Indeed, ART 
and the quinoline drugs CQ and MQ were shown to inhibit endocytosis in P. falciparum 
(Hoppe et al., 2004). Besides CQ, ionophores such as monensin (MNS) and nigericin were 
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also shown to alkalinize the food vacuole and inhibit lysosomal protein degradation 
(Adovelande and Schrevel, 1996; Hoppe et al., 2004). Endocytosis requires energy and thus 
sodium azide (NaN3) treatment was reported to deplete ATP levels in P. falciparum (Haldar et 
al., 2002) and inhibit protein uptake (Tahir et al., 2003). Nevertheless it remains unclear how 
P. falciparum sorts host-acquired proteins to different organelles as reported to the cytosol 
and food vacuole. Identification of species-specific sorting mechanisms may yield novel drug 
targets. 
 
1.2.3 Development of a rapid method for gametocytocidal activity  
Sustainable control or eradication of malaria will require not only treatment of asexual 
stages but also targeting of transmissible stages (White, 2008). Transmission of P. falciparum 
malaria from the infected vertebrate host to the female Anopheles mosquito vector, thus 
ensuring continuity of the life cycle, is undertaken by gametocytes. P. falciparum 
gametocytes develop from blood stage parasites that stop asexual multiplication, diverting 
into the sexual differentiation pathway (Figure 1.26). However, a small population of asexual 
parasites commits to sexual development, and in vitro isolates in continuous culture tend to 
produce fewer gametocytes over time (Graves et al., 1984). Hence, difficulties in producing 
large amounts of P. falciparum gametocytes have restricted research in development of 
transmission-blocking drugs. As a result, several methods including the continuous flow 
method, the suspension culture system (Ifediba and Vanderberg, 1981), and tipper system 
(Ponnudurai et al., 1982) have been developed for the production of viable gametocytes. Yet 
the molecular mechanisms involved in the commitment of parasites to sexual differentiation 
still remain obscure (Silvestrini et al., 2005). 
 
 
Figure 1.26: Stages of gametocyte development. Adapted from Alano (2007). 
 
To produce gametocytes, a culture with a low synchronous asexual parasitemia and 
high hematocrit is set up. Without the addition of new erythrocytes, a high parasitemia is 
attained while the medium is changed daily until the parasites become visibly stressed (a 
noticeable medium color change to yellow). The hematocrit is then lowered by increasing the 
medium volume to stimulate gametocyte production (Ifediba and Vanderberg, 1981). 
Furthermore, Williams (1999) suggested that spent parasite-conditioned medium may contain 
factors that enhance sexual differentiation. In contrast, a sudden increase in the hematocrit of 
a fast-growing ring stage culture in the presence of partially spent medium stimulates sexual 
differentiation. Thus, gametocyte production may be triggered by conditions negatively 
affecting asexual multiplication such as stress (Ifediba and Vanderberg, 1981) or drug 
treatment with CQ or SP (Buckling et al., 1999), two inhibitors of the enzyme cAMP 
phosphodiesterase, caffeine (Brockelman 1982), and 8-bromo cAMP (Trager and Gill, 1989), 
and the polypeptide cholera toxin (Dyer and Day, 2003), although no single molecule has 
been so far conclusively shown to act as an inducing factor. Nevertheless, none of these 
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methods eliminates the limitations associated with the production of low gametocyte 
numbers. A few parasite lines such as NF54, 3D7A, HB3A, and P2G12 are reported to have a 
high sexual conversion rate especially when low-passage isolates are used (Fivelman et al., 
2007). Improvements in culturing methods coupled with enrichment by use of MACS® 
magnetic affinity columns (Ribaut et al., 2007; Fivelman et al., 2007) has allowed the 
availability of synchronous gametocytes suitable for drug development assays. 
Not surprisingly, few significant advances in techniques used for assessing drug 
susceptibility of gametocytes have been undertaken. Besides ART derivatives (Benoit-Vical 
et al., 2007) and primaquine (White, 2008) mature gametocytes, especially stages IV and V 
rather than stages I, II, and III, are resistant to other antimalarial drugs including quinolines 
(Benoit-Vical et al., 2007) and antifolates. However, primaquine is inactive under in vitro 
conditions yet it is transformed into an active metabolite in the mammalian host (White 2008). 
Nearly all methods depend on microscopic counting of gametocytes (counts per 10,000 
erythrocytes on thin film), which is an extremely time-consuming and laborious process. Due 
to the tedious nature of microscopic examination, several methods based on [3H]- 
hypoxanthine incorporation (Desjardins et al., 1979), enzyme-linked immunosorbent assay 
using monoclonal antibodies to plasmodial lactate dehydrogenase (Makler et al., 1993), and 
histidine-rich protein II (Noedl et al., 2001) were developed in order to determine drug 
susceptibility against asexual stages. Recently, new nonradioactive methods have been 
reported that use DNA stains including SYBR Green I (Smilkstein et al., 2004) DAPI 
(Baniecki et al., 2007), PicoGreen (Corbett et al., 2004), and as a reporter to measure asexual 
parasite growth. Remarkably, the use of DNA stains to detect parasite DNA has significantly 
simplified drug susceptibility testing of asexual stages. 
Due to the huge reliance on hypoxanthine for growth of gametocytes and in order to 
avoid safety and disposal problems associated with use of radioactive materials, GFP - based 
methods have also been developed for sexual stages. Recently, Dixon et al. (2008) and 
Buchholz et al. (2011) developed an assay utilizing a GFP fused to an sexual protein Pfs16. 
Pfs16 is the earliest known gametocyte marker detectable 30 h post-invasion of a sexually 
committed parasite (Alano et al., 1991). Despite variations, this marker is expressed 
throughout and only in sexual stage parasites. The expression of the chimeric Pfs16-GFP 
allows for the analysis of parasite cultures by fluorescence-activated cell sorting (FACS), 
enabling the accurate identification of gametocytes well before they are morphologically 
distinguishable from asexual stage parasites. This significantly reduces assay times and 
eliminates the possibility of operator bias associated with morphological identification of 
gametocytes in standard gametocyte assays. However, in order to maintain GFP fluorescence, 
parasites are treated with antifolate selection agent WR92210 and thus may not be suitable for 
assay against other antimalarial drugs. Moreover, the proportion of gametocytes produced is 
in such assays still very small compared to asexual parasites while both are exposed to the 
drug, but the GFP signal is exclusively from asexual parasites. Above all, GFP fluorescence 
has been reported to reduce over long gametocyte development periods. 
To overcome limitations of low gametocyte production and eliminate asexual stages, 
modifications to current protocols were undertaken. In order to eliminate asexual stages 
(trophozoites and schizonts), two sorbitol treatments at 12 and 31 h following the first 
treatment were carried out as described by Saul et al. (1990). In order to enrich gametocytes 
and eliminate ring asexual stages and non-infected RBCs, a MACS® magnetic affinity 
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column (Ribaut et al., 2007; Fivelman et al., 2007) was used. After drug exposure in 
microtitre plates, the gametocytes were frozen at -80ºC and thawed before the SYBR1 assay 
as described (Smilkstein et al., 2004). To support clinical trials of MB based combinations, 
the gametocytocidal activity of MB was determined, along with that of its analog PYO and  
CQ as control. Furthermore, a novel, simple, and inexpensive fluorescence-based technique 
for determining activity of antimalarial drugs against gametocytes was developed. 
 
1.3 Objectives of the study 
The overall strategic objective of my thesis was to contribute to the fight against drug-
resistant malaria through an improved understanding of the mechanism of drug action and 
resistance in order to rationally design new drugs. This thesis explores the role of the EGSH in 
antimalarial action and resistance, evaluates the uptake of host hPrx2 into P. falciparum and 
its inhibition as well as the gametocytocidal activity of MB and its analogs. In order to do this, 
the following objectives with respect to each project were drawn. 
 
1.3.1 SPECIFIC OBJECTIVES 
 
1.3.1.1 Glutathione system 
1. To establish a redox sensitive green fluorescence (hGrx1-roGFP2) protein-based 
method for real time imaging of the EGSH in P. falciparum. 
2. By real time imaging of hGrx1-roGFP2 in the cytosol, to determine the effect of 
classical redox-active agents and antimalarial drugs including MB and its analogs, 
quinolines, and ART derivatives on the EGSH in sensitive (3D7) and resistant (Dd2) 
strains of P. falciparum. 
3. To characterize the direct interaction of recombinant hGrx1-roGFP2 with the 
antimalarial drugs MB and its analogs, quinolines, and ART derivatives. 
 
1.3.1.2 Uptake of host human peroxiredoxin 2 (hPrx2) into P. falciparum 
1. To identify protein sequence motifs required for the import of hPrx2 into P. 
falciparum. 
2. To clone, overexpress and purify recombinant protein mutants of hPrx2. 
3. To characterize the uptake of recombinant hPrx2 from hypotonically dialyzed 
erythrocytes into P. falciparum by Western blotting and confocal microscopy.  
4. To evaluate the effect of inhibitors of endocytosis on the uptake of hPrx2 into P. 
falciparum. 
 
1.3.1.3 Gametocytocidal activity of methylene blue and its analogs 
1. To determine the gametocytocidal activity of MB and its analog PYO. 
2. To develop a novel rapid assay to evaluate the activity of antimalarial drugs against 
gametocytes of P. falciparum. 
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2 MATERIALS AND METHODS 
 
2.1  Materials 
All materials used were of the highest purity and were obtained from the sources indicated 
below. 
2.1.1 Chemicals  
Chemical Source  
Acetic acid  Roth, Karlsruhe 
Acrylamide solution  BioRad, München 
Albumax Gibco, Karlsruhe 
Ammonium persulphate  Merck, Darmstadt 
Ammonium chloride Sigma, Steinheim 
Bacto-Agar  Roth, Karlsruhe 
Boric acid  Roth, Karlsruhe 
Bovine serum albumin Roth, Karlsruhe 
Bromophenol blue  Sigma, Steinheim 
Coomassie brilliant blue R250  Sigma, Steinheim 
Diamide Sigma, Steinheim 
Ethylenediaminetetraacetate Roth, Karlsruhe 
Ethidium bromide  Sigma, Steinheim 
Hydrogen peroxide Sigma, Steinheim 
Glucose  Merck, Darmstadt 
Hypoxanthine  Sigma, Steinheim 
Imidazole  Roth, Karlsruhe 
Isopropanol  Roth, Karlsruhe 
Isopropylthiogalactoside Roth, Karlsruhe 
Magnesium chloride  Roth, Karlsruhe 
Menadione Sigma, Steinheim 
Milk powder  BioRad, München 
Nickel-nitrilotriacetic acid  Qiagen, Hilden 
Paraquat Sigma, Steinheim 
Saponin  Roth, Karlsruhe 
Sodium azide  Roth, Karlsruhe 
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Sodium dodecyl sulphate  Merck, Darmstadt 
Sodium nitroprusside Sigma, Steinheim 
Sorbitol  Roth, Karlsruhe 
TEMED  Sigma, Steinheim 
Tris base Roth, Karlsruhe 
Trypton  Roth, Karlsruhe 
Tween-20  Merck, Darmstadt 
Yeast extract  Oxoid LTD, U.K 
 
2.1.2 Enzymes  
Enzyme Source 
DNA ligase  New England Biolabs, U.K 
DNase I  Roche, Mannheim 
Lysozyme  Sigma, Steinheim 
Pfu polymerase  Promega, Mannheim 
Restriction enzymes  Fermentas, St. Leon-Rot 
 
2.1.3 Antibodies 
Antibody Source 
Mouse anti-histidine tag antibody Qiagen, Hilden 
Anti-mouse antibody  Pierce, Rockford 
Anti-rabbit antibody Pierce, Rockford 
Anti-GFP antibody Roche, Mannheim 
Rabbit-anti-hPrx-2 Axxora.com 
Anti-rabbit antibody conjugated to Cy3  Dr. J. Przyborski, Marburg University 
Anti-mouse antibody conjugated to Cy5 Dr. J. Przyborski, Marburg University 
 
2.1.4 Antibiotics 
Antibiotic Source Stock 
concentration 
Working 
concentration 
Carbenicillin Roth, Karlsruhe 50 mg/ml in 50% 
ethanol 
100 µg/ml 
Kanamycin Roth, Karlsruhe 25 mg/ml in water 50 µg/ml 
Gentamycin 
sulphate 
Gibco, Karlsruhe 50 mg/ml 22 µg/ml 
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2.1.5 Kits 
Kit Source 
Bradford kit Biorad, München 
QIA prep spin mini prep kit Qiagen, Hilden 
QIA quick PCR purification kit Qiagen, Hilden 
Western blot chemiluminescence reagent Perkin Elmer, Boston, U.S.A. 
 
2.1.6 Protease Inhibitors 
Inhibitor Source Stock solution Working 
concentration 
Cystatin Roth, 
Karlsruhe 
40 µM in US 
buffer 
10 µl /10 ml US 
buffer 
Pepstatin A Sigma, 
Steinheim 
0.3 mM in DMSO 5 µl /10 ml US 
buffer 
Phenylmethylsulphonylfluoride 
(PMSF)  
Sigma, 
Steinheim 
100 mM in 
ethanol 
10 µl /10 ml US 
buffer 
Protease Inhibitor Cocktail 
Tablets 
Roche, 
Mannheim 
100 mM in 
phosphate buffer, 
pH 7.0 
1 tablet in 50 ml 
 
2.1.7 Antimalarial drugs and inhibitors 
Drug / inhibitor Source 
Amodiaquine  Sigma, Steinheim 
Artemisinin  Sigma, Steinheim 
Artemether Sigma, Steinheim 
Artesunate Sigma, Steinheim 
Brefeldin A Sigma, Steinheim 
L-Buthionine sulphoximine Sigma, Steinheim 
Chloroquine  Sigma, Steinheim 
Cytochalasin D Merck, Darmstadt 
Dynasore Sigma, Steinheim 
Jasplankinolide Sigma, Steinheim 
Mefloquine Roche, Mannheim 
Methylene blue  Roth, Karlsruhe 
Monensin sodium salt Sigma, Steinheim 
Latrunculin A Merck, Darmstadt 
Paraquat Sigma, Steinheim 
Pyrimethamine  Sigma, Steinheim 
Pyocyanin Cayman Chemical, USA 
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2.1.8 Plasmodium falciparum strains 
P. falciparum strain Origin Source 
3D7 (Chloroquine-sensitive) Netherlands AG Prof. Lanzer, 
Heidelberg University 
Dd2 (Chloroquine-resistant) 
 
Indochina AG Prof. Lanzer, 
Heidelberg University  
 
2.1.9 Escherichia coli cells 
E. coli strain Genotype Source 
XL1-Blue 
 
recA1, endA1, gyrA96, thi-1, 
hsd-r17,supE44, relA1, lac, 
[F' pro AB, laclqZ M15, 
Tn10, (Tetr)] 
Stratagene, LaJolla, USA 
M15 [pREP4] 
 
nalS, StrS, rifS, KmR, lac -, 
ara -, gal -, mtl -,F -, recA +, 
uvr + 
Qiagen, Hilden 
 
2.1.10 Plasmids 
Plasmids Antibiotic resistance Source 
pQE 30 Carbenicillin Qiagen, Hilden 
pREP Kanamycin Qiagen, Hilden 
pSK Carbenicillin Stratagen 
pARL-1a+[hGrx1-roGFP2] WR99210* AG Prof. Meyer, Bonn 
University  
*Antifolate selection agent against human dihydrofolate reductase (dhfr) resistance gene 
provided by Jacobus Pharmaceuticals, Princeton, NJ.  
 
2.1.11 Medium for E. coli culture 
Medium Composition 
Luria-Bertani (LB) 5 g/l Trypton, 10 g/l yeast extract, 5 g/l NaCl 
2 x YT 16 g/l Trypton, 10 g/l yeast extract, 5 g/l NaCl 
 
2.1.12 Solutions and buffers 
2.1.12.1 DNA agarose gel electrophoresis 
Buffer Composition 
10 x TBE 1 M Tris, 1 M boric acid, 20 mM EDTA, pH 8.0 with acetic acid 
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2.1.12.2 SDS-polyacrylamide gel electrophoresis buffers and solutions 
Buffer  Composition 
Sample buffer 62.5 mM Tris-HCl, 25% glycerin, 2% SDS, 0.01% bromophenol 
blue, 5% mercaptoethanol 
Electrophoresis buffer 1.5 M Tris-HCl pH 8.8 
Coomassie staining 
solution 
0.5% Coomassie brillant blue R250, 10% acetic acid, 30% 2-
propanol 
Coomassie destaining 
solution 
10% acetic acid, 40% methanol 
 
2.1.12.3 Western blot analysis  
Buffer / solution Composition 
Anode buffer I 300 mM Tris (36.3 g/1000 ml ddH2O) 
Anode buffer II 25 mM Tris (3.03 g/1000 ml ddH2O) 
Cathode buffer 40 mM 6-aminohexanoic acid (2.6 g/500 ml ddH2O) 
TBS buffer 10 mM Tris, 155 mM NaCl, pH 8.0 with HCl 
TBST buffer 0.05% Tween 20 make up to 1,000 ml with TBS buffer 
Blocking buffer 5% Milk powder in TBST buffer (1 g/20 ml TBST) 
Ponceau staining 
solution 
1% Ponceau S, 1% acetic acid 
Ponceau destaining 
solution 
1% Acetic acid 
Luminol 1.25 mM luminol, 0.0093% H2O2, 0.1 M Tris HCl pH 8.6 
(10 mg/40 ml, in 0.1 M Tris HCl pH 8.6 plus 12.4 µl of 30% H2O2 
store in the dark at 4ºC) 
 
2.1.12.4 Cell culture buffers 
Buffer Composition 
Saponin lysis buffer 0.15% saponin, 10 mM NaH2PO4, 10 mM Na2HPO4, 145 mM 
NaCl, 3 mM KCl, pH 7.2 with protease inhibitor cocktail set 
Freezing medium 28% glycerol, 3% sorbitol, 0.65% NaCl 
Ringer solution 122.5 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 0.8 mM MgCl2, 11 
mM D-glucose, 25 mM Hepes,1 mM NaH2PO4, pH 7.4 
Cytomix 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM 
K2HPO4/KH2PO4, 25 mM Hepes pH 7.6 
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2.1.13 Primers 
 Primer   Nucleotide sequence 
hPrx2 C51s 5’-TTCACTTTTGTGAGCCCCACCGAGAT-3‘ 
hPrx2 C51as 5’-ATCTCGGTGGGGCTCACAAAAGTGAA-3‘ 
hPrx2 C172s 5’AGCCAGCGGACTAACTTCCCCAT-3‘ 
hPrx2 C172as 5’ATGGGGAAGTTAGTCCCGCGCTGGCT-3‘ 
hPrx2 Clats 5’-GGCAAGGGTGTCCTTCGCCA-3‘ 
hPrx2 Clatas 5’-GCCCCTGTAGGCAATGCCCT-3‘ 
hPrx2 SISs 5’-CACGGAGCGTCCCACAGGCA-3‘ 
hPrx2 SISas 5’- CAGGCCTTCCAGTACACAGAC-3‘ 
OhPrx2 N 5’- GCGCGGATCCGCCTCC GGTA ACGCGCGCATC- 3‘ 
OhPrx2 N15 5’- GCGCGGATCCTTCAAGGCCACAGCGGTGG- 3‘ 
OhPrx2 K177as 5’- CGCGAAGCTTCTACTTCCAGCCAGCGGGACAA- 3‘ 
OhPrx2 H168as 5’- CGCGAAGCTTCTAATGCTCGTCTGTGTACTGGAA-3‘ 
OhPrx2 C 5’- CGCGAAGCTTCTAATTGTGTTTGGAGAAATATTCC- 3‘ 
       The BamH1 (GGATCC) and HindIII (AAGCTT) restriction sites are underlined 
 
2.1.14 Equipment 
Equipment Source 
ÄKTA/Unicorn- FPLC system Amershan Pharmacia Biotech 
Analytical balance Scaltec Instruments, Göttingen 
Beckmann spectrophotometer DU® 650 Beckman, München 
Biophotometer Eppendorf, Hamburg 
Confocal microscope TCS SP5 Leica, Wetzlar 
Hitachi spectrophotometer U-2001 Hitachi Ltd, Tokyo 
Infinite M200 multiplate reader Tecan, Männedorf 
Incubator shaker Thermo Life Sciences, Egelsbach 
Gene pulser electroporator with capacitance 
extender 
Bio-Rad, München 
Megafuge 1.0 R Heraus Instruments, Hanau 
Mini-spin table centrifuge Eppendorf, Hamburg 
Microscope axiostar Zeiss, Jena 
OptimaTM TLX ultracentrifuge Beckman, München 
PCR – normal and – gradient cyclers Eppendorf, Hamburg 
pH-meter Beckman, München 
Sonicator Bandelin Electronics, Berlin 
Sorvall centrifuge RC5C Du Pont Company, Wilmington 
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2.2 METHODS 
2.2.1 Cell culture methods 
 
2.2.1.1 P. falciparum cell culture 
The 3D7 and Dd2 strains of P. falciparum were cultured according to Trager and 
Jensen (1976) with slight modifications. The strains were propagated in RBC (A+) in 
complete medium (RPMI 1640 medium supplemented with 0.5% Albumax, 9 mM glucose, 
0.2 mM hypoxanthine, 2.1 mM L-glutamine, and 22 µg/ml gentamycin) at 3.3% haematocrit 
and at 37°C in a gaseous mixture consisting of 3% O2, 3% CO2 and 95% N2. On a daily basis, 
parasite growth was monitored by use of Giemsa-stained thin blood films (10% Giemsa, 20 
min). 
 
2.2.1.2 Synchronisation 
Synchronisation of P. falciparum parasites was carried out with 5% (w/v) sorbitol as 
described (Lambros and Vanderberg, 1979). Briefly, a cell culture (5% hematocrit, 10 ml) 
with predominantly ring stages was centrifuged (2100 rpm, 3 min) to obtain a pellet of 500 µl 
of parasitised RBC. Then the pellet was re-suspended in 5 ml of 5% (w/v) sterile sorbitol (pre-
warmed to 37°C) and incubated for 10 min at room temperature. The parasites were then 
centrifuged (2,100 rpm for 3 min at room temperature) to spin down the parasitised RBC. The 
sorbitol was then aspirated and the pellet washed twice by re-suspending it in complete 
medium, after which the parasites were returned to culture. The procedure was repeated after 
4 h to attain a more synchronised culture. 
 
2.2.1.3 Cryopreservation of P. falciparum strains 
P. falciparum strains were frozen and stored in liquid nitrogen as described (Trager 
and Jensen, 1976) with minor modifications. Briefly, a ring stage culture (5-8% parasitaemia, 
5% haematocrit) was centrifuged (800 x g, 5 min) to pellet the cells, and the supernatant was 
aspirated. The pellet (~500 µl) was mixed with 500 µl of freezing medium (28% glycerol, 3% 
sorbitol, 0.65% NaCl) and transferred into a cryovial (Nunc). The vial was frozen at -70 ºC 
for 24 h and transferred to liquid nitrogen for long-term storage. 
 
2.2.1.4 Thawing of cryopreserved P. falciparum strains 
The cryopreserved P. falciparum strains were thawed as described (Trager and Jensen, 
1976) with minor modifications. Briefly, the cryovial was removed from its storage in liquid 
nitrogen and thawed (37°C, 2 min). Next, the parasites (~1 ml) were transferred into a 50 ml 
tube, and 100 µl of 12% NaCl was slowly added while the tube was shaken gently. The tube 
was left to stand for 5 min. Then, 10 ml of 1.6% NaCl was added slowly, drop-wise while 
shaking the tube and centrifuged (800 x g, 5 min). The supernatant was aspirated and 10 ml of 
complete RPMI 1640 medium was added slowly and drop-wise while shaking the tube. The 
supernatant was again aspirated, and the pellet was washed two times with complete RPMI 
1640 medium. The pellet volume was measured and if necessary additional RBCs were added 
to the final pellet volume of 500 µl. Finally, a culture (haematocrit 5%, 10 ml) was transferred 
to an incubator at 37°C with a gaseous mixture consisting of 3% O2, 3% CO2 and 95% N2. 
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2.2.1.5 Purification of trophozoite stage P. falciparum by magnetic separation 
Trophozoite stages of P. falciparum were purified and concentrated by magnetic 
separation as described (Ribuat et al., 2008). Accordingly, magnetic separation removes ring 
stages and non-infected RBCs that do not contain haemozoin. In contrast, trophozoites, 
schizonts, and gametocytes that have haemozion bind to the column. Initially the 
QuadroMACSTM separation system was attached to a multi-stand. Next, an LS column was 
placed in a QuadroMACSTM separation system (Miltenyi Biotec, Germany) and connected to 
a 26 G flow resistor through a 3-way stopcock. LS columns have a capacity of 1 x 108 
magnetically labelled cells from 2 x 109 total cells. Prior to purification, the LS columns were 
filled with warmed (37°C), complete RPMI 1640 medium, and the flow rate was adjusted. 
Next, a culture of P. falciparum-infected erythrocytes was harvested by centrifugation (2,100 
rpm, 3 minutes) and re-suspended to 5% haematocrit. Subsequently, 1 ml of the cell 
suspension was deposited on the top of the column and then washed with 2 ml of pre-warmed 
(37°C) culture medium until the flow through the medium was apparently free of red blood 
cells. This step was repeated until column capacity for magnetically labelled cells was 
reached. After this, the column was removed from the magnetic support, a further 4 ml of 
culture medium was added, and the trophozoites (enriched to 80-90%) were eluated. A similar 
procedure was followed for the purification and concentration of P. falciparum gametocytes 
except that prior to separation the cell culture was treated with 5% sorbitol as described (Saul 
et al., 1990). 
 
2.2.1.6 Determination of parasite counts using the Neubauer haemocytometer 
Following MACs (Miltenyi Biotec, Germany), trophozoite stages of P. falciparum 
parasites were counted using the improved Neubauer haemocytometer. Briefly, the parasite 
pellet was re-suspended in an appropriate volume of complete RPMI medium (usually 10 ml) 
and 10 µl were placed on the improved Neubauer haemocytometer.  
 
 
Figure 2.1: Counting of parasites/ml using the improved Neubauer haemocytometer 
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Using the 10x objective of the light microscope the central large square (number 3) with 25 
squares was detected. Next the cells in one square (of the 25 squares) were counted under the 
light microscope using the ×40 objective. Subsequently, the average of 5 squares was used for 
calculation of the number of parasites/ml. The central square (Figure 2.1) of the grid is ruled 
into 25 groups of 16 smaller squares (area of each smaller square is 0.0025 mm2) with each 
group separated by triple lines, the middle one of which is the boundary. The area of the 
central square is: 25 x 16 x 0.0025 = 1 mm2 and the volume is: 1 mm2 x 0.1 mm = 0.1mm3 or 
0.1 µl (1 ml = 1000 mm3). The number of parasites counted per ml = number of cells counted 
per square mm x dilution x 10,000. 
 
2.2.1.7 In vitro P. falciparum drug susceptibility assays 
The [3H]-hypoxanthine incorporation assay (Desjardins et al., 1979) was used to 
determine the susceptibility of the parasites to inhibitors or antimalarial drugs. In order to 
investigate the effect oxidants and antimalarial drugs on EGSH, their IC50s on 3D7 and Dd2 
were first determined. Stock solutions of MB, CQ, PYO, BSO, PQT, and SNP were dissolved 
in sterile ddH2O, while AQ, QN, MQ, ART, ATM, and ATS were dissolved in DMSO. 
Dilutions were prepared in hypoxanthine-free medium. Serial double dilutions (100 µl) of the 
compounds were carried out in 96 well microtitre plates (Figure 2.2). Synchronised ring-stage 
parasites in hypoxanthine-free complete medium (100 µl) were added to each well to a 
volume of 200 µl (0.5% parasitaemia and 2% haematocrit). The negative control wells 
contained only Normal RBC (NRBC), while the positive control wells contained parasitised 
RBC (PRBC). 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Positive control Negative control 
B 
C 
D 
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F 
G 
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Figure 2.2: Plate diagram for the [3H]-hypoxanthine incorporation assay. 
Arrangement of compounds on a 96 well microtitre well plate. A1-A7: Parasitised red blood cells 
(positive control, PRBC), A9-A12: Red blood cells (negative control, NRBC), B(1-12) to H(1-12) 
serial drug dilutions (1:1) of compounds in duplicate. 
 
After a 48-h incubation period at 37°C in a gaseous mixture (3%O2, 3% CO2, and 95% N2), 
50 µl (final concentration of 0.5 µCi/well) of [3H]-hypoxanthine was added per well, and the 
plate was further incubated for 24 h. Following incubation (total of 72 h), the plates were 
frozen at -80°C for at least 1 h. Plates were then thawed, each well was harvested on a glass 
fibre filter (Perkin-Elmer, Rodgau-Jügesheim, Germany), dried, and radioactivity in counts 
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per minute (cpm) from each well was measured and considered to be proportional to the 
respective growth of P. falciparum in the well in comparison to NRBC and PRBC. The 50% 
inhibitory concentrations (IC50) were determined by curve-fitting the percentage growth 
inhibition (in relation to controls) against log drug concentration with a variable-slope 
sigmoidal function (Prism 4.0 GraphPad Software, San Diego, CA). A similar procedure was 
used to determine the IC50 of compounds which were investigated to inhibit the uptake of 
hPrx2 into P. falciparum. To inhibit the uptake of hPrx2 into P. falciparum, stock solutions of 
CTD (in DMSO), JAS (in DMSO), MNS (in ethanol), BFA (in methanol), NH4Cl (in ddH2O), 
NaN3 (in ddH2O), and DYN (in DMSO) in respective solvents were prepared (Table 2.2). 
 
2.2.2 hGrx1-roGFP2 methods 
 
2.2.2.1 Preparation of hGrx1-roGFP2 plasmid DNA 
The pARL-1a+[hGrx1-roGFP2] plasmid (Appendix 4) was kindly provided by Prof. A 
Meyer, Bonn University. The plasmid DNA (pARL-1a+ hGrx1-roGFP2) for transfection of P. 
falciparum was prepared according to the plasmid Maxiprep kit (Qiagen, Hilden) following 
the manufacturer’s instructions. Transformation of the hGrx1-roGFP2 plasmid into the XL 
Blue E. coli cells was carried out as described below. To prepare Maxiprep Plasmid DNA a 
250 ml LB medium (with 100 µg/ml carbenicillin) was inoculated with 10 ml of starter 
culture and grown overnight (at 37°C for 12-16 h with vigorous shaking). The culture was 
harvested by centrifugation (6,000 x g for 20 min at 4°C) and completely suspended in 10 ml 
of Buffer P1 (RNAse A and Lysosensor blue had been added). Then 10 ml of Buffer P2 were 
added and mixed gently but thoroughly by inverting 4-6 times and then incubated (room 
temperature, 5 min). Following incubation, 10 ml of chilled Buffer P3 were added, mixed 
immediately but gently by inverting 4-6 times, and transferred to a QIAfilter tip and incubated 
for 5 min. The supernatant was filtered into a pre-equilibrated QIAGEN-tip (by applying 10 
ml of Buffer QBT), and the column was allowed to empty by gravity flow. The QIAGEN-tip 
was then washed with Buffer QC (2 x 30 ml) and the DNA eluted with Buffer QF (15 ml). 
The DNA was precipitated by adding 10.5 ml room-temperature isopropanol to the eluted 
DNA. The precipitated DNA mixture was filtered through a smaller tip and then washed twice 
with 70% ethanol, before being eluted with 1 ml of double distilled water. This DNA solution 
was re-precipitated with sodium acetate (3% with ethanol) for 1 h at -20°C. Following 
centrifugation (1,300 rpm, 15 min), the DNA pellet was washed twice with 70% ethanol, air 
dried, and dissolved in sterile TE Buffer (50-100 µl). 
 
2.2.2.2 Transfection of P. falciparum 
Briefly, a 5 ml culture (ring stage 8-10 h, 5-8% parasitaemia, 5% haematocrit) was 
centrifuged (1,500 x g, 5 min), and the supernatant was aspirated. The parasite pellet (250 µl) 
was mixed with 150 µg of purified plasmid (pARL-1a+[hGrx1-roGFP2]) in 400 µl of cytomix 
and then electroporated at 0.310 kV and 950 µF (Gene pulser, Bio-Rad) as described (Crabb 
et al., 2004). The resulting time constant was between 7 and 12 s. The electroplated sample 
was returned to a 10 ml culture with 5% final haematocrit. To select for transfectants, six 
hours post transfection, 2 nM WR99210 was added to the culture and later increased, usually 
after 3-4 weeks [after appearance of 3D7 (3D7hGrx1-roGFP2) and Dd2 (Dd2hGrx1-roGFP2 ) strains 
expressing hGrx1-roGFP2], to 5 nM (Fidock and Wellems, 1997). The complete RPMI 
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medium (with 2 nM WR99210) was changed every day and 100 µl of fresh RBC were added 
every week.  
 
2.2.2.3 Determination of the glutathione redox potential in P. falciparum using hGrx1-
roGFP2 
To determine the effect of drugs on the EGSH in P. falciparum, short term (time series / 
course for 5 or 10 min), 4 and 24 h incubation experiments were carried out. For the short 
term experiments, the classical oxidants diamide, H2O2, 3-morpholinosydnonimine 
hydrochloride (SIN1), the reducing agent DTT and antimalarial drugs (Table 2.1) were added 
to magnetically enriched trophozoite stage parasites (26-30 h) of the 3D7hGrx1-roGFP2 and 
Dd2hGrx1-roGFP2 strains. 
 
Table 2.1: Redox agents and antimalarial drugs tested for their effect on the glutathione 
redox potential. 
 
Drugs Abbreviation IC50 for 3D7 IC50 for Dd2 
Inhibitors of glutathione 
synthesis  
   
Methylene blue  MB* 3.24 nM 5.24 nM 
Pyocyanin  PYO** 58 nM 194.0 nM 
L-buthionine sulphoximine BSO 26.3 µM 58 µM 
Menadione MNA NA NA 
ROS inducers    
Diamide DMD NA NA 
Hydrogen peroxide H2O2 NA NA 
Paraquat PQT 45 µM 21.0 µM 
RNS inducers    
Sodium nitroprusside SNP 6 µM 7.4 µM 
3-Morpholinosydnonimine 
hydrochloride 
SIN1 NA NA 
Quinoline drugs    
Chloroquine CQ* 8.6 nM 90.2 nM 
Amodiaquine AQ* 18.6 nM 7.2 nM 
Quinine QN* 210 nM 136 nM 
Mefloquine MQ 8 nM 19.5 nM 
Artemisinin derivatives    
Artemisinin ART* 17.3 nM 20.4 nM 
Artesunate  ATS* 4.35 nM 5.2 nM 
Artemether ATM* 5.8 nM 8.4 nM 
NA- Not applicable        * Akoachere et al. (2005)    ** Kasozi et al. (2011) 
 
The parasites were monitored for 4 or 9 min after 1 min of basal measurements (10 or 20 s / 
image). For 4 h incubation experiments, after enrichment of 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 
trophozoite stage parasites (26-30 h), the parasites were allowed to recover for 2 h under 
standard culture conditions and then treated with antimalarial drugs at concentrations ranging 
from ~ 1 x IC50 to 100 x IC50 for 4 h. Each drug concentration had 5 ml with ~ 5.0 x 103 
trophozoites/µl. For 24 h experiments, a 10 ml culture (2.5% haematocrit, 3-4% parasitaemia) 
of ring stage 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 strains were treated with antimalarial drugs at 
4 x IC50. Following incubation, cultures were treated with 20 mM N-ethylmaleimide (NEM) 
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for 30 min and then enriched by magnetic separation. Additionally, all experiments included a 
negative control (no drug treatment) and a positive control (treated with 1 mM diamide), and 
all measurements were done immediately after incubation. All experiments were carried out 
within 3 and 4 weeks for Dd2hGrx1-roGFP2 and 3D7hGrx1-roGFP2  parasites, respectively. 
 
2.2.2.4 Confocal live cell imaging of hGrx1-roGFP2 in P. falciparum 
The 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 trophozoite stage parasites (26-30 h) were 
washed three times with pre-warmed (37 ºC) ringer solution (122.5 mM NaCl, 5.4 mM KCl, 
1.2 mM CaCl2, 0.8 mM MgCl2, 11 mM D-glucose, 25 mM Hepes, 1 mM NaH2PO4, pH 7.4; 
Rohrbach et al., 2005) and seeded on poly-L-lysin-coated µ-slides VI (Ibidi) (Figure 2.3). A 
Leica confocal system TCS SP5 inverted microscope equipped the objective (HCX PL APO 
63.0x1.30 GLYC 37 °C UV) and 37oC temperature chamber was used. The argon laser power 
was set to 20%. The smart gain and smart offset were 950.0 V and -0.9% respectively. 
Scanning was performed at 400 Hz frequency. For time series, images acquired every 10 s or 
20 s for 5 or 10 min respectively in a frame size of 512 x 512. By a sequential scan, the 405 
nm (15% laser intensity) and 488 nm (2% laser intensity) were excited and emissions in the 
green channel (500–530 nm) were detected. Files were saved as Leica lif files and also 
exported as tiff files with and without overlay. 
 
 
Figure 2.3: Confocal imaging of glutathione redox potential. (A) Following 4 and 24 h incubation 
with antimalarial drugs or redox agents, P. falciparum parasites were washed with Ringer solution and 
seeded into poly-L-lysin-coated µ-slides VI (Ibidi), then confocal imaging was carried out. For time 
course experiments, cells (A) were seeded into poly-L-lysin-coated µ-slides VI (Ibidi), allowed to 
adhere for 30 min, and then washed with Ringer solution (B). Series were started with images taken 
every 10 s or 20 s, and after 1 min of basal measurements, redox agents or antimalarial drugs were 
added (C). Adapted and modified from Markvicheva et al. (2011). 
 
2.2.2.5 Image analysis 
A redox ratio analysis suite (kindly provided by Prof. A. Meyer, Bonn University), 
Image J and the Leica software were used to analyse the data. The region of interest was a 
well defined cytosol compartment and only parasites with intact food vacuoles were analysed. 
It has been previously reported that P. falciparum is sensitive to photo toxicity accompanied 
by rupture of the food vacuole (Wissing et al., 2002). Image analysis using the Image J 
software (www.macbiophotonics.ca) was carried out as described (Morgan et al., 2011). 
Briefly, to export images into Image J software, a folder of overlay tiff images was dragged 
and dropped onto the Image J software (Click ‘Yes’ to open as a stack). First, the channels 
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were separated (Image → color→ split channels. Close the blue channel). Then the 405 nm 
(green) and 488 nm (red) stacks were converted to 32 bit (Image → type → 32 bit). Next, the 
threshold for both 405 nm and 488 nm channels was adjusted (Image →Adjust →threshold. 
Check dark background, click ‘apply’. Set background pixels to NaN (not a number) click 
‘OK’ and then ‘Yes’ to process all images). To determine the ratio (405/488 nm), the 405 nm 
stack was divided (operation) by 488 nm stack. (Process→ image calculator → 405 nm image 
(green) divide by 488 nm (red). Click ‘OK’ and then ‘Yes’ to process all images). The Image 
J look up table ‘Fire’ was used for creating false color ratio images. To obtain the ratio (405/ 
488 nm) (Image → stacks → Plot Z-axis profile) was used and then the excel data file was 
saved. To color the resultant gray ratio image with ‘Fire’, (Image→ Lookup table → Fire) 
was used. The calibration bar was inserted using (analyze → tools → calibration bar). 
Following conversion to RGB color (Image →type →RGB color), tiff mages were saved as 
sequence (File → save as → image sequence). Indicate the number of images and click ‘OK’ 
to save the tiff images. The graphs were plotted using GraphPad Prism 4 software (San Diego 
CA USA) 
 
2.2.2.6 Computation of basal redox potentials 
The basal intracellular EGSH were calculated from fluorescence intensity measurements 
as described (Gutscher et al., 2008; Schwarzlander et al., 2008). To calibrate the experiment, 
the minimal (100% sensor reduction) and maximal (100% sensor oxidation) fluorescence 
ratios were determined by reduction with 10 mM DTT and oxidation with 1 mM diamide 
respectively. The degree of oxidation of roGFP2 depends on EGSH. The corresponding degree 
of sensor oxidation (OxDroGFP2) was calculated from this equation (1). 
 
 
Where 
R: refers to the basal ratio of excitation at 405/488 nm. 
  Rred : refers to ratio of completely reduced roGFP2 with 10 mM DTT. 
Rox : refers to the ratio of completely oxidized roGFP2 with 1 mM diamide. 
I 488min: refers to the fluorescence intensity measured with excitation at 488 nm for 
fully oxidized roGFP2. 
I 488max: refers to the fluorescence intensity measured with excitation at 488 nm for 
fully reduced roGFP2. 
Then the intracellular sensor redox potential (EroGFP2) was calculated from OxDroGFP2 using the 
Nernst equation. 
 
Where 
        R: is the gas constant (8.315 J K-1 mol-1). 
T: is the absolute temperature (298.15 K). 
F: is the Faraday constant (96,485 C mol-1). 
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2: is the number of transferred electrons. 
E0’ roGFP2 = -280 mV (Hanson et al., 2004) is the average consensus midpoint redox 
potential of roGFP2. 
Yet roGFP2 (sensor) and the glutathione redox couple (GSH/GSSG) are in equilibrium, thus  
EGSH = EroGFP2. Glutaredoxin (Grx1) mediates the exchange of electrons between roGFP2 and 
glutathione, resulting in redox equilibrium. Hence this redox equilibrium is described by the 
equation  
 
Where E0GSH is the standard redox potential of glutathione at pH 7, which is -240 mV (Schafer 
and Buettner 2001). Thus the sensor reports the intracellular EGSH. 
 
2.2.2.7 Heterologous overexpression of hGrx1-roGFP2 protein 
The recombinant hGrx1-roGFP2 protein was overexpressed as described (Gutscher et 
al., 2008) with modifications. Briefly, the E. coli M15 strain (Qiagen) was transformed with 
pQE60[hGrx1-roGFP2] plasmid (kindly provided by Prof. A. Meyer, Bonn University). The 
hGrx1-roGFP2 protein was expressed in 2YT medium and purified via hexahistidine affinity 
chromatography, concentrated and desalted (Centri-spin 20 columns, Princeton Separations 
Inc.) and stored at -80°C. Briefly, a pre-culture of LB medium (3 ml containing 100 µg/ml 
carbenicillin and 50 µg/ml kanamycin) was inoculated with a colony and grown for 8 h at 
37°C with vigorous shaking. Then 100 ml of 2YT medium (containing 100 µg/ml 
carbenicillin and 50 µg/ml kanamycin) were inoculated with 3 ml culture and grown at 37°C 
overnight. The overnight culture (~20-30 ml) was added to 1,000 ml 2YT medium (containing 
100 µg/ml carbenicillin and 50 µg/ml kanamycin) up to an OD = 0.1 and grown until OD = 
0.6 before induction with 1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG). Following 
induction, the culture was grown overnight at 25°C, and the cells were harvested by 
centrifugation (8,000 g for 15 min at 4°C). Then the pellet was re-suspended in 50 mM 
sodium phosphate, 300 mM NaCl, pH 8.0 buffer (1 g pellet/4 ml buffer) and mixed with 
protease inhibitors namely 150 nM pepstatin, 40 nM cystatin and 100 µM PMSF and then 
stored at -20°C. The recombinant hGrx1-roGFP2 protein was purified as described for hPrx2 
mutants below. 
 
2.2.2.8 In vitro interaction of antimalarial drugs with the hGrx1-roGFP2 protein 
 Stock solutions of CQ, MB, BSO, PQT, GSSG, diamide, SIN1 and SNP were 
dissolved in distilled H2O while AQ, QN, MQ, ART, ATS, and ATM were dissolved in 
DSMO. MNA and PYO were dissolved in methanol and ethanol respectively. T-butyl 
hydroperoxide (THBP), H2O2 and all drugs were diluted with a standard reaction buffer (100 
mM potassium phosphate, 1 mM EDTA, pH 7.0, N2 saturated) and used immediately. 
Initially, the reaction buffer (100 ml) was degassed for 1 h and then saturated with N2 for 2 h 
on ice. To calibrate the assay, all experiments included 1 mM diamide or 10 mM H2O2 and 20 
mM DTT as controls to achieve maximum oxidation and reduction respectively. The purified 
hGrx1-roGFP2 protein was reduced with 20 mM DTT for 45 min on ice, desalinated (Zeba 
Desalt spin columns, Pierce), and diluted in reaction buffer to a final concentration of 1.25 
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µM. The 5 fold drug dilution (50 µl) was mixed with 200 µl of 1.25 µM hGrx1-roGFP2 in 96 
well plate (black, µClear TC Greiner). The emission of hGrx1-roGFP2 (505–515 nm) after 
excitation at 405 and 488 nm in a plate reader (M200, Tecan) was measured with optimal read 
setting. Then the ratio of the emission (405/488 nm) was calculated and plotted it against time 
or concentration of antimalarial drugs. An excitation spectrum was scanned from 340-512 nm 
with emission at 530-540 nm. 
 
2.2.3 hPrx2 methods 
 
2.2.3.1 Vector construction for hPrx2 mutants 
 
2.2.3.1.1 Site-directed mutagenesis of hPrx2 
Site-directed mutagenesis as described by the QuikChange® site-directed mutagenesis 
kit (Stratagene, La Jolla, CA) was carried out with modifications. This method was used to 
mutate the active site cysteine (C51) to serine (S51), or the resolving cysteine (C172) to a 
serine (S172) generating the pQE30[hPrx2(C51S)] and pQE30[hPrx2(C172S)] plasmids, 
respectively, using the pQE30[hPrx2(full length)] as template (Figure 2.4). The forward and 
reverse primers were phosphorylated at the 5’ end. The forward primer and the reverse primer 
used to construct pQE30[hPrx2(C51S)] were hPrx2C51s and hPrx2C51as respectively. The 
forward primer and the reverse primer used for pQE30[hPrx2(C172S)] were hPrx2C172s and 
hPrx2C172as respectively. The nucleotide sequences of the primers are in section 2.1.13. 
 
 
 
Figure 2.4: Site-directed mutagenesis of hPrx2. The active site (C51) and resolving (C172) cysteine 
were mutated to serine residues using overlapping primers. To mutate C51 to S51 a pair of forward 
(hPrx2C51s) and reverse (hPrx2C51 as) primers was used to amplify and mutate the hPrx2 full-length 
gene cloned into the pQE30 vector. Similarly, to mutate C172 to S172 a pair of forward (hPrx2C172s) 
and reverse (hPrx2C172 as) primers was used. 
 
To generate the double mutant pQE30[hPrx2(C51/172S)] plasmid, the pQE30[hPrx2(C51S)] 
plasmid was used as a template with the forward primer hPrx2C172s and reverse primer 
hPrx2C172as. The reaction conditions were as follows. Following PCR, the template was 
digested with Dpn1 restriction enzyme, ligated, and transformed as described below. 
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PCR mixture  PCR programme 
 Volume (µl) Programme Time (min) 
Template 1 (50 ng) Initial denaturation 95°C for 5 min 
100 µM forward primer 1 Denaturation 95°C for 1 min 
100 µM reverse primer 1 Annealing 52°C for 1 min 
2 mM dNTPs 5 Extension 68°C for 8 min 
10 x Pfu buffer 5 Cycles 18 cycles 
DMSO 2.5 Final extension 68°C for 15 min 
Pfu polymerase 1   
ddH2O 33.5   
Total 50    
 
2.2.3.1.3  Dpn 1 digestion and ligation of hPrx2 mutants 
The pQE30[hPrx2] mutant PCR products were purified using the QIAquick PCR 
purification kit and the templates digested with Dpn1 and then purified again using the 
QIAquick PCR purification kit. The conditions for Dpn1 digestion (at 37°C for 3 h) and 
plasmid ligation were as follows. Following ligation, the plasmids were transformed into XL 
Blue E. coli cells as described below. 
 
Dpn 1 digestion* Ligation reaction** 
 Volume (µl)  Volume (µl) 
pQE30[hPrx2] mutant plasmid  30 pQE30[hPrx2] mutant plasmid  3.5 
10 x tango buffer 5 10 x T4 ligase buffer  3 
Dpn 1 (10 U/µl) 2.5 T4 ligase 3 
ddH2O 12.5 ddH2O 20.5 
Total  50  Total 30 
* At 37°C for 3 h.     ** At 4°C overnight 
 
Subsequently, a colony was inoculated into LB medium (3 ml containing 100 µg/ml 
carbenicillin) and grown overnight (~16 h) with constant shaking at 37°C. Next, 
pQE30[hPrx2] mutant plasmid DNA (~100 µg/ml) was prepared using the Minprep plasmid 
kit (Qiagen Hilden) following the manufacturer’s instructions. To confirm the presence of the 
mutation, the plasmid DNA was sequenced, and sequences were compared with those in the 
databases. 
 
2.2.3.2.4 Purification of plasmid DNA  
For cloning purposes, plasmid DNA was prepared by using the QIAprep spin minprep 
kit (Qiagen Hilden) following the manufacturer’s instructions. Briefly, 1.5 ml of overnight 
culture (~16 h) was centrifuged (8,000 rpm, 3 min) to pellet the cells, and the supernatant was 
discarded. Next the pellet was re-suspended in 250 µl of buffer P1 (supplemented with Dnase 
1 and lysosensor blue) by pipetting up and down or vortexing. Then it was mixed with 250 µl 
of buffer P2 by inverting 4-6 times until the solution was homogenously blue. Next, 350 µl of 
buffer N3 was added and mixed 4-6 times until the solution was colourless again. Following 
centrifugation (13,000 rpm, 10 min) the supernatant was transferred to the QIAprep spin 
column and centrifuged (13,000 rpm, 1 min). The QIAprep spin column was washed by 
adding 500 µl of buffer PB and centrifuged (13,000 rpm, 1 min), and the flow-through was 
discarded. Furthermore, the QIAprep spin column was washed by adding 750 µl of buffer PE 
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and centrifuged (13,000 rpm, 1 min), and flow through was discarded. Following an 
additional centrifugation (13,000 rpm, 1 min) to remove residual buffer PE, the DNA was 
eluted by adding 50 µl of water to the centre of each QIAprep spin column then left to stand 
for 1 min and centrifuged for 1 min. 
 
2.2.3.2.5 Deletion mutagenesis of hPrx2 
Deletion mutagenesis (Williams et al., 2007) was used to delete internal sequences: 
the clathrin sequence (129 LFIID133) and the sorting and internalisation signal (154 VDEALRL 
159) to generate the pQE30[hPrx2(Clat129-133)] and pQE30[hPrx2(SIS154-159)] mutants, 
respectively, using pQE30[hPrx2(full length)] plasmid as a template. The nucleotide sequences of 
the primers are in section 2.1.13. The forward and reverse primers were phosphorylated at the 
5’ end. 
 
pQE30[hPrx2(Clat129-133)] 
 
pQE30[hPrx2(SIS154-159)] 
Figure 2.5: Deletion mutagenesis of hPrx2. 
To delete the clathrin sequence, a pair of forward (OhPrx2 Clats) and reverse (OhPrx2 Clatas) primers 
that start at the opposite ends of the desired area to be deleted were used to amplify all sequences 
except those to be deleted. Similarly, in order to delete the sorting and internalisation signal, a pair of 
forward (OhPrx2 Siss ) and reverse (OhPrx2 Sisas) primers that start at the opposite ends of the 
desired area to be deleted were used. 
 
The forward primer and the reverse primer used to construct pQE30[hPrx2(Clat129-133)] were 
hPrx2Clats and hPrx2Clatas respectively. The forward primer and the reverse primer used to 
construct pQE30[hPrx2(SIS154-159)] were hPrx2SISs and hPrx2SISas respectively. The reaction 
conditions were as follows. 
PCR mixture PCR programme 
 Volume (µl) Programme Time (min) 
Template 2 (50 ng) Initial denaturation  95°C for 5 min 
100 µM Forward primer  1 Denaturation 95°C for 1 min 
100 µM Reverse primer 1 Annealing 50°C for 1 min 
2 mM dNTPs 5 Extension 68°C for 8 min 
10x Pfu buffer 5 Cycles 18 cycles 
DMSO 5 Final extension 68°C for 15 min 
Pfu polymerase 1   
ddH2O 30   
Total 50    
 
Similarly, the pQE30[hPrx2] mutant PCR product was cleaned using the QIAquick PCR 
purification kit, and the template was digested with Dpn1 restriction enzyme and then purified 
again using the QIAquick PCR. The conditions for Dpn1 digestion (at 37°C for 3 h) and 
plasmid ligation were as described above. Following ligation, the plasmids were transformed 
LFIID 
 
VDEALRL 
 
OhPrx2 Clats 
OhPrx2 Clatas 
OhPrx2 SISas 
OhPrx2 SIS 
579 bp 
576 bp 
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into XL Blue E. coli cells as described below. Subsequently, a colony was inoculated into LB 
medium (3 ml containing 100 µg/ml carbenicillin) and grown overnight (~18 h) with constant 
shaking at 37°C. Then, plasmid DNA (~100 µg/ml) was prepared using the Mini plasmid kit 
(Qiagen Hilden) following the manufacturer’s instructions. Next, the plasmid DNA was 
digested with BamH1 and Hind III restriction enzymes in order to check for the deletion. In 
order to confirm the presence of the deletion, the plasmid DNA was sequenced, and the 
sequences were compared to those in the databases. 
 
2.2.3.2.4 Cloning of ∆N, ∆C and ∆NC terminal end deletion hPrx2 mutants 
The ∆N and ∆C terminal end deletion mutants of hPrx2 were generated by amplifying 
the flanking regions using the hPrx2 (full length) gene as the template (Figure 2.6) and 
cloning then into the BamH1 (underlined in forward primers) and Hind III (underlined in 
reverse primers) sites of the pQE30 vector (Appendix 6). 
 
 
pQE30[hPrx2(full-length)] 
 
pQE30[hPrx2∆N(15-198)] 
 
pQE30[hPrx2∆NC(1-177)] 
 
pQE30[hPrx2 ∆C(1-168)] 
 
pQE30[hPrx2∆NC(15-177)] 
 
pQE30[hPrx2∆NC(15-168)] 
 
Figure 2.6: Cloning of N- and C-terminal deletion mutants of hPrx2.Different pairs of forward 
(OhPrx2 and OhPrx2 N15) and reverse (OhPrx2H168as, OhPrx2K177as, OhPrx2C) primers were 
used to amplify flanking sequence fragments of hPrx2 full-length genes and were cloned into the 
pQE30 vector. 
 
The forward primers OhPrx2 N, OhPrx2 N15 and reverse primers OhPrx2 K 177as, OhPrx2 
H 168as, OhPrx2 C were used to generate the PCR products: hPrx2∆N(15-198) with 533 bp, 
hPrx2∆NC(15-177) with 487 bp, hPrx2∆N(15-168) with 460 bp, hPrx2∆C(1-177) with 530 bp and 
OhPrx2 N15 
OhPrx2 N15  
OhPrx2 H 168as 
OhPrx2 K177as 
OhPrx2 C  
C172 
 
C51 
 
530 bp 
533bp 
OhPrx2 N15  
OhPrx2 N 
OhPrx2 N 
503 bp 
OhPrx2 K177as 
OhPrx2 H 168as 
487 bp 
460 bp 
597 bp 
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hPrx2∆C(1-168) with 503 bp. The nucleotide sequences of the primers are in section 2.1.13. The 
PCR reaction conditions were as follows: 
 
PCR mixture The PCR programme 
 Volume (µl) Programme Time (min) 
Template 1 (10 ng)  Initial denaturation  94°C for 2 min 
100 µM forward primer 1 Denaturation 94°C for 30 seconds 
100 µM reverse primer 1 Annealing 58°C for 30 seconds 
2 mM dNTPs 5 Extension 72°C for 1 min 
10x Pfu buffer 5 Cycles 35 cycles 
Pfu polymerase 1 Final extension 72°C for 5 min 
ddH2O 36   
Total 50    
 
The PCR products were cleaned using the QIAquick PCR purification kit and digested with 
BamH1 and Hind III restriction enzymes and then purified again using the QIAquick PCR. 
The conditions for digestion (at 37°C for 1 h) and plasmid ligation were as follows. 
 
BamH1 and Hind III digestion Ligation reaction 
 Volume (µL)  Volume (µL) 
PCR product or pQE30 vector  15 pQE30 (digested) 2.2 
BamH1 Buffer 4 PCR product (3:1 ratio) 2.2 
BamH1 1 10x T4 ligase buffer  3 
Hind III 1.5 T4 ligase 3 
ddH2O 18.5 ddH2O 19.6 
Total  40  Total 30 
 
Following ligation, the plasmids were transformed into XL Blue E. coli cells as described 
below. Subsequently, a colony was inoculated into LB medium (3 ml containing 100 µg/ml 
carbenicillin) and grown overnight (~18 h) with constant shaking at 37°C. Next, plasmid 
DNA (~100 µg/ml) was prepared using the Min plasmid kit (Qiagen Hilden) following the 
manufacturer’s instructions. Next, the plasmid DNA was digested with BamH1 and Hind III 
restriction enzymes in order to check for the presence of the insert. To confirm the presence of 
the insert, the plasmid DNA was sequenced, and the sequences were compared to those in the 
databases. 
 
2.2.3.3 Over-expression of hPrx2 mutants 
2.2.3.3.1 Transformation of E. coli cells 
To 125 µl of competent E. coli cells (M15 cells or XL-1 blue cells), 5 µl of the 
pQE30[hPrx2] mutant plasmid was added, mixed thoroughly, and left to stand on ice for 30 
min. Then heat shock was carried out for 90 s at 42°C in a heat block, and the cells were then 
placed on ice again for 2 min. LB medium (400 µl) was added, and cells were incubated (1 h 
at 37°C). Following the incubation, cells were plated on LB agar plates containing the 
appropriate antibiotic. The plates were incubated overnight at 37°C, and colonies were 
observed the following day. 
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2.2.3.3.2 Heterologous overexpression of hPrx2 mutants  
The hPrx2 mutant proteins were expressed in E. coli M15 cells transformed with 
pQE30/ hPrx2 mutant plasmid. A pre-culture of LB medium (3 ml containing 100 µg/ml 
carbenicillin and 50 µg/ml kanamycin) was inoculated with a colony and grown for 8 h at 
37°C with vigorous shaking. For expression of hPrx2(C51S), hPrx2(C172S), hPrx2(C51S/C172S), 
hPrx2∆C(1-177) , and hPrx2∆C(1-168) mutant proteins, LB medium was used. Then 100 ml of LB 
culture (containing 100 µg/ml carbenicillin and 50 µg/ml kanamycin) were inoculated with 3 
ml culture and grown at 37°C overnight. The overnight culture (~ 20-30 ml ) was added to 
1,000 ml LB medium (containing 100 µg/ml carbenicillin and 50 µg/ml kanamycin) up to an 
OD = 0.1, and grown until an OD = 0.6 before induction with 1 mM IPTG. Following 
induction, the culture was grown for additional 4 h, and the cells were harvested by 
centrifugation (8,000 g for 15 min at 4°C). Then the pellet was re-suspended in 50 mM 
sodium phosphate, 300 mM NaCl, pH 8.0 buffer (1 g pellet/4 ml buffer) and mixed with 
protease inhibitors namely 150 nM pepstatin, 40 nM cystatin, and 100 µM PMSF and then 
stored at -20°C. A similar protocol was used for expression of hPrx2∆N(15-198), hPrx2∆NC(15-177), 
hPrx2∆N(15-168), hPrx2(Clat129-133), and hPrx2(SIS154-159) except that 2YT medium was used, and 
following induction the culture was grown overnight at 25°C. 
 
2.2.3.3.3 Purification of hPrx2 mutants 
Protein pellets were thawed and lysozyme (1 mg/g pellet) as well as DNase I were 
added and then stirred on ice for 1 h. The cells were sonicated (4 times for 30 s each) at 
maximum power (60%) and centrifuged (16,000 g for 30 min at 4°C). Following 
centrifugation, the clear supernatant was then applied to a 1 ml Ni-NTA column, washed with 
10 column volumes (CV) of US buffer (50 mM sodium phosphate buffer, 300 mM NaCl, pH 
8.0), and 10 CV of US buffer containing 10 mM imidazole. Finally, the hPrx2 mutants were 
eluted using a stepwise imidazole concentration (2 CV of 75 mM, 5 CV of 200 mM and 5 CV 
of 500 mM) gradient. Thereafter, the pellet, flow through, wash, and elution fractions were 
run on an SDS gel. 
 
2.2.3.3.4 SDS-polyacrylamide gel electrophoresis 
SDS-PAGE of hPrx2 mutants was carried out as described (Laemmli, 1970). Protein 
samples (flow through, wash, and elution fractions) from the purifications of hPrx2 mutants 
were mixed in 4x reducing SDS sample buffer and boiled at 95°C for 5 min in order to 
denature the proteins. The denatured samples were run at 200 V on 15% SDS-PAGE gels in a 
Bio-Rad Mini PROTEAN® II electrophoresis apparatus. The 15% precast gels consisted of a 
collecting gel (Tris buffer pH 6.8, 4% acrylamide, 1% SDS) containing pockets on which the 
samples were loaded and a separating gel (Tris buffer pH 8.8, 7.5-15% acrylamide, 10% SDS) 
on which the proteins were separated according to their molecular weight. After the run, the 
gel was stained with Coomassie blue and de-stained with Coomassie de-staining solution until 
protein bands were clearly visible. However, gels meant for Western blot were immediately 
placed in a cathode buffer rather than stained. A similar protocol was used for parasite pellets 
from P. falciparum cell culture except that the pellets were heated for 10 minutes in 1x 
reducing SDS sample buffer and loaded at 3 x 107 parasites/lane. 
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2.2.3.3.5 Western blotting 
The semi-dry Western blot method (Towbin et al., 1979) was used to confirm 
expression and evaluate the uptake of recombinant hPrx2 mutants and assess the uptake host 
hPrx2 into P. falciparum after inhibition with different compounds. To begin with, 5 filter 
papers and the SDS-PAGE gel, 2 filter papers and the PVDF membrane (first activated for 30 
s in methanol), and 3 filter papers were soaked for 10-15 min in the cathode buffer, anode 
buffer 2, and anode buffer 1, respectively. In order to transblot the separated proteins, a 
sandwich (Figure 2.7) between the anode and cathode was set up consisting of 5 filter papers 
and the SDS-PAGE gel, followed by a PVDF membrane and 2 filter papers (from anode 2) 
and 3 filter papers (from anode 1). 
 
Figure 2.7:  Semi-dry Western blot Analysis 
Arrangement of the 5 filter papers (from cathode buffer), the SDS-PAGE gel, PVDF membrane, 2 
filter papers (from anode buffer II) and 3 filter papers (from anode buffer I).  
 
The transfer process was carried out at 0.8 mA/cm2 of gel for 55 min. To view the efficiency 
of the transfer process, the PVDF membrane was stained with Ponceau solution (for 30 s) and 
immediately de-stained with 1% acetic acid then washed with TBST until the protein bands 
became invisible. The non-protein-bound sites on the PVDF membrane were blocked by 
incubation in blocking buffer (5% milk powder in TBST) overnight at 4°C ( for P. falciparum 
parasite lysates) or 1 h at room temperature with gentle shaking ( for recombinant hPrx2 
proteins). Then the PVDF membrane was washed (3 x 5 min) in TBST and incubated in the 
primary antibody (mouse anti-His tag at 1:50,000 in 3% BSA or rabbit anti-hPrx2 at 1:10,000 
in 5% milk buffer) for 1 h with gentle shaking at room temperature. Following another wash 
in TBST (3 x 5 min), the membrane was incubated in a secondary antibody (anti-mouse at 
1:10,000 or anti-rabbit at 1:10,000) for 1 h at room temperature with gentle shaking. After 
another wash with TBST (3 x 5 min), the proteins were identified with an enhanced 
chemiluminescence (ECL)-Kit in a dark room. The membrane was incubated in luminol (for 
30 s) and wrapped in a plastic foil and then exposed to an x-ray film for periods of about 30 s 
to 10 min. The exposure time is dependent on the strength of the signals obtained. 
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2.2.3.3.6 Concentration of hPrx2 mutant proteins 
Following SDS-PAGE of hPrx2 mutants, elution fractions containing clean proteins of 
interest were combined and concentrated. Protein fractions were concentrated using a 
centriprep tube (3,000 MWCO, Amicon, Beverly, USA) by centrifugation (3,500 rpm for 45 
min at 4°C) until a desired volume was obtained. Subsequently, the protein concentration was 
determined by the Bradford method (Biorad Protein Kit) 
 
2.2.3.3.7 Determination of protein concentration 
To determine protein concentration, the Bradford method was used (Bradford 1979, 
Noble and Bailey, 2009). Protein concentration determination was carried out with the 
Bradford Kit (Bio-Rad, Munich) following the manufacturer’s instructions. This colorimetric 
protein assay is based on the detection of a blue colouration that results from an absorbance 
shift of the red dye Coomassie Brilliant Blue G-250 upon binding to a protein. A standard 
curve was determined by plotting known concentrations of BSA against their OD at a 
wavelength of 595 nm. The concentrations of different hPrx2 mutants were determined by 
interpolation on the standard curve using their OD595. 
 
2.2.3.3.8 Specific Binding of hPrx2 mutants to the P. falciparum membrane 
Binding of hPrx2 mutants to the P. falciparum membrane was evaluated as described 
(Bonday et al., 2000) with modifications. Briefly, P. falciparum parasites were isolated from 
red blood cells by saponin lysis as described above. The parasites were then lysed in 20 mM 
Tris-HCl buffer (pH 7.5) containing 0.2% Triton X-100 for 1 h at 4°C. The lysate was 
centrifuged (12,000 × g for 30 min), and the pellet was washed five times with PBS. The 
membrane pellet was suspended in 20 mM Tris-HCl buffer (pH 7.5) containing 0.5% Triton 
X-100, and an aliquot (200 µg of protein) was incubated with hPrx2 mutants (10 µg) at room 
temperature for 1 h with gentle shaking. Following the incubations, the membrane fractions 
were re-isolated by centrifugation and washed repeatedly with PBS, and the pellet was then 
subjected to SDS-PAGE (10% gels) followed by Western analysis with anti-His tag antibody 
as described. 
 
2.2.3.3.9 Immunofluorescence assays of hPrx2 in P. falciparum 
Immunofluorescence assay (IFA) experiments were carried out as described (Tonkin 
et al., 2004) with minor modifications. To localise the host hPrx2 in P. falciparum, 
trophozoite stage parasites (100 µl pellet, 6% parasitemia) were washed (three times with 
PBS) then fixed in a fixing solution (4% paraformaldehyde and 0.0075% glutaraldehyde in 
PBS) for 30 min. The fixed cells were washed once in PBS and then permeabilised with 0.1% 
Triton X-100/PBS for 10 min. Cells were then washed again in PBS and then treated with 100 
mM glycine/PBS for 10 min to reduce any free aldehyde groups. Following another PBS 
wash, cells were blocked in 3% BSA/PBS for 1 h and then incubated overnight at 4°C with 
the first antibody (rabbit anti-hPrx2 (1:100 in PBS/BSA axxora). Cells were washed three 
times in PBS for 10 min each to remove excess primary antibody. Then Cy3 anti-rabbit 
secondary antibody (Dianova) was added at 1:200 dilution (in 3% BSA/PBS) for 1 h. The 
cells were further washed (three times in PBS for 10 min each), then treated with 1 µg/ml 
Hoechst nuclear stain, washed again, and mounted onto a slide with the cover slip.  
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2.2.3.3.10 Encapsulation of hPrx2 into human erythrocytes  
Human erythrocytes of blood group A+ were washed three times (2100 rpm, 3 min) 
with cold isotonic PBS supplemented with 20 mM glucose. Subsequently the erythrocytes 
were re-suspended to a haematocrit of 70% and a final concentration of 40 µM of hPrx2 
mutants in cold PBS supplemented with 20 mM glucose, 3 mM reduced GSH, 2 mM ATP 
(final pH 7.4). Next samples were chilled on ice and dialysed with stirring against 50 volumes 
of ice cold hypotonic solution (5 mM K2HPO4 supplemented with 3 mM reduced GSH, 2 mM 
ATP, 20 mM glucose, pH 7.4) for 1 h at 4°C. Dialysis (Figure 2.8) was undertaken in pre-
wetted 3.5 kDa molecular weight cut off slide A lyzer dialysis cassettes (Piece 
Biotechnology). ATP and reduced glutathione were added in order to preserve cellular energy 
and maintain a reduced environment, respectively. Afterwards, an annealing step was 
introduced by dialysis against the isotonic PBS for 10 min at 37°C. Resealing the erythrocytes 
was achieved by dialysis against a hypertonic buffer (50 volumes of 10x concentrated PBS 
containing 50 mM glucose) for 30 min at 37°C. In order to remove external non-encapsulated 
hPrx2, resealed erythrocytes were washed three times (600 x g, 10 min, 4°C) with incomplete 
RPMI 1640. These loaded erythrocytes were then infected with enriched trophozoites and 
cultured for 48 h to the trophozoite stage (8% parasitaemia). 
 
 
Figure 2.8:  Hypotonic dialysis for loading of erythrocytes with hPrx-2 mutants. 
Erythrocytes were mixed with hPrx2 mutants to a haematocrit of 50% and then dialysed against a 
hypotonic buffer at 4°C for 1 h. Following an annealing step (at 37°C for 1 h), erythrocytes were 
washed in order to complete resealing and remove external hPrx2 mutant proteins (Murphy et al., 
2006). 
 
In order to assess the uptake of hPrx2 mutants, after cell culture the trophozoite stage 
parasites were enriched by magnetic-assisted cell sorting (MACS, Miltenyi Biotech, 
Germany). The parasites were then lysed by the addition of saponin (0.15% in PBS, pH 7.2 
for 1 min) and washed extensively (5 times) to remove extracellular haemoglobin and hPrx2 
mutant protein. The parasite pellets were prepared for Western blotting as described above. 
For localisation of hPrx2 mutants in P. falciparum, immunofluorescence assay (IFA) 
experiments were carried out as described above. 
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2.2.3.1.1 Inhibition of the uptake of hPrx2 into P. falciparum 
Inhibitors at 4 x IC50 (Table 2.2) were added to synchronized ring stage parasite 
cultures (~6 h) for 24 h and harvested at the trophozoite stage (~32-36 h) by magnetic 
separation. The parasite cultures consisted of 4-6% parasitemia at 2.5% haematocrit (1.25 ml 
packed cell volume, 50 ml complete RPMI 1640 medium). Following magnetic separation, 
parasites (~80-90% trophozoites) were lysed in saponin (0.15% in PBS for 1 min). The 
released parasites were pelleted at (1,500 x g for 5 min) and washed five times in cold PBS to 
remove excess haemoglobin. The parasite pellets were either stored at -70ºC or immediately 
processed for Western blot analysis. 
 
Table 2.2 Inhibitors tested for effects on uptake of hPrx2 in P. falciparum. 
Inhibitors Abbreviation Solvent IC50 for 3D7 
Actin inhibitors    
Cytochalasin D CTD DSMO 13.1 nM 
Jasplankinolide JAS DSMO 73.5 nM 
Dynamin inhibitor    
Dynasore DYN DMSO 1.34 µM 
Alkalising agents     
Monensin sodium salt MNS Ethanol 1.00 nM 
Ammonium chloride NH4Cl ddH2O 2.05 mM 
ATP depleting agent    
Sodium azide NaN3 ddH2O 210 nM 
Antimalarial drugs     
Chloroquine CQ ddH2O 8.6 nM  
Mefloquine MQ DMSO 8 nM  
Artemisinin ART DMSO 17.3 nM  
Others    
Brefeldin A  BFA Methanol  1310 nM 
Paraquat  PQT ddH2O 45 µM 
 
The parasite pellet was solubilised in reducing 1 x SDS-PAGE sample buffer and loaded at 
3x107 parasites/lane for Western blot analysis. Alternatively, the parasite pellet was lysed by 
freezing and thawing, followed by ultrasonication on ice. Subsequently, the lysate was 
centrifuged (12,000 x g for 30 min, 4°C) and the supernatant (the total parasite lysate) after 
centrifugation (23,000 x g for 30 min) was loaded at 30 µg/lane for Western blot analysis. 
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2.2.4.1 In vitro P. falciparum gametocytes susceptibility assay 
P. falciparum (strain 3D7) gametocytes were cultured as described (Ifediba and 
Vanderberg 1981; Fivelmann et al., 2007) with modifications. Briefly, following 
synchronisation with 5% sorbitol (Lambros and Vanderberg 1979), a ring stage culture was 
set up (day 1) with 1.5-2% parasitaemia at 6% haematocrit with fresh A+ erythrocytes; no 
further erythrocytes were used during the experiment. Gametocytes were cultured in RPMI 
1640 medium (Gibco) supplemented with A+ human serum (10%), 1.96 g/l glucose, 50 mg/l 
hypoxanthine, and 22 µg/ml gentamycin. Cultures were kept under 3% O2, 3% CO2, and 94% 
N2 at 37°C. The medium was changed daily and Giemsa-stained slides were prepared for 
monitoring gametocyte development. On day 3 the cultures were diluted from 6% to 3% 
haematocrit. To inhibit further asexual parasite growth (Fivelmann et al., 2007), cultures were 
supplemented with 50 mM N-acetylglucosamine (Sigma) from day 5 onwards and then 
treated with 5% sorbitol on day 8 as described (Saul et al., 1990). To remove haemozoin, the 
cultures were washed and centrifuged (at 750 g for 10 min) four times. To eliminate ring 
stages and enrich the gametocytes, the cultures were passed through a magnetically mounted 
MACS® LS separation column fitted with a 21G flow resistor (Miltenyi Biotech, Germany) as 
described (Ribaut et al., 2008). Cultures were continued at a 2% gametocytaemia and 3% 
haematocrit until day 9 (stages II and III) or day 13 (stages IV and V) when drug treatment 
started. Activity of PYO, MB, and CQ against gametocytes was assessed as described 
(Chutmongkonkul et al., 1992) with modifications. Briefly, stock solutions of CQ and MB 
were freshly dissolved in distilled water while PYO was dissolved in DMSO. The drugs (50 
µl) were added to 450 µl of gametocytes culture (final haematocrit ~2.0%, 2% 
gametocytaemia) to each well in 24-well plates. After 24 h, solvent-containing media 
(controls) and drug-containing media were replaced. After 48 h all wells received fresh 
medium without drugs for an additional 2 days. On day 14 (for immature gametocytes) and 
day 18 (for mature gametocytes) thin blood films were prepared, then Giemsa-stained, and 
gametocytes were counted per 10,000 erythrocytes. The 50% inhibitory concentrations (IC50) 
were determined by curve-fitting the percentage of gametocyte inhibition (in relation to 
control) against log drug concentration with a variable-slope sigmoidal function and 
compared using the F-test (GraphPad Software Prism 4.0, San Diego, CA). 
 
2.2.4.2 In vitro gametocyte SYBR green I-based fluorescence assay 
P. falciparum (strain 3D7) gametocytes were cultured as described above, and the in 
vitro gametocyte drug sensitivity method was modified and adapted so that inhibition of 
gametocyte growth was determined by measuring the fluorescence of SYBR green I. 
Following the drug assay, the multi-well plates were frozen at -70°C. Next, the multi-well 
plates were thawed and 100 µl from each well was transferred into black 96-well plates for 
fluorescence analysis. Then, 100 µl of lysis buffer (20 mM Tris, 5 mM EDTA, 0.008% 
saponin, and 0.08% Triton X-100 pH 7.5) containing SYBR green I (0.2 µl of 10,000x/ml 
buffer Molecular Probes/Invitrogen) were added to each well. After 4 h of incubation at 37°C 
in the dark, the fluorescence was determined in a plate reader (M200, Tecan) with excitation 
and emission wavelengths of 485 and 535 nm, respectively (Smilkstein et al., 2004).
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3 RESULTS 
 
3.1 Real time imaging of the glutathione redox potential  
3.1.1 hGrx1-roGFP2 in different life cycle stages of P. falciparum  
To gain insights into the redox-sensing properties of hGrx1-roGFP2 in P. falciparum, the 
hGrx1-roGFP2 gene (Figure 3.1A) cloned in the pARL-1a+ expression vector (Crabb et al., 
2004) was transfected into the CQS 3D7 and the CQR Dd2 strains. Following 3-4 weeks of 
selection with 2 nM WR99210, the transfectants showed a strong hGrx1-roGFP2 fluorescence 
signal in the parasite’s cytosol when visualized by confocal live cell microscopy (Figure 3.1B). 
 
 
 
 
 
 
 
 
 
Figure 3.1:  Sub-cellular localisation of hGrx1-roGFP2 in P. falciparum. 
(A) A schematic drawing of the hGrx1-roGFP2 fusion protein showing human glutaredoxin (hGrx1, 
black) fused to N-terminal of roGFP2 (green) through a linker (Red) comprising a 30-amino-acid spacer, 
(Gly-Gly-Ser-Gly-Gly)6. (B) Confocal live cell images of 3D7 and Dd2 showing expression of hGrx1-
roGFP2 (green) exclusively localized within the cytosol. (C) Western blot analysis of hGrx1-roGFP2 in 
parasite lysates of 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 strains of P. falciparum showing the predicted hGrx1-
roGFP2 fusion protein band of 47 kDa. 
 
Furthermore, the expression of the full length fusion hGrx1-roGFP2 protein in the parasite 
lysates of 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 parasites was confirmed by Western blotting 
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showing a single band of predicted size of 47 kDa (Figure 3.1C). Notably, the hGrx1-roGFP2 
fluorescence was excitable at both the 405 nm and 488 nm not only in all the asexual stages 
(Figure 3.2A, B) but also in gametocytes (Figure 3.2C).  
 
 
 
 
Figure 3.2:  Expression of hGrx1-roGFP2 in different stages of P. falciparum. 
Images show the trophozoite (A), schizont (B) and gametocyte (C) stages of P. falciparum expressing 
hGrx1-roGFP2. 
 
However, during the development of P. falciparum organelles and intracellular 
compartments have been reported to change shape not only from ring, to trophozoites and to 
schizonts (Van Doreen et al., 2005) but also into gametocytes. To maintain a defined region of 
interest, all measurements were carried out on only the trophozoite stage (26-30 h post invasions) 
that has a single fully enlarged cytosol (Figure 3.2A) excluding the haemozoin containing food 
vacuole. These data suggest that hGrx1-roGFP2 can be used to monitor the EGSH across different 
life cycle stages of P. falciparum. 
 
3.1.2 In vivo excitation spectra of hGrx1-roGFP2 in P. falciparum  
  P. falciparum infected erythrocytes contain large amounts of photo-active compounds 
including haem, hemozoin and haemoglobin that may interfere with ratiometric hGrx1-roGFP2 
spectra by shifting the isosbestic point of a fluorochrome (Takahashi et al., 1999; Rohrbach et 
al., 2005; Kuhn et al., 2007) or quenching the fluorescence signals. To address these concerns, a 
lambda scan was carried out to determine the excitation spectrum of hGrx1-roGFP2 in P. 
falciparum. As shown in Figure 3.3A, the spectrum has two excitation maxima at 405 nm and 
490 nm. This spectrum is characteristic of roGFP2 as previously reported (Hanson et al., 2004). 
Furthermore, due to differences in the strength of the intensities at 405 nm and 488 nm, the 
3D7 
 
Dd2 
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intensity from both channels was balanced and it varied proportionally in the reduced state 
(Figure 3.3B) and upon oxidation (Figure 3.3C, D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: In vivo spectra of hGrx1-roGFP2 in P. falciparum. 
(A) Spectrum of hGrx1-roGFP2 in P. falciparum has the characteristic excitation maxima at 405 nm and 
488 nm. Variation of the 405 nm channel (green) and 488 nm channel (red) during the reduced state (B) 
and upon oxidation (C, D) during live cell imaging of P. falciparum parasites expressing hGrx1-roGFP2. 
 
3.1.3 hGrx1-roGFP2 is a dynamic redox biosensor in P. falciparum  
To validate the use of hGrx1-roGFP2 in imaging EGSH changes, P. falciparum-infected 
erythrocytes were treated with 1 mM diamide and followed 4 min later by 10 mM DTT. Unlike 
the natural oxidant GSSG that is impervious to cells, diamide is a membrane permeable and 
powerful oxidizing agent (Kosower and Kosower, 1987). Initially, different concentrations (~ 0 
to 1 mM) of diamide were evaluated and it was established that 1 mM diamide caused maximum 
oxidation in the trophozoite stages of both 3D7hGrx1-roGFP2 (Figure 3.4) and Dd2hGrx1-roGFP2 (Figure 
3.5) parasites. The kinetics of oxidation were dependant on the concentration of diamide with 
higher concentrations causing faster oxidation in 3D7hGrx1-roGFP2 (Figure 3.4B) and Dd2 hGrx1-
roGFP2
 (Figure 3.5B). 
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Figure 3.4: Effect of diamide on the glutathione redox potential in the 3D7 strain of P. falciparum. 
(A) Merge (405/488 nm) images at different time points and concentrations ranging from 0 - 1 mM are 
shown. Diamide was added after 1 min of basal measurements and 3D7hGrx1-roGFP2 parasites were followed 
for 4 min. (B) Kinetic analysis of cellular oxidation of hGrx1-roGFP2 by selected concentrations of 
diamide. Each data point comprises 3 trophozoites. (C) Concentration response curves. 
 
Similar to the trophozoite stages, 1 mM diamide also fully oxidized schizont (Figure 
3.6A) and gametocyte stages of both the 3D7 (Figure 3.6B) and the Dd2 strain (Figure 3.6C) 
expressing hGrx1-roGFP2. Furthermore, as expected, 10 mM DTT reduced the cytosol of 
trophozoite stages of P. falciparum (Figure 3.7). Next 3D7 hGrx1-roGFP2 and Dd2 hGrx1-roGFP2 were 
sequentially treated with 1 mM diamide and 4 min later with 10 mM DTT.  
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Figure 3.5:  Effect of diamide on the glutathione redox potential in the Dd2 strain of P. falciparum. 
Different concentrations of diamide (~ 0 to 1 mM) were evaluated to establish the concentration that 
caused maximum oxidation. One millimolar concentration (1 mM) of diamide was found to cause 
maximum oxidation. (A) Merge of 405 nm and 488 nm images for Dd2 strain of P. falciparum expressing 
hGrx1-roGFP2 treated with different concentrations of diamide. (B) After 60s, the parasites were treated 
with different concentrations of diamide and monitored for 4 min. The ratio of emissions after excitation 
at 405 and 488 nm was computed and plotted against time. For each concentration, data from 3 
trophozoites was analyzed. (C) A plot of maximum ratio against concentrations of diamide.  
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Figure 3.6: Effect of diamide on the glutathione redox potential in schizont and gametocyte stages 
of P. falciparum. A concentration of 1 mM diamide was found to cause maximum oxidation. Confocal 
images of schizont (A) and gametocyte stages of 3D7 (B) and Dd2 (C).  The 405 nm, 488 nm and merge  
(405/488 nm) images at different time points are shown. 
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Figure 3.7:  Effect of DTT on the glutathione redox potential of P. falciparum. 
A concentration of 10 mM DTT caused maximum reduction of hGrx1-roGFP2 in P. falciparum. Merge 
and ratio (405/488 nm) images at different time points are shown for Dd2hGrx1-roGFP2 parasites treated with 
10 mM DTT. 
 
 
   
 
Figure 3.8:  hGrx1-roGFP2 imaging of intracellular redox changes in 3D7 strains of P. falciparum. 
3D7hGrx1-roGFP2 parasites were excited at 405 and 488 nm and the ratio of emissions in the green channel 
(500–530 nm) was calculated. After 60 s, cells were treated with 1 mM diamide and followed 4 min later 
by 10 mM DTT. (A) The 405 nm, 488 nm, merge (405/488 nm) and false-color ratio images at different 
time points are shown. (B) Kinetic analysis of cellular oxidation and reduction of hGrx1-roGFP2 by 1 
mM diamide and 10 mM DTT. Each point in the graph comprises 5 trophozoites. 
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Figure 3.9:  hGrx1-roGFP2 imaging of intracellular redox changes in the Dd2 strain of P. 
falciparum. Dd2hGrx1-roGFP2 parasites were excited at 405 and 488 nm and the ratio of emissions in the 
green channel (500–530 nm) was calculated. After 60 s, cells were treated with 1 mM diamide and 
followed 4 min later by 10 mM DTT. (A) The 405 nm, 488 nm, merge (405/488 nm) and  false-color ratio 
images at different time points are shown. (B) Kinetic analysis of cellular oxidation and reduction of 
hGrx1-roGFP2 by 1 mM diamide and 10 mM DTT. Each point in the graph comprises 5 trophozoites. 
 
Within 20 s after addition of 1 mM diamide, the fluorescence ratio 405/488 nm increased 
from 0.50 ± 0.02 and 0.37 ± 0.01 to 1.79 ± 0.04 and 1.49 ± 0.03 in 3D7 hGrx1-roGFP2 and Dd2 hGrx1-
roGFP2
, respectively indicating oxidation of hGrx1-roGFP2 (Figures 3.8 and 3.9). Subsequently, 
following addition of 10 mM DTT, the fluorescence ratio 405/488 nm decreased to 0.34 ± 0.01 
and 0.26 ± 0.01 in 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 respectively indicating reduction of hGrx1-
roGFP2 (Figures 3.8 and 3.9). In accordance with previous studies (Gutscher et al., 2008), the 
rapid, dynamic and ratiometric response of hGrx1-roGFP2 to oxidation with diamide and 
reduction by DTT confirms its applicability, as EGSH biosensor in P. falciparum. 
 
3.1.5 Glutathione protects P. falciparum against oxidative stress. 
GSH is known to play a central role in anti-oxidative defense (Schafer and Buettner, 
2001) in P. falciparum (Becker et al., 2003). However, real time monitoring of the protective 
effects of GSH have been limited. Although diamide oxidizes GSH, excess GSH has been shown 
to protect against oxidation by diamide (Kuhn, 2002). To investigate whether hGrx1-roGFP2 
A 
 
Dd2
0 60 120 180 240 300 360 420 480 540 600
0.0
0.5
1.0
1.5
2.0
10 mM DTT
1 mM Diamide
B
Time (s)
R
at
io
 
40
5/
48
8n
m
Results   
 62 
would detect protection of P. falciparum against oxidative stress, Dd2hGrx1-roGFP2 parasites were 
incubated with 1 mM diamide and 1 mM diamide with either 2.5 mM or 5 mM GSH and 1 mM 
diamide for 24 h. Initially, it was demonstrated that 20 mM NEM as previously shown (Gutscher 
et al., 2008), would facilitate instant clamping of redox state of using the Dd2hGrx1-roGFP2 (Figure 
3.10A). Following incubation, the fluorescence of hGrx1-roGFP2 at 405 and 488 nm was 
determined and the ratio was computed. As shown in Figure 3.10B, the ratio of 405 /488 nm of 
parasites treated with diamide only, and diamide with either 2.5 mM or 5 mM GSH were 2.38 ± 
0.11 (n =28), 0.52 ± 0.03 (n = 28) and 0.53 ± 0.02 (n = 28) respectively. As expected, parasites 
treated with diamide only as compared to untreated (control) parasites and those treated with 
both diamide with either 2.5 mM or 5 mM GSH were significantly different (P = 0.01). In 
contrast, untreated parasites (control) and parasites treated with both diamide with either 2.5 mM 
(P = 0.01) or 5 mM GSH were significantly not different (P = 0.05). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10:  Protection of P. falciparum by glutathione against oxidation by diamide.  
(A) A 20 mM concentration of N-ethylmaleimide (NEM) facilitates instant clamping of redox state of 
hGrx1-roGFP2 in Dd2. (B) Protection of P. falciparum against oxidative stress.  
 
These data not only confirm that hGrx1-roGFP2 responds to changes in intracellular GSH but 
also detects protection of P. falciparum from oxidation by oxidants like diamide.  
 
3.1.6 The cytosolic basal glutathione redox potential is highly reducing in P. falciparum 
To determine the basal EGSH in the cytosol of the trophozoite stage of P. falciparum, the 
degree of oxidation (OxDroGFP2) was computed from the fluorescence intensity measured in 3D7 
hGrx1-roGFP2
 and Dd2hGrx1-roGFP2 at the resting state (basal), maximal oxidation (after treatment with 
1 mM diamide) and full reduction (after treatment with 10 mM DTT). Interestingly, the basal 
fluorescence ratio remained constant in 3D7hGrx1-roGFP2 (Figure 3.11A) and Dd2hGrx1-roGFP2 (Figure 
3.11B) strains but differed between both P. falciparum strains (Figure 3.11C). The fluorescence 
ratio 405/488 nm values of 0.59 ± 0.03 (n = 30) and 0.22 ± 0.01 (n = 30) for 3D7hGrx1-roGFP2 and 
Dd2hGrx1-roGFP2 were significantly different (P < 0.01). The difference in basal fluorescence ratio 
405/488 nm might be explained by the fact that the GSH concentrations in the Dd2 strain are 
twice that in the 3D7 strain (Meierjohann et al., 2002). Next, the basal EGSH was computed as 
described (Gutscher et al., 2008) using a midpoint redox potential of roGFP2 of –280 mV 
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(Dooley et al., 2004), a consensus cytoplasmic pH = 7.20 (Saliba and Kirk, 1999; Hayashi et al., 
2000; Kuhn et al., 2007), at 37.0 ºC and the 10 mM DTT minimal and 1 mM diamide maximal 
fluorescence ratios.  
 
 
 
 
  
Figure 3.11:  Basal hGrx1-roGFP2 fluorescence ratio in the cytosol of P. falciparum strains.  
Merge (405/488 nm) and false-color ratio images at different time points are indicated for the 3D7 (A) 
and the Dd2 (B) strain of P. falciparum. (C) Basal hGrx1-roGFP2 fluorescence ratio as function of time. 
The ratio remained constant for over 10 min. 
  
In previous studies, no significant cytosolic pH differences were found between sensitive 
and resistant strains of P. falciparum. The consensus cytoplasmic pH value of 7.2 was based on 
previous determinations using fluorescein isothiocyanate [(6.85 ± 0.08 for FCR3TC strain) 
(Yayon et al., 1984); BCECF (2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein) [7.29 ± 
0.01 for CQR FAF-6 strain (Saliba and Kirk, 1999) and 7.31 ± 0.02 for FCR-3 strain (Hayashi et 
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al., 2000)]; pHluorin [7.03 ± 0.09 for HB3 and 7.20 ± 0.06 for Dd2 (Kuhn et al., 2007)] and 
SNARF-5F [7.09 ± 0.11 for HB3 and 7.13± 0.04 for Dd2 (Kuhn et al., 2007)]. 
Notably, the basal EGSH of the cytosol of 3D7 and Dd2 was found to be -314.2 ± 3.1 mV 
and - 313.9 ± 3.4 mV respectively, thus suggesting a highly reducing redox state in the cytosol 
which does not differ significantly (P = 0.841) between drug resistant and sensitive parasites. 
 
3.1.7 The dynamic range of hGrx1-roGFP2 in cytosol  of P. falciparum. 
Previously, the dynamic range of roGFP2 has been reported to differ within different 
compartments in Arabidopsis (Schwarzlander et al., 2008) and yeast cells (Morgan et al., 2011). 
To determine the dynamic range of hGrx1-roGFP2 in the cytosol of P. falciparum, the average 
highest fluorescence ratio of the diamide time course in 3D7hGrx1-roGFP2 (Figure 3.8) and Dd2hGrx1-
roGFP2
 (Figure 3.9) was divided by the average lowest fluorescence ratio in the DTT time course 
of both strains. The dynamic range of hGrx1-roGFP2 in 3D7 and Dd2 strains of P. falciparum 
were 6.36 ± 0.73 and 5.29 ± 0.49 respectively. Previously, a dynamic range of 4.4 (Gutscher et 
al., 2008) and 4 to 8 (Morgan et al., 2011) have been reported for hGrx1-roGFP2. Clearly, the 
dynamic range of hGrx1-roGFP2 in both 3D7 and Dd2 strains is in agreement with previously 
reported data. These data suggest, as expected, that the presence of higher GSH levels confer 
greater redox buffering capacity in Dd2 compared to the 3D7 strain. 
 
3.1.8 hGrx1-roGFP2 facilitates imaging of oxidative and nitrosative stress  
Typically, treatment of cells with H2O2 is a common tool for probing the sensitivity of 
biosensors such as hGrx1-roGFP2 in vivo to oxidative stress. Despite the importance of oxidative 
and nitrosative stress, the effects of ROS and RNS on the GSH redox system have been 
immensely difficult to measure in real time in P. falciparum. To investigate the effects of 
oxidative stress, P. falciparum strains expressing hGrx1-roGFP2 were treated with H2O2, TBHP 
and PQT (a superoxide donor). Frequently, THBP is used instead of H2O2 as an inducer of ROS 
since it is not a substrate for catalase. Notably, after treatment of 3D7hGrx1-roGFP2 (Figure 3.12) 
and Dd2hGrx1-roGFP2 (Figure 3.13) with millimolar concentrations of H2O2, rapid increases in 
fluorescence ratio 405/488 nm (on a scale of seconds) were observed but much higher 
concentrations (50 mM) were required to attain full oxidation. In both 3D7hGrx1-roGFP2 and 
Dd2hGrx1-roGFP2 parasites, the minimal concentration of H2O2 required to induce immediate 
increase in the fluorescence ratio 405/488 nm was 1 mM.  As expected, at the same 
concentration of H2O2 (such as 10 mM H2O2) a stronger oxidation was observed in 3D7 hGrx1-
roGFP2
 (Figure 3.12C) than Dd2hGrx1-roGFP2 (Figure 3.13C) reflected by increase in fluorescence 
ratio 405/488 nm to 1.70 ± 0.02 and 0.69 ± 0.01 respectively with in 1 min. This data is 
explained by the facts that the hGrx1-roGFP2 sensor is not sensitive to micromolar 
concentrations of H2O2 and that H2O2 is detoxified by host erythrocytic GSH and antioxidant 
enzymes such as catalase.Similar to H2O2, treatment of the Dd2hGrx1-roGFP2 with millimolar 
concentrations of THBP resulted in rapid increases in fluorescence ratio 405/488 nm within 5 
min indicating oxidation of hGrx1-roGFP2 (Figure 3.14). As expected, a stronger oxidation was 
observed with THBP compared to that caused by equal concentrations of H2O2. For instance, 4 
min after addition of 10 mM THBP (Figure 3.14) and 10 mM H2O2 (Figure 3.13), the 
fluorescence ratio 405/488 nm increased to 0.87 ± 0.67 and 0.69 ± 0.01 in Dd2 hGrx1-roGFP2, 
respectively. Surprisingly, PQT failed to rapidly (within 5-10 min) elicit any increase 
fluorescence ratio 405/488 nm changes (Figure 3.16A) in 3D7hGrx1-roGFP2 parasites.  
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Figure 3.12 Effect of H2O2 on the glutathione redox potential of the 3D7 strain of P. falciparum. P. 
falciparum cells expressing hGrx1-roGFP2 were treated with different concentrations of H2O2. After 60 s, 
cells were treated with H2O2 for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio images at 
different time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 by 
different concentrations of H2O2. Each point in the graph comprises 3 trophozoites. 
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Figure 3.13: Effect of H2O2 on the glutathione redox potential of the Dd2 strain of P. falciparum.  
Dd2 hGrx1-roGFP2 parasites were treated with different concentrations of H2O2. After 60 s, parasites were 
treated with H2O2 and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio images at 
different time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 by 
different concentrations of H2O2. Each concentration in the graph comprises 3 trophozoites. 
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Figure 3.14: Effect of t-butyl hydroperoxide on the glutathione redox potential in P. falciparum 
(Dd2). Dd2hGrx1-roGFP2 parasites were treated with different concentrations of TBHP. After 60 s, cells were 
treated with TBHP and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio images at 
different time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 by 
different concentrations of TBHP.  Each point in the graph comprises 3 trophozoites. 
 
P. falciparum has been reported to be susceptible to nitrosative stress (Komaki-Yasuda et al., 
2003). To induce nitrosative stress, SNP (a nitric oxide generator) and SIN-1 (a peroxynitrite 
generator) were used. Interestingly, SIN1 caused rapid increases in the fluorescence ratio 405/ 
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488 nm (Figure 3.15). At 1 mM concentration of SNP, low fluorescence ratio 405/488 nm 
changes were observed (Figure 3.16B).  
 
 
 
 
  
 
Figure 3.15: Effect of 3-morpholinosydnonimine hydrochloride on the glutathione redox potential 
in P. falciparum (Dd2). P. falciparum cells expressing hGrx1-roGFP2 were treated with different 
concentrations of SIN-1. After 60 s, cells were treated with SIN-1 and monitored for 4 min. (A) Merge 
(405/488 nm) and (B) false-color ratio images at different time points are shown. (C) Kinetic analysis of 
the cellular oxidation of hGrx1-roGFP2 by different concentrations of SIN1. For each concentration 3 
trophozoites were analyzed. 
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Figure 3.16:  Effect of SNP and PQT
 
on the glutathione redox potential in P. falciparum. After 60 s, 
cells were treated with 1 mM PQT (A) or SNP (B) and monitored for 4 min. Merge (405/488 nm) and 
false-color ratio images at different time points are shown. P. falciparum cells of 3D7 and Dd2 strains 
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expressing hGrx1-roGFP2 were treated at ring and trophozoite stage for 24 h (E) at a concentration of 4 x 
IC50 and for 4 h (C,D) at concentrations ranging from ~ 1 x IC50 to 100 x IC50. Each data point in A, B 
and C comprises 8-10 trophoziotes. For each drug (E) data are representative of 10-15 (3D7) and 25-30 
(Dd2) trophozoites. Control: untreated sample. Data is mean ± SEM. The mean fluorescence ratio 
405/488 nm for 3D7 strain was significantly different from that of the Dd2 strain as indicated (*, p < 
0.001).  
 
In Dd2hGrx1-roGFP2 parasites, the lowest concentration of SIN1 required to induce immediate 
increase in  the fluorescence ratio 405/488 nm was 2.5 mM. In Dd2 hGrx1-roGFP2 parasites, 4 min 
after addition of 10 mM SIN1 (Figure 3.15), the fluorescence ratio 405/488 nm increased to 1.10 
± 0.01 indicating oxidation of hGrx1-roGFP2. 
To evaluate the effects of SNP and PQT, initially the susceptibility of 3D7 and Dd2 
strains to PQT and SNP was determined using the 72 h isotopic assay (Desjardins et al., 1979). 
The IC50 values of PQT and SNP against 3D7 were 45.4 µM and 6.6 µM  respectively as well as 
21.1 µM and 7.4 µM against Dd2. Next, ring and trophozoite stage 3D7hGrx1-roGFP2 and Dd2hGrx1-
roGFP2
 parasites were treated for 24 h with a concentrations of 4 x IC50 and for 4 h with 
concentrations ranging from ~ 1 x IC50 to 100 x IC50. As a control, following 24 h incubation 
with  1 mM diamide, the fluorescence ratio 405/488 nm values for 3D7 hGrx1-roGFP2  and Dd2hGrx1-
roGFP2
 were 2.92 ± 0.13 (n = 15) and 2.05 ± 0.08 (n = 30) respectively and were  significantly 
different (P < 0.01). Following 4 and 24 h incubation, stronger oxidation was observed with SNP 
than PQT (Figure 3.16 C-E). Similar to H2O2, oxidation was stronger for 3D7hGrx1-roGFP2 than for 
Dd2 hGrx1-roGFP2 (Figure 3.16 C-E). 
 
3.1.9 Depletion of glutathione causes oxidation of the cytosol of P. falciparum 
To investigate whether hGrx1-roGFP2 is responsive to depletion of GSH in situ, P. 
falciparum strains expressing hGrx1-roGFP2 were treated with inhibitors of de novo GSH 
biosynthesis and reduction of GSSG. To inhibit γ-GCS, BSO was used and for PfGR both MB 
and PYO. First, it was tested whether MB, PYO and BSO would rapidly oxidize the cytosol. 
Interestingly, following treatment with different micromolar drug concentrations, only MB [for 
3D7 (Figure 3.17) and for Dd2 (Figure 3.18)] and PYO (Figure 3.20) rapidly (with in 5 min) 
caused increases in fluorescence ratio 405/488 nm of hGrx1-roGFP2. However, the PYO 
concentrations required to deplete GSH in 5 min were 10 fold higher than those of MB. For 
instance, 4 min after addition of 50 µM MB (Figure 3.18) and 500 µM PYO (Figure 3.20), the 
fluorescence ratio 405/488 nm increased to 1.21 ± 0.19 and 0.97 ± 0.03 in Dd2 hGrx1-roGFP2, 
respectively. 
In Dd2hGrx1-roGFP2 parasites, the minimal concentration of PYO required to induce 
immediate increase in the fluorescence ratio 405/488 nm was 250 µM. In Dd2 hGrx1-roGFP2 
parasites, 4 min after addition of 1 mM PYO (Figure 3.20), the fluorescence ratio 405/488 nm 
increased to 1.44 ± 0.04 indicating oxidation of hGrx1-roGFP2. 
In contrast, even at concentrations of 1 mM, BSO did not rapidly (within 5 min) oxidize 
the cytosol of both 3D7hGrx1-roGFP2 (Figure 3.19A) and Dd2hGrx1-roGFP2 (Figure 3.19B) parasites.  
Nevertheless, the concentrations of MB and PYO required to rapidly deplete GSH in the 
cytosol of P. falciparum were significantly higher than the concentrations at which these 
compounds exhibit in vitro antimalarial activity. Thus, ring and trophozoite stage P. falciparum 
strains expressing hGrx1-roGFP2 were incubated for 24 h at concentration of 4 x IC50 and for 4 h 
at concentrations ranging from ~ 1 x IC50 to 100 x IC50, respectively.  
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Figure 3.17: Effect of methylene blue on the glutathione redox potential in the 3D7 strain of P. 
falciparum. 3D7hGrx1-roGFP2 parasites were treated with different concentrations of methylene blue (MB). 
After 60s, cells were treated with MB and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-
color ratio images at different time points are shown. (C) Kinetic analysis of the cellular oxidation of 
hGrx1-roGFP2 by different concentrations of MB. Each point in the graph comprise 3 trophozoites. 
 
Previously, using the 72 h isotopic assay (Desjardins et al., 1979; Akoachere et al., 2005) 
the IC50 values of MB against the strains 3D7 and Dd2 were determined to be 3.26 ± 0.57 nM 
and 5.24 ± 0.18 nM respectively (Akoachere et al., 2005). Additionally, the IC50 values of PYO 
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against the strains 3D7 and Dd2 were determined to be 86 nM and 194.7 nM, respectively 
(Kasozi et al., 2011).  
 
 
 
 
 
 
 
 
  
 
Figure 3.18:  Effect of methylene blue on the glutathione redox potential in P. falciparum.  
Dd2hGrx1-roGFP2 parasites were treated with different concentrations of methylene blue (MB). After 60s, 
cells were treated with MB and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio 
images at different time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 
by different concentrations of MB. Each point in the graph comprise 3 trophozoites. 
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Furthermore, the IC50 values of BSO against the 3D7 and Dd2 strains of P. falciparum were 
reported to be 26.3 µM and 58.9 µM, respectively (Meierjohann et al., 2002).  
Following 4 h (Figure 3.21A) and 24 h (Figure 3.21D) incubation with MB, the 
fluorescence ratio 405/488 nm increased significantly in 3D7hGrx1-roGFP2 when compared to 
Dd2hGrx1-roGFP2 parasites indicating stronger oxidation of hGrx1-roGFP2 in the 3D7 strain. 
Similar to MB and PYO, after 4 and 24 h of incubation, BSO exerted stronger oxidation on 
3D7hGrx1-roGFP2 than on Dd2hGrx1-roGFP2 parasites (Figure 3.21). 
 
 
 
 
 
 
Figure 3.19: Effect of BSO on the glutathione redox potential in P. falciparum. After 60s, cells were 
treated with 1 mM buthionine sulfoximine (BSO) and monitored for 4 min. Merge (405/488 nm) and 
false-color ratio images at different time points are shown for 3D7hGrx1-roGFP2 (A) and Dd2 hGrx1-roGFP2 (B). 
 
Besides inhibiting PfGR, MB and PYO are redox cyclers like menadione (MNA), a 
naphthoquinone generally utilized as a model for studing oxidative damage. Additionally, MNA 
derivatives are lead compounds in antimalarial drug development as suicide substrates of PfGR 
(Bauer et al., 2006). Similar to MB and PYO, MNA induced a stronger oxidation of hGrx1-
roGFP2 in 3D7hGrx1-roGFP2 (Figure 3.22) than Dd2hGrx1-roGFP2 (Figure 3.23), parasites suggesting 
fast depletion of GSH. For instance, 4 min after addition of 500 µM MNA the fluorescence ratio 
405/488 nm increased to 1.85 ± 0.01 (Figure 3.22) and 0.95 ± 0.02 in 3D7hGrx1-roGFP2 and Dd2 
hGrx1-roGFP2 
  (Figure 3.23) parasites, respectively. 
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Figure 3.20: Effect of pyocyanin on the glutathione redox potential in P. falciparum. Dd2hGrx1-roGFP2 
parasites were treated with different concentrations of pyocyanin (PYO). After 60 s, cells were treated 
with PYO and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio images at different 
time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 by different 
concentrations of PYO. Each point in the graph comprise 3 trophozoites. 
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Figure 3.21: Effect of MB, PYO and BSO on the glutathione redox potential in P. falciparum. P. 
falciparum cells of 3D7 and Dd2 strains expressing hGrx1-roGFP2 were treated at ring and trophozoite 
stage for 24 h (D) at a concentration of 4 x IC50 and for 4 h (A-C) at concentrations ranging from ~ 1 x 
IC50 to 100 x IC50. Each data point in A, B and C comprises 8-10 trophoziotes. For each drug (D) data are 
representative of 10-15 (3D7) and 25-30 (Dd2) trophozoites. Data is mean ± SEM. The fluorescence ratio 
405/488 values for 3D7 strain was significantly different from that of the Dd2 strain as indicated (* , p < 
0.001). 
 
Furthermore, P. falciparum parasites were treated with 1-chloro-2, 4-dinitrobenzene 
(CDNB) an electrophilic xenobiotic compound that is detoxified by conjugation to GSH (Ayi et 
al., 1998). In 3D7hGrx1-roGFP2 parasites, the minimal concentration of CDNB required to induce 
immediate increase in the fluorescence ratio 405/488 nm was 1.25 mM. Within 1.5 min after 
addition of 5 mM CDNB, the fluorescence ratio 405/488 nm increased from 0.47 ± 0.03 to 0.89 
± 0.14 in 3D7hGrx1-roGFP2 indicating depletion of GSH (Figure 3.24). Depletion of GSH by CDNB 
was rapidly detected by hGrx1-roGFP2 although the extent of oxidation was much lower 
compared to inhibitors of PfGR (Figure 3.24). The lower level of oxidation of hGrx1-roGFP2 
may be due to the fact that CDNB reacts with the cysteine residues of roGFP2. As previously 
reported (Meyer et al., 2007), although CDNB rapidly depletes GSH, cysteine alkylation of 
roGFP2 would block disulfide bridge formation.  
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Figure 3.22: Effect of menadione on the glutathione redox potential of the 3D7 strain of P. 
falciparum. P. falciparum parasites of the 3D7 strain expressing hGrx1-roGFP2 were treated with 
different concentrations of menadione (MNA). After 60 s, cells were treated with MNA and monitored 
for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio images at different time points are shown. 
(C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 by different concentrations of MNA. Each 
point in the graph comprises 3 trophozoites. 
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Figure 3.23:  Effect of menadione on the glutathione redox potential in P. falciparum. Dd2hGrx1-roGFP2 
parasites were treated with different concentrations of menadione (MNA). After 60 s, cells were treated 
with MNA and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-color ratio images at different 
time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-roGFP2 by different 
concentrations of MNA. Each point in the graph comprise 3 trophozoites. 
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Figure 3.24:  Effect of CDNB on the glutathione redox potential in P. falciparum. 3D7hGrx1-roGFP2 
parasites were treated with different concentrations of -chloro-2, 4-dinitrobenzene (CDNB). After 60 
s, cells were treated with CDNB and monitored for 4 min. (A) Merge (405/488 nm) and (B) false-color 
ratio images at different time points are shown. (C) Kinetic analysis of the cellular oxidation of hGrx1-
roGFP2 by different concentrations of CDNB. Each point in the graph comprise 3 trophozoites. 
B: Ratio images  
 
A: Merge images  
 
3D 7
0 60 120 180 240 300 360
0.0
0.5
1.0
1.5 1.25 mM 2.5 mM 5 mM
C D N B
C
Time( s)
R
at
io
 
40
5/
48
8 
n
m
Results   
 79 
3.1.10 Glutathione redox potential changes induced by artemisinin derivatives 
Although the molecular mechanism of action remains debatable (O’Neil and Posner, 
2004), current evidence suggests that ART derivatives are activated via reductive cleavage of the 
peroxide bond by intracellular Fe(II) iron or haem generating carbon centered free radicals 
(Stocks et al., 2007) with the potential to alkylate vital cellular components including GSH 
(Mukanganyama et al., 2001) leading to parasite death. Surprisingly, in short term experiments 
(within 5 min), and in contrast to MB, ART derivatives failed to oxidize the cytosol of P. 
falciparum expressing hGrx1-roGFP2 even at concentrations up to 100 µM (Figure 3.25). 
 
 
 
 
 
 
 
 
 
Figure 3.25: Effect of artemisinin derivatives on the glutathione redox potential in P. falciparum.  
After 60 s, P. falciparum parasites expressing hGrx1-roGFP2 were treated with 100 µM of artemisinin 
(ART, A), artesunate (ATS, B) and artemether (ATM, C) and monitored for 4 min. Merge (405/488 nm) 
and false-color ratio images at different time points are shown. 
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Nevertheless, ART derivatives are active against malarial parasites at 10,000 lower 
concentrations (Akoachere et al., 2005). Next, ART derivatives were tested at concentrations at 
which they exert antimalarial activity but with longer incubation times. Prior studies indicated 
that the IC50 of ART, ATS and ATM were 17.29 ± 1.53 nM, 4.35 ± 0.29 nM and 5.87 ± 0.45 nM 
against 3D7 and 20.36 ± 2.09 nM, 5.22 ± 0.40 nM and 8.40 ± 1.63 nM against Dd2 (Akoachere 
et al., 2005). To investigate whether hGrx1-roGFP2 is able to detect EGSH changes induced by 
ART, ATS and ATM, ring and trophozoite - stage of 3D7 hGrx1-roGFP2 and Dd2hGrx1-roGFP2  parasites 
were incubated for 24 h at concentrations of 4 x IC50 and 4 h at concentrations ranging from ~ 1 
x IC50 to 100 x IC50.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: Effect of 4 and 24 h incubation with artemisinin derivatives on the glutathione redox 
potential in P. falciparum. P. falciparum parasites expressing hGrx1-roGFP2 were treated at ring and 
trophozoite stage for 24 h (D) at a concentration of 4 x IC50 and for 4 h (A-C) at concentrations ranging 
from ~ 1 x IC50 to 100 x IC50. ART: artemisinin, ATS: Artesunate, ATM: artemether. Each data point in 
A, B and C comprises 8-10 trophoziotes.  For (D) each drug data are representative of 10-15 (3D7) 
and 25-30 (Dd2) trophozoites. Control: untreated sample. Data is mean ± SEM. The fluorescence 
ratio 405/488 values for 3D7 strain was significantly different from that of the Dd2 strain as 
indicated (* , p < 0.001). 
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Following 4 h incubation (Figure 3.26 A-C), a stronger oxidation was observed with 3D7hGrx1-
roGFP2 than Dd2hGrx1-roGFP2 parasites by ATS and ATM but not ART. However, after 24 h of 
incubation, all ART derivatives induced significantly stronger oxidation in 3D7hGrx1-roGFP2 than in 
Dd2hGrx1-roGFP2 strains (Figure 3.26D). Importantly, all ART derivatives after 24 h of incubation 
at concentrations of 4 x IC50 induced stronger oxidation than any other drug tested. Together, 
these data suggest that ART, ATM and ATS induce highly significant but down stream effects 
on the EGSH. 
 
3.1.11 Glutathione redox potential changes induced by quinoline drugs  
Conflicting findings have been reported on the role of oxidative stress in the mechanism 
of action of CQ. Previously, Loria et al. (1999) and Graves et al. (2002) provided support for a 
possible role for CQ-FP induced oxidative stress as part of the mechanism of action of CQ, 
however this has been questioned (Monti et al., 2002). Furthermore, although initially suggested 
(Ginsburg et al.,1998) the contribution of GSH levels in the mechanism of resistance to CQ and 
AQ remains incomplete since principal roles for mutations in pfcrt (Fidock et al., 2000) and 
possibly pfmdr1 (Reed et al., 2000) have been demonstrated. The activity of CQ differs 
significantly (~10 fold) between 3D7 (IC50 = 8.6 nM) and Dd2 strains (IC50 = 90.2 nM) 
(Akoachere et al., 2005). By contrast, AQ has been reported to have comparable activity on the 
3D7 strain (IC50= 18.6 nM) and the Dd2 strain (IC50 = 7.2 nM). Similar to AQ, QN has been 
reported to have comparable activity on the 3D7 strain (IC50= 210 nM) and the Dd2 strain (IC50 = 
136 nM). Furthermore, the activity of MQ on 3D7 strain (IC50= 8 nM) was two times that of the 
Dd2 strain (IC50 = 19.5 nM). 
To clarify the role of GSH in the mode of action and resistance to CQ and explore its role 
for AQ, QN and MQ, ring and trophozoite stage 3D7hGrx1-roGFP2 and Dd2hGrx1-roGFP2 parasites were 
treated for 5 min with 100 µM, for 24 h at 4 x IC50 and for 4 h at concentrations ranging from ~ 1 
x IC50 to 100 x IC50 respectively. In short term experiments (within 5 min), in contrast to MB, 
quinoline antimalarial drugs failed to oxidize the cytosol of P. falciparum expressing hGrx1-
roGFP2 even at concentrations up to 100 µM (Figure 3.27). Following 4 h incubation, oxidation 
induced by CQ, MQ, and QN but not AQ was stronger in 3D7hGrx1-roGFP2 than Dd2hGrx1-roGFP2 
(Figure 3.28A-C). In contrast to the 4 h incubation (Figure 3.28B), the oxidative effect of AQ 
after 24 h of incubation (Figure 3.28E) was more pronounced than that of CQ in the 3D7 strain 
suggesting that despite similarities in structure suggesting that 4- aminoquinolines exert 
differential effects on EGSH. Furthermore, MQ and QN have been reported not to interfere with 
GSH-mediated ferriprotoporphyrin IX (FIX) degradation (Ginsburg et al., 1998). Interestingly, 
both after 4 h (Figure 3.28C,D) and 24 h (Figure 3.28E) of incubation, the oxidative effects of 
MQ and QN were stronger than that of CQ or AQ. Notably all quinoline drugs CQ, AQ, MQ and 
QN elicited more pronounced EGSH changes in the 3D7hGrx1-roGFP2 than in the Dd2hGrx1-roGFP2 
strain. 
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Figure 3.27:  Effect of quinoline antimalarial drugs glutathione redox potential in P. falciparum.  
After 60 s, P. falciparum parasites expressing hGrx1-roGFP2 were treated with 100 µM of chloroquine 
(CQ, A), amodiaquine (AQ, B), quinine (QN, C) and mefloquine (MQ, D) and monitored for 4 min. 
Merge (405/488 nm) and false-color ratio images at different time points are shown. 
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Figure 3.28:  Effect of quinoline drugs on the glutathione redox potential in P. falciparum. 
P. falciparum parasites expressing hGrx1-roGFP2 were treated at ring and trophozoite–stage for 24 h (E) 
at a concentration of 4 x IC50 for 4 h (A-D) at concentrations ranging from ~ 1 x IC50 to 100 x IC50 
concentrations respectively, CQ: Chloroquine, MQ: Mefloquine, QN: Quinine. For each drug data are 
representative of 10-15 (3D7) and 25-30 (Dd2) trophozoites. Control: untreated sample.  Data is 
mean ± SEM. The fluorescence ratio 405/488 value for 3D7 strain was significantly different 
from that of the Dd2 strain as indicated (*, p < 0.001). 
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Table 3.1 summaries the oxidative effects of antimalarial drugs on 3D7 hGrx1-roGFP2 and 
Dd2hGrx1-roGFP2 parasites. 
 
Table 3.1 Effect of antimalarial drugs on the glutathione redox potential in P. falciparum. 
 
Drugs Fluorescence ratio 405/488 nm  
 3D7 Dd2 
24 h at 4 x IC50 24 h at  4 x IC50 Incubation  5-10 
min 
IC50 
(nM) Ratio Fold* 
10 
min 
IC50 
(nM) Ratio Fold
* 
Inhibitors of GSH 
synthesis 
 
     
  
Methylene blue  
(MB) * 
+ 3.24  1.19 ± 0.08 3.5 + 5.24 0.40 ± 0.07 2.67 
Pyocyanin (PYO) ** + 58  1.18 ± 0.11 3.47 + 194 0.31± 0.02 2.16 
Menadione (MNA) + NA NA  + NA NA  
L-buthionine 
sulphoximine (BSO) 
*** 
- 26.3 
µM 
1.361± 0.08 4.0 - 58 
µM 
0.33± 0.03 2.2 
Artemisinin 
derivatives* 
 
  
  
  
 
Artemisinin (ART) - 17.3  2.62 ± 0.36 7.70 - 20.4  0.17± 0.01 1.13 
Artesunate  (ATS) - 4.35  2.09 ± 0.19 6.14 - 5.2 0.24 ± 0.01 1.6 
Artemether (ATM) - 5.8 1.60 ± 0.11 4.71 - 8.4  0.23 ± 0.19 1.5 
Quinoline drugs* 
 
  
  
  
 
Chloroquine (CQ) - 8.6 1.11 ± 0.07 3.26 - 90.2 0.17 ± 0.01 1.13 
Amodiaquine (AQ) - 18.6  1.28 ± 0.14 3.76 - 7.2 0.20 ± 0.01 1.33 
Quinine (QN) - 210  1.58 ± 0.16 4.64 - 136 0.23 ± 0.01 1.53 
Mefloquine (MQ) - 8  1.57 ± 0.09 4.61 - 19.5 0.21 ± 0.02 1.4 
 
 
 
+ Oxidation and - No Oxidation. NA- Not applicable.    * IC50 from [34].   ** IC50 from [31]. 
*** IC50 from [33]. *Fold change in fluorescence ratio = Ratio 405/488 nm of hGrxl-roGFP2 
after incubation with compound /Ratio 405/488 nm of reduced hGrx1-roGFP2.  The fluorescence 
ratio 405/488 nm for fully reduced hGrx1-roGFP2 were 0.34 ± 0.01 and 0.15 ± 0.01 in 3D7 hGrx1-
roGFP2
 and Dd2 hGrx1-roGFP2, respectively. 
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3.1.12 Effect of antimalarial drugs on recombinant hGrx1-roGFP2  
  
3.1.12.1 Effect of oxidants on the recombinant hGrx1-roGFP2 protein 
Additionally, the direct in vitro interaction of recombinant hGrx1-roGFP2 protein with 8 
antimalarial drugs including MB, quinolines (CQ, AQ, QN and MQ) and ART derivatives (ART, 
ATM and ATS) was characterized. First, the effects of 11 oxidants on recombinant hGrx1-
roGFP2 protein were investigated. Figure 3.29 shows the purification of hGrx1-roGFP2 from 
M15 E.coli cells and confirmation of overexpression by Western blot analysis. 
 
Figure 3.29:  Overexpression of hGrx1-roGFP2 protein. 
(A) Coomassie stained-SDS gel for the purification of hGrx1-roGFP2 protein. M – marker; F - flow 
through; 1x - wash ; 1- 5 represent 10, 75, 100, 200 and 500 mM immidazole eluation fractions (B) 
Western blot of recombinant hGrx1-roGFP2 using the anti-His tag antibody.  
 
Previously Dooley et al. (2004) reported that GSSG required longer reaction times and 
higher concentrations to partially oxidize roGFP2 (without hGrx1). As recently reported by 
Gutscher et al. (2008), it was demonstrated that fusion of hGrx1 to roGFP2 led to a rapid full 
oxidation (on a scale of seconds) of the hGrx1-roGFP2 (Figure 3.30A). The dynamic range in 
presence of 10 µM GSSG was 6.478 ± 0.020 and decreased to 6.199 ± 0.010, 5.744 ± 0.0037, 
5.256 ± 0.008 and 4.451 ± 0.103 with increase in GSH concentration from 1 mM, 2.5 mM, 5 
mM and to 10 mM (Figure 3.30B) respectively. However, GSSG is cell impermeable hence 
additional powerful cell permeable oxidants such as diamide, H2O2 and THBP were tested. 
Notably, the concentration of GSSG that was required to attain maximum oxidation on the 
recombinant hGrx1-roGFP2 was comparable to that of diamide (Figure 3.30D) and hence 
diamide was used as a positive control.  
Previously Dooley et al. (2004) reported that H2O2 required longer reaction times (> 30 
minutes) and higher concentrations to fully oxidize roGFP2 (without hGrx1). As previously 
reported (Gutscher et al., 2008), the fusion of hGrx1 to roGFP2 resulted in rapid increase in 
fluorescence ratio (on a scale of seconds) after addition of H2O2 (Figure 3.30A) although still 
high concentrations (10 mM) were required to attain full oxidation compared to diamide and 
GSSG (Figure 3.30C). Frequently, THBP is used instead of H2O2 as ROS inducer since it is not a 
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substrate for catalase. Surprisingly, THBP even at 10 mM did not cause any changes in hGrx1-
roGFP2 fluorescence ratio.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Figure 3.30:  Effect of oxidants on recombinant hGrx1-roGFP2 protein. 
 
To produce a superoxide anion, PQT an oxidant previously reported to induce oxidative 
stress in P. falciparum (Komaki-Yasuda et al., 2003) was used. Surprisingly, PQT at 1 mM 
failed to induce an increase in the hGrx1-roGFP2 fluorescence ratio (Figure 3.30A,D). 
Furthermore to produce a peroxyl radical, 2, 2’azobios (2-amidinopropane) dihydrochloride 
(AAPH) was used. In contrast to PQT, AAPH at 1 mM caused an increase in the fluorescence 
ratio of hGrx1-roGFP2 (Figure 3.30D). 
P. falciparum has been reported to be susceptible to nitrosative stress (Komaki-Yasuda et 
al., 2003). Killing of P. falciparum in vitro by nitric oxide derivatives has been demonstrated 
(Rockett et al., 1991). To evaluate if hGrx1-roGFP2 would respond to nitrosative stress, SIN-1 
(a peroxynitrite generator) and SNP (a nitric oxide generator) were initially tested on 
recombinant hGrx1-roGFP2. Interestingly both SIN1 (Figure 3.30D) and SNP (Figure 3.30A, D) 
at 1 mM slowly caused changes in fluorescence of hGrx1-roGFP2. However, SNP was a 
stronger oxidizing agent that SIN1. As shown in Figure 3.30D after 24 h incubation, SNP but not 
SIN1 fully oxidized hGrx1-roGFP2. 
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3.1.12.1 Spectral changes of the hGrx1-roGFP2 protein upon exposure to oxidants  
Next the spectral changes of recombinant hGrx1-roGFP2 upon exposure to several 
oxidants were evaluated (Figure 3.31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: Spectral changes of the recombinant hGrx1-roGFP2 upon exposure to redox active 
agents. GSSG: glutathione disulfide, SIN1: 3-morpholinosydnonimine hydrochloride and AAPH: 2, 
2’azobios (2-amidinopropane) dihydrochloride. 
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The excitation spectrum was scanned from 340-512 nm with emission at 530 ± 10 nm. All 
oxidants induced changes in the hGrx1-roGFP2 fluorescence spectra at the two distinct 
excitation maxima at 400 nm and 490 nm. Upon increasing concentrations of oxidants the 
excitation maxima at 400 nm increases while that at 490 nm decreases. For the rapidly oxidizing 
agents such as GSSG, H2O2 and diamide, spectra were determined after 10 min incubation while 
for AAPH and SIN-1 after 1 h and 24 h, respectively. As shown in Figure 3.31 the spectra were 
determined at different concentrations. The hGrx1-roGFP2 spectra were similar to those for 
roGFP2 (Dooley et al., 2004). This suggests that the fusion of hGrx1 to roGFP2 did not have any 
effect on the spectral characteristics of roGFP2. 
 
3.1.12.3 Effect of methylene blue on recombinant hGrx1-roGFP2 protein 
Next different classes of antimalarial drugs were examined for direct effects on 
recombinant hGrx1-roGFP2. Of note MB, PYO and MNA are active as redox cycling agents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32:  In vitro interaction of hGrx1-roGFP2 protein with methylene blue. 
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Notably among the antimalarial drugs tested, only MB ratiometrically caused 
fluorescence ratio (Figure 3.32A) and spectral changes after 24 h (Figure 3.32B) with 
recombinant hGrx1-roGFP2 although the changes were slower than observed for GSSG, H2O2 
and diamide (Figure 3.31). Within 15 min after addition of 1 mM MB (Figure 3.32A), the 
fluorescence ratio increased from 0.48 ± 0.01 to 1.84 ± 0.02 indicating progressive oxidation of 
recombinant hGrx1-roGFP2. Like MB, PYO slowly caused fluorescence ratio (Figure 3.32A) 
and spectral changes after 24 h (Figure 3.32D) with the hGrx1-roGFP protein (Figure 3.32A,C). 
Compared to MB, the fluorescence ratio 15 min after addition of PYO increased to 1.23 ± 0.04 
indicating a slower oxidation of the recombinant hGrx1-roGFP2. However, MNA was unable to 
fully oxidize hGrx1-roGFP2 even after 24 h of incubation (Figure 3.32C). In contrast, BSO 
caused no increase in fluorescence ratio of hGrx1-roGFP2 even after 24 h of incubation (Figure 
3.32C). Importantly, this study reveals the superiority of MB and PYO over MNA as oxidizing 
agents. 
 
3.1.12.4 Effect of quinolines and artemisinin derivatives on the hGrx1-roGFP2 protein 
Quinoline antimalarial drugs do not produce any radicals. ART derivatives produce 
carbon centered free radicals unlike classical oxidants that release oxygen free radicals (O’Neil 
and Ponser, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: Effect of quinoline drugs and artemisinin derivatives on hGrx1-roGFP2. 
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Furthermore, unlike most oxidant drugs such as MB, ART cannot be cyclically oxidized 
and reduced. Therefore, only one free radical can result from one drug molecule. In contrast to 
MB, both quinoline antimalarial drugs including CQ, MQ or QN (Figure 3.33 A and B) and ART 
derivatives such as ART, ATS and ATM (Figure 3.33 C and D) even at 100 µM were unable to 
cause any spectral and fluorescence ratio change after 24 h of incubation suggesting that their 
effects on P. falciparum strains expressing hGrx1-roGFP2 would be due to reactive 
intermediates. Table 3.2 summaries the effects of the 8 antimalarial drugs and 11 oxidants tested 
on recombinant hGrx1-roGFP2. 
 
Table 3.2 Effect of antimalarial drugs and redox compounds on recombinant hGrx1-
roGFP2 protein 
 
 
*Fold change in fluorescence ratio = Ratio 405/488 nm of hGrxl-roGFP2 after incubation with compound 
/Ratio 405/488 nm of reduced recombinant hGrx1-roGFP2 (0.49 ± 0.01). 
 
 
 
 
Drugs or redox 
compounds 
Abbreviation concentration Incubation 
 (h) 
Fold change 
in ratio  
(405/488 nm)* 
Diamide (Control) DMD 1 mM 5 min 6.24  
ROS inducers     
Glutathione disulfide GSSG 1 mM  5 min 6.54  
Hydrogen peroxide H2O2 10 mM 5 min 6.56  
tert-butyl hydroperoxide THBP 10 mM 5 min 1.16  
2,2'-azobis-2-methyl-
propanimidamide, 
dihydrochloride 
AAPH 10 mM 1 h 3.36  
Paraquat PQT 10 mM 5 min 1.09  
RNS inducers     
Sodium nitroprusside SNP 1 mM 10 min 3.36  
3-morpholinosydnonimine 
hydrochloride 
SIN 10 mM 10 min 3.11  
Inhibitors of GSH synthesis     
Methylene blue MB 1 mM 15 min , 
 24 h 
3.44  
7.35  
Pyocyanin PYO 1 mM  24 h 6.39  
Menadione MNA 1 mM 15 min  
, 24 h 
2.10  
2.58  
L-buthionine sulphoximine BSO 1 mM 24 h 1.01  
Quinoline drugs     
Chloroquine CQ 100 µM 24 h 1.19  
Amodiaquine AQ 100 µM 24 h 1.01  
Quinine QN 100 µM 24 h 1.23  
Mefloquine MQ 100 µM 24 h 1.01  
Artemisinin derivatives     
Artemisinin ART 100 µM 24 h 1.39  
Artesunate  ATS 100 µM 24 h 1.29  
Artemether ATM 100 µM 24 h 1.42  
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3.2 Uptake of host hPrx2 into P. falciparum 
3.2.1 Mechanism of uptake of hPrx2 into P. falciparum 
3.2.1.1 Identification of endocytosis associated motifs in imported proteins  
 Previous studies strongly suggest that human host erythrocytic proteins are imported into 
P. falciparum to play crucial roles in specific processes including parasite biochemistry, 
physiology (Foth et al., 2011) and antioxidant defense (Koncarevic et al., 2009). Notably, some 
of the imported proteins, have been reported to be sorted to specific organelles, mainly the 
cytosol and food vacuole which strongly suggests that P. falciparum may be able to traffic host 
proteins to different locations. However, the mechanism of import of host erythrocytic proteins 
into different sub-cellular compartments in P. falciparum remains poorly understood. To identify 
novel sorting motifs in host proteins reported to be imported in P. falciparum, a bioinformatics 
analysis of their protein sequences (~30) was carried out. Using the Eukaryotic Linear Motif 
(ELM, www. expasy.org) resource for functional sites in proteins, 4 endocytic vesicle associated 
motifs including: the tyrosine-based sorting signal (TSS), sorting and internalisation signal (SIS) 
and clathrin box motif (Clat) were identified.  The positions of endocytic vesicle associated 
motifs in all the human erythrocytic proteins reported to be imported in significant quantities in 
P. falciparum are shown in Table 3.3. Figure 3.34 shows the multiple sequence alignment 
(kalign, www.ebi.ac.uk) of a selection of proteins reported to be imported into P. falciparum. 
The consensus sequences of TSS were ([Y..[LMVIF]), SIS ([DER]...L[LVI]) and Clat 
(L[IVLMF].[IVLMF][DE). Surprisingly, with exception of superoxide dismutase, endocytic 
vesicle associated motifs were identified in all other imported proteins.  
 Interestingly, the TSS that is responsible for the interaction with the subunit of Adaptor 
Protein (AP) complex was found on average 2-5 times in nearly all proteins. By contrast, the SIS  
that targets proteins from the Trans Golgi Network to the lysosomal-endosomal-melanosomal 
compartments was found on average 1-2 times in all proteins except calpain and calreticulin 
Interestingly, the SIS sequence was present in the 93-amino-acid smallest fragment (ALAD-
∆NC) of host delta-aminolevulinate dehydratase that was imported into P. falciparum (Bonday 
et al., 2000). Unexpectedly, the Clat motif that is found on cargo adaptor proteins and it interacts 
with the beta propeller structure located at the N-terminus of the clathrin heavy chain was found 
on average 1-2 times in fewer proteins (Table 3.3) including hPrx2. Notably, very few proteins 
(Table 3.3) including hPrx2 had all three endocytosis associated motifs namely the TSS, SIS and 
Clat. Although less frequently encountered, several interesting motifs (Table A1 and A2 in the 
Appendix section) that may play a role in protein traffic were identified.  
 Additionally, the WXXXY|F motif that is part of the peroxisomal matrix protein import 
system was identified in the beta subunit of hemoglobin, biliverdin reductase B and carbonic 
anhydrase I.  Interestingly, plasmepsin II a parasite encoded protein reported to be exported to 
the food vacuole (Klemba et al., 2004) had TSS but not SIS and Clat (Table 3.3). Similar to 
plasmpesin II, parasite proteins exported to host RBC such as PfEMP1 and KAHRP also had 
TSS but not SIS and Clat (Table 3.3). However, the role of these motifs in the uptake of 
erythrocytic proteins into P. falciparum remains unknown. The role of SIS and Clat in hPrx2 was 
investigated.
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Table 3.3: Endocytic vesicle associated motifs in erythrocytic proteins imported into P. falciparum. 
 
Human Protein    Sorting and 
internalize-
tion signal 
Tyrosine-based 
sorting signal 
Clathrin box motif Peroxisomal matrix 
protein import system 
 Reference  [DER]...L[L
VI] 
Y..[LMVIF] (L[IVLMF]. 
[IVLMF][DE) 
W...[FY] 
Peroxiredoxin 2 (hPrx2) 
 
Koncarevic et 
al. (2009) 
P32119 154-159 37-40 
115-118 
126-129 
129-133  
Hemoglobin subunit beta 
(Hb) 
 
Lazarus et al. 
(2008) 
P68871.2 102-107 131-134 
 
38-42 
Aminolevulinate, delta-, 
dehydratase(LAD) 
Bonday et al. 
(2000) 
CAH70099.3 103-108 33-36 
205-208 
257-260 
  
Ferrochelatase 
(FC) 
Varadharajan 
et al. (2004) 
CAB65962.1 327-332 123-126 
160-163 
210-213 
297-300 
352-355 
  
Tyr3/Trp5-
monooxygenase 
activation protein 
Foth et al. 
(2011) 
NP_003397.1 2-7 
39-44 
96-101 
19-22 
48-51 
118-121 
126-129 
178-181 179-182 
  
Annexin I Foth et al. 
(2011) 
NP_000691.1 133-138 
292-297 
39-42 
230-233 
315-318 
335-338 
  
Biliverdin reductase B 
(BRLB) 
Foth et al. 
(2011) 
NP_000704.1 29-34 
 
146-149 
  
Carbonic anhydrase I Foth et al. 
(2011) 
NP_001729.1 181-186 89-92 
129-132 
 
17-21 
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205-208 
Calpain, small subunit 1 Foth et al. 
(2011) 
NP_001740.1 
 
87-90 
178-181 
210-213 
233-237 174-178 
Calreticulin Foth et al. 
(2011) 
NP_004334.1 
 
109-112 
128-131 
172-175 
308-311 
  
Catalase (CAT) Fairfield et al. 
(1983) 
NP_001743.1 47-52 370-373 
447-450 
84-87 
231-234 
280-283 
308-311 
  
Glyceraldehyde-3-
phosphate 
dehydrogenase 
(GAPDH) 
Foth et al. 
(2011) 
NP_002037.2 13-18 
63-68 
255-258 
  
Heat shock 70 kDa 
protein 8 isoform 1 
Foth et al. 
(2011) 
NP_006588.1 69-74 
46-51 
192-197 
15-18 
41-44 
288-291 
294-297 
391-395  
Lactoferrin Foth et al. 
(2011) 
NP_002334.2 656-661 
244-249 
398-403 
111-114 
246-249 
454-457 
592-596  
Mitochondrial ATP 
synthase beta subunit 
precursor 
Foth et al. 
(2011) 
NP_001677.2 91-96 
179-184  
317-322 
395-398 
499-502 230-233 
247-250 
269-272 
431-434 
302-306  
Mitochondrial HSP60 Foth et al. 
(2011) 
NP_002147.2 241-246 
353-358 
90-93 
243-246 
503-506 
  
Paraoxonase 1 (PAR) Foth et al. 
(2011) 
NP_000437.3 149-154 
263-268 
71-74 
197-200 
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352-355; 128-131 
234-237 
Protein disulfide-
isomerase A3 precursor 
Clarebout et 
al. (1998 
NP_005304.3 250-255 264-267; 100-103 
416-419 
47-51  
Rho GDP dissociation 
inhibitor (GDI) beta 
Foth et al. 
(2011) 
NP_001166.3 41-46 153-156 
  
Selenium binding 
protein 1 
Foth et al. 
(2011) 
NP_003935.2 305-310 56-59 
414-417 
248-252 
314-318 
 
Superoxide dismutase 1 
(SOX) 
Fairfield et al. 
(1983) 
NP_000445.1 
    
Erythrocyte band 7 Foth et al. 
(2011) 
NP_004090.4 
 
123-126 
  
Triosephosphate 
isomerase 1 isoform 1 
Foth et al. 
(2011) 
NP_000356.1 105-110 48-51 
165-168 
  
Food vacuole proteins        
Plasmepsin II 
 
 
 
 
 
Klemba et al. 
(2004) 
PF14_0077  281-284 
224-227, 
308-311, 316-319, 
369-372 
433-436 
 
  
Parasite proteins in 
host RBC  
   
 
  
PfEMP2 
 
 
 
Przyborski and 
lanzer (2005) 
PFE0040c  1358-1361 
  
KAHRP Przyborski and 
lanzer (2005) 
PFB0100c  343-346 
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Figure 3.34: Multiple sequence alignment of proteins imported into P. falciparum. The sorting 
and internalization motif (SIS) as well as the tyrosine based sorting signal (TSS) are indicated. Details 
of proteins are shown in table 3.3. 
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3.2.1.2 Identification of structural and functional motifs in hPrx2 
 
To thoroughly investigate the trafficking of hPrx2 into P. falciparum from the host 
 
 
Figure 3.35:  Functional motifs in hPrx2.  
The details of these functional short sequence motifs are shown in the Tables A1 and A2 in the 
appendix section. Clathrin box (LIG_ Clathr_ Clatbox), sorting and internalisation signal 
(TRG_ENDOCYTIC_2), tyrosine-based sorting signal (TRGLysEND_APsACLL_1).  
 
erythrocyte cytosol, the hPrx2 sequence (hTPx1, hPrx-2, Uniprot Accession Number P32119) 
was further searched and several structural and functional domains and motifs which may be 
involved in the uptake process were identified (Figure 3.35) using the Simple modular 
architecture research tool (SMART, http://smart.embl.de/, Letunic et al., 2009). Overall, the 
hPrx2 protein comprises a redoxin domain of 153 amino acids (starts at 7 and ends at position 
158), an AhpC-TSA domain of 134 amino acids (alkyl hydroperoxide reductase and thiol 
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specific antioxidant starts at 8 and ends at position 141) and 1-CysPrx_C domain (starts at 
161 and ends at position 196). Additionally hPrx2 contains short functional sequence motifs 
(Figure 3.35). The details of these functional short sequence motifs are shown in the Tables 
A1 and A2 in the appendix section. 
 
 
Figure 3.36:  Structural and functional motifs in hPrx2.  
Selected domains and motifs of hPrx2. hPrx2(1-198), GAGs (2-5), Clat (129-133), SIS (154-159),1-
CysPrx_C (161-196), redoxin domain (7-158), AhpC-TSA (8-141). 
 
Figure 3.36 shows the selected structural domains which were identified. Several 
studies report that structural domains play important roles in uptake of proteins into cells 
(Morris et al., 2011). Morris et al. (2011) demonstrated that the α6 helix of the C-terminal 
domain of human glutathione transferase was vital for its uptake into L929 cells. A total of 8 
α helices and 7 β strands were identified in hPrx2. The α helices were H1 (31-34), H2 (52-60), 
H3 (62-67), H4 (79-88), H5 (90-94), H6 (109-115), H7 (151-169) and H8 (186-198). 
 
3.2.2 Heterologous over-expression of hPrx2 mutants 
3.2.2.2 N- and C-terminal deletion mutants of hPrx2 
 Usually proteins destined for transport to organelles contain signal sequences which 
may be located at the N-terminal or C-terminal end of a protein. However, the signal 
sequences that direct proteins from the host erythrocytes cytosol into P. falciparum are poorly 
understood. To identify motifs involved in sorting, a series of N- and C-terminal end  deletion 
constructs of hPrx2 were generated. Figure 3.37 shows schematic diagrams of N- and C-
terminal end deletion protein mutants of hPrx2. All N- and C-terminal end deletion mutants 
were cloned in the pQE30 vector and overexpressed in M15 E.coli cells. Figure 3.38 shows 
SDS PAGE analysis of the purification of N- and C-terminal deletion mutants and their 
confirmation by Western blot analysis. The characteristics of the N- and C- terminal end 
deletion mutants of hPrx2 are shown in Table 3.4. Although there was variation in expression 
level and solubility of the hPrx2 mutants, all were successfully expressed and purified. 
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hPrx2(full length) 
 
hPrx2∆N(15-198) 
 
hPrx2∆C(1-177) 
 
hPrx2∆C(1-168) 
 
hPrx2∆NC(15-177) 
 
hPrx2∆NC(15-168) 
Figure 3.37:  N- and C- terminal hPrx2 deletion mutants.  
Schematic diagrams of N- and C- terminal end deletion protein mutants of hPrx2. The numbers 
indicate the positions of relevant amino acid residues. 
 
Table 3.4: Properties of the N- and C-terminal deletion mutants of hPrx2 
 
hPrx2 mutant Delet- 
ion 
Molecular 
mass (Da) 
Amino 
acid 
number 
Isolectric  
point (pI) 
Characteristic feature 
hPrx2(full length) Full 
length 
23159.2 
 
209 
 
6.53 
 
Has all signal motifs 
hPrx2∆N (15-198)  ∆N 21792.6 
 
195 6.32 
 
Lacks the first 14 amino acids 
which include the glycosamino 
glycan attachment site 
hPrx2∆C(1-177) ∆C 20798.6 
 
188 
 
6.77 
 
Lacks the C-terminal end which 
includes the last 21 amino acids 
hPrx2 ∆C(1-168) ∆C 19870.6 
 
179 6.77 
 
Lacks the C-terminal end  which 
includes the last 30 amino acids 
with the resolving cysteine 
hPrx2∆NC (15-177) ∆NC 19432.1 
 
174 
 
6.47 
 
Lacks the N-terminal with first 14 
amino acids and C-terminal end 
which includes the last 21 amino 
acids 
hPrx2∆NC(15-168) ∆NC 18504.0 
 
165 
 
6.47 
 
Lacks the N-terminal end with 
first 14 amino acids and C-
terminal end which includes the 
last 30 amino acids 
23.1 kDa 
 
+1 
 
+198 
 
+172 
 
+51 
 
+15 
 
+172 
 
+51 
 
21.8 kDa 
 
20.8 kDa 
 
+172 
 
+51 
 
+177 
 
+1 
 
19.9 kDa 
 
+1 
 
+51 
 
+168 
 
+51 
 
+15 
 
+172 
 
+177 
 
19.4 kDa 
 
+15 
 
+51 
 
+168 
 18.5 kDa 
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Figure 3.38: SDS PAGE and Western blot analysis of N- and C- terminal deletion mutants of 
hPrx2. (A-E) SDS PAGE of hPrx2 N-and C-terminal end deletion mutants. M – marker; F - flow 
through; 1x - wash ; 1-5 represent 10 mM, 20 mM, 75 mM, 200 mM and 500 mM immidazole 
eluation fractions, respectively. (F) Confirmation of expression by Western blot analysis using a 
hexahistidyl-tag monoclonal antibody. 
 
A: hPrx2 ∆N(15-198) 
 
B: hPrx2 ∆C(1-177) 
 
C: hPrx2 ∆C(1-168) 
 
D: hPrx2 ∆NC(15-177) 
 
F 
 
E: hPrx2 ∆C(15-168) 
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As compared to the full length recombinant hPrx2 (32 mg/l), the N-terminal end deletion 
mutants had lower expression levels with 1.1 mg/l, 3.6 mg/l and 0.75 mg/l for hPrx2∆N(15-198), 
hPrx2∆NC(15-177), and hPrx2∆NC(15-168), respectively. Although better expression levels were 
achieved with the C-terminal end  deletion mutants with 27 mg/l and 18.3 mg/l for hPrx2∆C(1-
177)
 and hPrx2∆N(1-168) respectively, they were also unstable in US buffer compared to  
hPrx2(full length). 
 
3.2.2.3 Deletion mutant of the clathrin box motif in hPrx2 
 The identified Clat sequence (129 LFIID133) was deleted in hPrx2 to examine its effect 
on the uptake of hPrx2 into P. falciparum. Figure 3.39 shows a sequence alignment of the 
clathrin box in hPrx2 with other imported proteins. 
 
 
hPrx2(Clat129-133)  
 
Figure 3.39: Multiple sequence alignment of the clathrin box in hPrx2 with other proteins.  
Sequence alignment illustrating the clathrin box in imported proteins. The numbers indicate the 
positions of relevant amino acid residues. It is reported that these proteins bind to the amino-terminal 
domain of clathrin. The hPrx2 protein has this potential clathrin-binding motif at residues 129 LFIID133. 
 
The Clat deletion mutant [hPrx2(Clat129-133)] was overexpressed and purified (Figure 3.40). The 
hPrx2(Clat129-133) mutant has 204 amino acids, a molar mass of 22.6 kDa and an isoelectric 
point (pI) of 6.82. As compared to the recombinant hPrx2(full length) (32 mg/l), the hPrx2(Clat129-
133) 
 a had lower expression level with 0.35 mg/l. 
+1 
 
+51 
 
+172 
 
22.6 kDa 
 
+129 
 
+133 
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 Figure 3.40:  SDS PAGE and Western blot analysis of the Clathrin deletion mutant of hPrx2. 
(A) Purification of the clathrin deletion mutant [hPrx2(Clat129-133)]. The hPrx2(Clat129-133) has a molecular 
mass of 22.5kDa. M - marker; F - flow through; 1x - wash ; 1-5 represent 10 mM, 20 mM, 75 mM, 
200 mM and 500 mM immidazole eluation fractions, respectively. (B) Confirmation of expression by 
Western blot analysis using a hexahistidyl-tag monoclonal antibody. 
 
 
3.2.2.4 Deletion mutant of the sorting and internalization signal of hPrx2  
 To evaluate its effect on the uptake of hPrx2 into P. falciparum, the identified SIS 
motif (154 VDEALRLV 159) in hPrx2 was deleted by deletion mutagenesis (Williams et al., 
2007) and overexpressed in M15 E. coli cells. Figure 3.41 shows a sequence alignment of the 
SIS motif in hPrx2 with other imported proteins.  
 
 
hPrx2(SIS154-159) 
 
Figure 3.41:  Multiple sequence alignment of the sorting and internalization signal motifs. 
Sequence alignment illustrating sorting and internalization signal motifs (SIS) in hPrx2 with other 
proteins. The numbers indicate the positions of relevant amino acid residues. The hPrx2 protein has 
this SIS  motif at residues 154 VDEALRL 159. 
 
The SIS deletion mutant [hPrx2(SIS154-159)] was overexpressed and purified (Figure 3.42) and 
confirmed by Western blot analysis (Figure 3.42). The hPrx2(SIS154-159) mutant has 202 amino 
acids, a molar mass of 22.36 kDa and an isoelectric point (pI) of 6.82. As compared to the full 
length recombinant hPrx2 (32 mg/l), the hPrx2(SIS154-159) mutant had a lower expression levels 
with 0.56 mg/l. 
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Figure 3.42:  SDS PAGE and Western blot analysis of the sorting and internalization signal 
deletion mutant of hPrx2. The sorting and internalization signal deletion mutant (hPrx2 sis) has a 
molecular mass of 22.36 kDa. (A) Purification of the hPrx1(SIS154-159) mutant. M – marker; F - flow 
through; 1x - wash ; 1-5 represent  10 mM, 20 mM, 75 mM, 200 mM and 500 mM immidazole 
eluation fractions respectively. (B) Confirmation of expression by Western blot analysis using a 
hexahistidyl-tag monoclonal antibody. 
 
 
3.2.2.5 Active site mutants of hPrx2  
 Frequently, proteins are sorted to different compartments to perform specific 
functions. Koncarevic et al. (2009) demonstrated the uptake of hPrx2 into P. falciparum for 
antioxidant functions. To investigate whether uptake of hPrx2 is dependant on function, three 
mutants of hPrx2 were generated by site directed mutagenesis of either the active site cysteine 
(C51) or the resolving cysteine (C172) and both to a serine amino acid (Figure 3.43).  
 
 
hPrx2(full length) 
 
hPrx2(C51S) 
 
hPrx2(C172S) 
 
hPrx2(C51/172S) 
Figure 3.43: Active site mutants of hPrx2. Schematic diagrams of cysteine to serine mutants 
either at active site C51 [hPrx2(C51S) ] or resolving cysteine C172 [hPrx2(C172S) ] or both [hPrx2 
(C51/172S)]. The numbers indicate the positions of relevant amino acid residues. 
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Figure 3.44: SDS PAGE and Western blot analysis of active site mutants of hPrx2. All mutants 
have the same molecular weigth of 23.1 kDa. (A-D) Purification of the active site mutants of hPrx2. M 
– marker; F - flow through; 1x - wash; 1-5 represent  10 mM , 20 mM, 75 mM, 200 mM and 500 mM 
immidazole eluation fractions. (E) Confirmation of expression by Western blot analysis using a 
hexahistidyl-tag monoclonal antibody. 
 
 
C: hPrx2 (C51/172S) 
A: hPrx2 (Full length) C: hPrx2 (C51S) 
D: hPrx2 (C172S) 
E 
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The mutants hPrx2(C51S), hPrx2(C172S) and the double mutant hPrx2(C51/172S)  were 
overexpressed and purified (Figure 3.44). All the three mutants hPrx2(C51S), hPrx2(C172S) and 
hPrx2 (C51/172S) have the same molar mass of 23.1 kDa, with 209 amino acid and an isoelectric 
point (pI) of 6.53. Except for the hPrx2(C172S) mutant (0.93 mg/l), as compared to  hPrx2 (full 
length)
 (32 mg/l), high expression levels were observed for the hPrx2(C51S) (50 mg/l) and 
hPrx2(C51/172S) (45 mg/l). Figure A4 (Appendix) shows a multiple sequence alignment 
illustrating differences between all mutants of hPrx2 as compared to the hPrx2 (full length). 
 
3.2.2.6 Western blot analysis of the uptake of hPrx2 mutants into P. falciparum 
 Following expression and purification, the uptake of hPrx2 mutants into P. falciparum 
was investigated. Previously, Bonday et al, (2000), evaluated the uptake of δ-aminolevulinate 
dehydratase by incubation of 5 µM of protein fragments in P. falciparum culture. Similar to 
Bonday et al. (2000), 5 µM of hPrx2 mutants were incubated with P. falciparum from the ring 
stage (~ 6 hour post invasion) for 24 h to the trophozoite stage (~ 30 h post invasion). The 
uptake of the hPrx2 mutants was determined by Western blot analysis using a hexahistidyl-tag 
monoclonal antibody (antibody against the 6x His-tag) as the primary antibody and an anti-
mouse secondary antibody. Similar to host hPrx2, Figure 3.45 shows that all recombinant 
hPrx2 mutants were taken up but hPrx2(C51S), hPrx2(C172S), hPrx2(C51/172S) , hPrx2(Clat129-133), 
hPrx2(15-198) and hPrx2(1-177) were digested. This data suggests that recombinant hPrx2 mutants 
follow the same route of uptake as the host hPrx2 into the food vacuole. 
 
 
 
 
Figure 3.45: Uptake of hPrx2 mutants into P. falciparum. Western blot analysis of hPrx2 mutants 
was carried out using a hexahistidyl-tag monoclonal antibody. All hPrx2 mutants were taken up but 
hPrx2(C51S), hPrx2(C172S), hPrx2(C51/172S) , hPrx2(Clat129-133), hPrx2(15-198) and hPrx2(1-177) were digested. All 
samples were run at 3 x 107 parasites/ lane.  
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3.2.3 Inhibition of the uptake of hPrx2 into P. falciparum 
3.2.3.1 Localisation of hPrx2 in P. falciparum 
Previously, Koncarevic et al. (2009) demonstrated the enhanced uptake of host hPrx2 
into the cytosol of P. falciparum after treatment with CQ. In addition, not only was hPrx-2 
reported to run in 3 bands at 15, 17, and 22 kDa but also the C-terminus was never identified 
(Koncarevic et al., 2009). Of note the C-terminal end contains the resolving cysteine (C172) 
that plays an important catalytic role. Furthermore, Foth et al. (2011) recently reported that 
the abundance of hPrx2 peaks in ring stage parasites (< 16 h post invasion) drastically 
reducing thereafter probably due to degradation by proteases or limitation in import 
transporters. Thus, to identify whether the 15 and 17 kDa proteins were conformations or 
digestion products, the protein sequence of hPrx2 was searched for protease cleavage sites. 
First, three falcipain-2 and falcipain-3 cleavage sites (Figure 3.45) previously reported by 
Sijwali et al. (2001) and Subramanian et al. (2009) were identified to be present in hPrx2. 
Interestingly, as shown in Figure 3.45, besides the 15 kDa and 17 kDa digestion products an 
additional 13 kDa protein fragment was predicted. 
 
Full length hPrx2 Protein (22 kDa) 
 
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPTEIIAFSNRA
EDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKTDEGI
AYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQAFQYTDEHGEVCPAGWKPGSDTIKPN
VDDSKEYFSKHN 
 
hPrx2 fragment (13 kDa)  
 
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPTEIIAFSNRA
EDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVL
 
 
hPrx2 fragment (15 kDa) 
 
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPTEIIAFSNRA
EDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKTDEGI
AYRGLFIIDGKGVL 
 
hPrx2 fragment (17.1 kDa) 
 
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPTEIIAFSNRA
EDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKTDEGI
AYRGLFIIDGKGVLRQITVNDLPVGRSVDEAL 
 
Figure 3.45:  Falcipain-2 and falcipain-3 cleavage sites in hPrx2. Cleavage at the predicated sites 
would result in the 13 kDa, 15 kDa and 17 kDa protein fragments. The falcipain -2 and -3 cleavage 
sites are underlined in the full length sequence (Sijwali et al., 2001, Subramanian et al., 2009). The 
antibodies recognizing the peptides L103LADVTRRLSED114 ( in blue, Axxora), C-terminal 184 
KPNVDDSKEYFSKHN198 (in red, Sigma)  and 19 VVDGAFKEVKL30 (in green, Dianova) were used 
for Western bloting or immunofluorescence. 
 
Next the localization of hPrx2 in P. falciparum by sub-cellular fractionation of cytosol and 
food vacuole was re-examined. As shown in Figure 3.46A,  the 17 kDa and 15 kDa digestion 
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products of hPrx2 initially identified in the total parasite lysate were only located in food 
vacuole fraction (Figure 3.46C) using an antibody recognizing the peptides 
L103LADVTRRLSED114 (Axxora). To confirm these digestion products an antibody directed 
against the C-terminal sequence 184 KPNVDDSKEYFSKHN198 (Sigma) were used. 
Figure 3.46:  Western blot analysis of hPrx2 in P. falciparum. 
Western blots with antibody against L103LADVTRRLSED114 (A) and C-terminal end 
184KPNVDDSKEYFSKHN198 (B) showing digestion of hPrx2. The two antibodies recognizing the 
peptides L103LADVTRRLSED114 ( in blue, Axxora) and C-terminal 184 KPNVDDSKEYFSKHN198 (in 
red, Sigma) are indicated in figure 3.45). (C) Sub-cellular analysis of cytosol and food vacuole (FV) 
fractions. hPrx2, SL and TPL are the full length recombinant hPrx2, saponin lysate and total parasite 
lysate, respectively. All samples were run at 3 x 107 parasites/ lane.  
 
As expected, the C-terminal 184 KPNVDDSKEYFSKHN198 (Sigma) recognised only the full 
length 22 kDa (Figure 3.46B) while L103LADVTRRLSED114 (Axxora) recognised all proteins 
including the digestion products 15 kDa and 17 kDa (Figure 3.46 A, C). Clearly, the presence 
of digestion products agrees with the presence of hPrx2 in the food vacuole that contains 
falcipain cleavage enzymes (Sijwali et al., 2001, Subramanian et al., 2009) rather than the 
cytosol. Next by confocal microscopy the sub-cellular localization of hPrx2 in P. falciparum 
was re-examined. Surprisingly, hPrx2 was located in the food vacuole (Figure 3.47A and B). 
To further confirm the presence of hPrx2 in the food vacuole, P. falciparum parasites 
expressing hGrx1-roGFP2 in the cytosol were used for colocalisation (Figure 3.1). As shown 
in Figure 3.47 C-F, hPrx2 was confirmed to be localized in the food vacuole. Taken together, 
the confocal microscopy and Western blot analysis data re-affirm the uptake of hPrx2 into P. 
falciparum but also reveal its degradation in the food vacuole. This is in clear agreement with 
Foth et al. (2011) that the abundance of hPrx2 peaks in ring stage parasites (< 16 h post 
invasion) dramatically reducing thereafter due to proteolytic degradation. 
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Figure 3.47: Confocal microscopy of host hPrx2 in P. falciparum. 
Host human peroxiredoxin 2 (hPrx2) is located in the food vacuole. The two antibodies recognizing 
the peptides L103LADVTRRLSED114 (in blue, Axxora) and 19VVDGAFKEVKL30 (in green, Dianova) 
are indicated in Figure 3.45 and were used for images A, C, D and B, E, F respectively. DIC is bright 
field while the Hoechst stain is used to locate the parasite nucleus.  
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3.2.3.2 Susceptibility of P. falciparum to inhibitors of endocytosis  
Inhibition of endocytosis of protein uptake into P. falciparum is a potential drug target 
(Hoppe et al., 2004). To investigate the effect of 12 inhibitors of endocytosis on the uptake of 
hPrx2 into P. falciparum (Koncarevic et al., 2009) initially the activity (IC50) of inhibitors on 
the 3D7 strain was determined by isotopic assay (Desjardins et al., 1979). Figures 3.48 and 
3.49 show the dose response curves of CTD, JAS, MNS, NH4Cl, BFA, NaN3, MQ and [AlF4]-
.The IC50 values of CTD, JAS, MNS and NH4Cl, on the 3D7 strain were determined to be 
13.1 nM, 73.5 nM, 1.01 nM and 2050 nM respectively. The IC50 values of BFA, NaN3, MQ 
and [AlF4]- against the 3D7 strain were determined to be 209.0 nM, 1310 nM, 16.8 nM and 
2330 nM respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.48: Dose response curves of actin inhibitors and alkalizing agents. 
The susceptibility of 3D7 strain of P. falciparum against cytochalasin D (CTD, A), jasplakinolide 
(JAS, B) monensin (MNS, C) and ammonium chloride (NH4Cl, D) was determined using the 72 h 
isotopic assay (Desjardins et al., 1979). 
 
The IC50 value of PQT against the 3D7 strain was determined to be 45µM. Besides inhibiting 
hemozion formation antimalarials including CQ MQ and ART were reported to block 
endocytosis in P. falciparum (Hoppe et al., 2004). Previously, the IC50 values of CQ and ART 
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against the 3D7 strain were determined to be 8.6 ± 0.4 nM and 17.3 ± 1.5 nM respectively 
(Akoachere et al., 2005). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.49: Dose response curves of inhibitors of endocytosis. 
The susceptibility of 3D7 strain of P. falciparum against brefeldin A (BFA, A), sodium azide (NaN3, 
B), mefloquine (MQ, C) and aluminum tetrafluoride ([AlF4]- , D) was determined using the 72 h 
isotopic assay (Desjardins et al., 1979). 
 
3.2.3.3 Effect of inhibitors of endocytosis on the uptake of hPrx2 
To examine whether inhibitors of endocytosis would block the uptake of hPrx2, 
synchronized ring stage P. falciparum parasites were incubated with 4 x IC50 of CTD, JAS,  
MNS, NH4Cl, AlF-4, CQ, MQ, ART for 24 h. Following incubation, trophozoite stage P. 
falciparum parasites were enriched by magnetic separation (80-90%) and then lysed by 
saponin and washed to remove extracellular proteins. Coomassie-stained gels showed uniform 
protein levels and no change in the 22 kDa hPrx2 protein band in treated samples (Figure 3.50 
A, B). The inhibition of the uptake of hPrx2 into P. falciparum was evaluated by Western blot 
analysis.  As shown in Figure 3.50, all samples (except BFA) were run in duplicate. After 24 
h of incubation MQ, ART, CTD, JAS, DYN, PQT, MNS, CQ and NaN3 inhibited uptake and 
digestion of host hPrx2. By constrast, NH4Cl increased uptake of hPrx2 while BFA had very 
minimal effect of inhibition of hPrx2 uptake. 
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Figure 3.50: Effect of actin inhibitors and alkalizing agents on the uptake of hPrx2. 
(A) Coomassie stained SDS PAGE with M the molecular weight marker, chloroquine (CQ), 
mefloquine (MQ), artemisinin (ART), cytochalasin D (CTD), jasplakinolide (JAS) monensin 
(MNS) and ammonium chloride (NH4Cl) brefeldin A (BFA), sodium azide (NaN3), mefloquine (MQ) 
and aluminum tetrafluoride ([AlF4]-) (B) Western blot analysis was done in duplicate using the 
antibody recognizing the peptides L103LADVTRRLSED114 (Axxora). All samples were run at 3 
x 107 parasites/ lane. Samples included a control (CTL), Dynasore (DYN) and paraquat (PQT).  
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3.3 Susceptibility of gametocytes of P. falciparum to antimalarial drugs 
3.3.1 In vitro activity of methylene blue against gametocytes of P. falciparum.  
 Previously, a clinical study by Coulibaly et al. (2009) revealed that MB in combination 
with AS or AQ had strong gametocytocidal activity against both existing and developing P. 
falciparum gametocytes. However, the in vitro gametocytocidal activity of MB had never 
been determined. To complement the clinical study by Coulibaly et al. (2009), the activity of 
MB on P. falciparum gametocytes in vitro was systematically investigated. Additionally, the 
activity of PYO and CQ (as a control) on P. falciparum gametocytes in vitro was investigated. 
Figure 3.51 and Table 3.5 show the dose response curves and the IC50-values, respectively, of 
day 9 (stages II & III) and day 13 (stages IV & V) against MB, PYO and CQ. Notably only 
MB had activity across all stages of gametocyte development. Interestingly, MB, PYO and 
CQ were found to be 2, 3 and 50 times respectively, more active against day 9 (stages II & 
III) than day 13 (stages IV & V) gametocytes of the P. falciparum strain 3D7. Collectively, 
these data reveal that MB is a potent inhibitor of all stages (II-V) of gametocyte development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.51: Dose response curves for activity of antimalarial drugs against gametocytes of P. 
falciparum. Methylene blue (MB, A) had activity against both day 9 (young, stage II and III) and day 
13 (mature, stage IV and V) gametocytes unlike pyocyanin (PYO, B) and chloroquine (CQ, C). Dose 
response curves were generated by GraphPad prism. 
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Table 3.5: Sensitivity of P. falciparum gametocytes to methylene blue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a95% Confidence interval. The IC50s between early (day 9, stages II & III) and late (day 13, stage IV 
& V) gametocyte stages were significantly different for all compounds: MB (P = 0.001), PYO (P = 
0.002) and CQ (P = 0.01). 
 
3.3.2 In vitro gametocyte assay based on SYBR green I fluorescence 
To identify novel agents that can kill gametocytes, simple, rapid and robust drug 
susceptibility assays are required (Adjalley et al., 2011). In this thesis, after drug exposure in 
microtiter plates, the gametocytes were frozen at -80 ºC and thawed before the SYBR1 assay 
as described (Smilkstein et al., 2004) was carried out. 
 
Table 3.6: Comparison of SYBR green I-based and microscopic drug susceptibility 
assays of P. falciparum gametocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.52 and Table 3.6 show the dose response curves and the IC50-values of day 9 (stages 
II & III) and day 13 (stages IV & V) against CQ.As expected, CQ was active against day 9 
(stage II-III) but not day 13 (stage IV-V) gametocytes validating microscopic methods. 
Although, further optimization of this assay may be required, the use of SYBR green-I 
fluorescence results in an assay suitable for the rapid and robust evaluation of susceptibility of 
gametocytes of P. falciparum to antimalarial drug. 
 
 
 
IC50 (95% CI)a [nM] 
 
Compound Day 9 gametocytes 
(stages II & III) 
Day 13 gametocytes 
(stages IV & V) 
Methylene blue  33.8 (32.1-35.7) 59.5 (37.3-94.8) 
Pyocyanin  178 (147-215)a 557 (262-1190) 
Chloroquine  8.60 (3.02-24.7) 487 (278-854) 
IC50 (95% CI) [nM] 
 
Chloroquine Day 9 gametocytes 
(stages II & III) 
Day 13 gametocytes 
(stages IV & V) 
Microscopy  8.60 (3.02-24.7) 487 (278-854) 
SYBR green I-based         11.26 214.0 
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Figure 3.52: Dose response curves for SYBR green-I fluorescence gametocytocidal assay. 
Following treatment with chloroquine (CQ) in microtiter plates, the gametocytes were frozen 
at -80 ºC and thawed before the SYBR1 assay as described (Smilkstein et al., 2004) was 
carried out. 
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4. DISCUSSION 
 
4.1 Real time imaging of the glutathione redox potential  
 In this thesis, for the first time, the rapid, dynamic and quantitative real time imaging of 
changes in the EGSH in the cytosol of P. falciparum was demonstrated, thereby offering novel 
spatiotemporal insights into the role of GSH metabolism in the mechanisms of drug action 
and resistance. Importantly, the cytosolic basal EGSH of Dd2 and 3D7 strains was found to be -
313.9 ± 3.4 mV and -314.2 ± 3.1 mV respectively suggestive of a highly reducing 
compartment. Previously, the useful reporting range of roGFP2 at pH 7.2 was ~ -312 mV to -
256 mV (Schwarzländer et al., 2008). Thus, the determined cytosolic EGSH are in the reporting 
range for roGFP2. The cytosolic basal EGSH in P. falciparum, are consistent with those of the 
cytosol of other organisms determined using roGFP-based probes such as -325 mV in HeLa 
cells (Dooley et al., 2004), -318 mV in Arabidopsis thaliana (Braun et al., 2010) and -310 to -
320 mV in Saccharomyces cerevisiae (Morgan et al., 2011; Braun et al., 2010). Previously, 
using global values (2.39 mM GSH; 8.4 µM GSSG, Atamna and Ginsburg, 1997) to represent 
the cytosol of trophozoite stage of P. falciparum, the basal EGSH was estimated to be -265 mV 
at 37°C and pH 7.2 (Becker et al., 2003). However, different concentrations of total GSH 
ranging from 0.4 mM to 2.3 mM in total parasite lysates taken to represent the cytosol of P. 
falciparum have been reported (Buchholz et al., 2008). Yet, EGSH depends not only on the 
ratio of GSH to GSSG but also on the concentration of GSH (Schafer and Buettner, 2001; 
Becker et al., 2003). These discrepancies may be due to the use of cell disruptive methods 
which not only result in loss but also in mixing of GSH or GSSG from different 
compartments and oxidation of GSH to GSSG. Compared with estimates using global 
cytosolic values, EGSH measurements determined using roGFP2 based methods give 
improvements of 2 to 3 orders of magnitude (Morgan et al., 2011). Here using a non-
disruptive genetically encoded biosensor (hGrx1-roGFP2), a more reliable estimate of the 
EGSH in the cytosol of P. falciparum is provided. 
 Notably, data in this thesis show that MB rapidly depletes cytosolic GSH but in 
contrast, other antimalarial drugs including quinolines and ART derivatives most likely have 
down stream effects on EGSH. A model (Figure 4.1) explains the differential changes in 
cytosolic EGSH induced by antimalarial drugs. In P. falciparum, the cytosol is the site of GSH 
biosynthesis. GSH metabolism is differentially regulated in the drug resistant (Dd2) and 
sensitive (3D7) strains mainly by γ-GCS, PfGR and GSSG efflux (Meierjohann et al., 2002). 
Indeed the GSH concentration in Dd2 was reported to be twice that in 3D7 and γ-GCS 
activity was 36 % higher in Dd2 compared to 3D7, but in contrast, GR activity was 1.5 fold 
higher in 3D7 than in Dd2 (Meierjohann et al., 2002). Interestingly, only upon drug treatment, 
the GSSG efflux is more reduced in Dd2 (by 20 %) than in 3D7 (by 10 %). Furthermore, 
transporters including PfCRT (Fidock et al., 2000) and PfMDR1 (Reed et al., 2000) on the 
food vacuole as well as PfMRP1 in the plasma membrane (Raj et al., 2009) mediate 
accumulation of drugs between the cytosol and different organelles (Sanchez et al., 2010), 
thereby influencing changes in cytosolic EGSH. Mutant PfCRT in Dd2 may transport CQ, AQ, 
QN and MQ out of the food vacuole where these drugs accumulate (Sanchez et al., 2010). In 
contrast PfMDR1 may pump CQ, QN MQ ART into the food vacuole. PfMRP1 may pump 
Discussion  
 115 
GSH, GSH- conjugates, CQ, QN, and ART out of the parasite’s cytoplasm (Raj et al., 2009; 
Sanchez et al., 2010). 
MB is the oldest synthetic antimalarial drug (Guttmann and Ehrlich, 1891; Schirmer et 
al., 2011) and has been shown to be active against asexual stages (Akoachere et al., 2005) and 
against gametocytes both in vitro (Kasozi et al., 2011) and in clinical studies (Coulibaly et al., 
2009). Recently, due to reduced susceptibility of P. falciparum strains to ART derivatives, 
there is a renewed interest in MB-based combination therapies (Zoungrana et al., 2008; 
Schirmer et al., 2011). Pharmacokinetically, MB is characterized by high bioavailability 
accumulating to concentrations up to 30 µM in blood (Schirmer et al., 2011; Kasozi et al., 
2011). Remarkably, MB rapidly depleted GSH from the cytosol of both resistant (Dd2) and 
sensitive (3D7) strains of P. falciparum at micromolar concentrations comparable to those 
observed in blood. MB both in vitro and in vivo oxidizes GSH with or without the formation 
of H2O2 (Kelner and Alexander, 1985). MB inhibits flavin-dependent disulfide reductases 
PfGR, thioredoxin reductase (TrxR) and other enzymes. MB is rapidly converted to its 
reduced conjugate leucomethylene blue (LMB) by endogenous flavin reductases. Then LMB 
is rapidly re-oxidized by oxygen to MB with concomitant generation of ROS that overwhelm 
the parasite redox defence processes (Kelner and Alexander 1985; Buchholz et al., 2010). In 
vivo MB can directly accept electrons from reducing agents such as NADH, NADPH, and 
GSH which are then transferred to oxygen to generate ROS such as H2O2. Prior studies 
indicate that MB inhibits PfGR (Färber et al., 1998) however wild type and GR knockout of 
P.berghei blood stages parasites had the same susceptibility to MB (Pastrana-Mena et al., 
2010; Buchholz et al., 2010) suggesting that GR may not be a primary target. Furthermore, 
MB exhibited comparable susceptibility against resistant and sensitive strains of P. 
falciparum suggesting that its activity is unaffected by mutations in PfCRT and PfMDR1. MB 
has also been reported to inhibit hemozion formation thereby ensuring that none polymerized 
heme exits into the cytosol exerting oxidative stress (Figure 4.1). Interestingly, after 4 h 
incubation at concentrations ranging from ~ 1 x IC50 to 100 x IC50 and 24 h at a concentration 
of 4 x IC50, oxidation by MB was stronger in sensitive (3D7) than resistant (Dd2) strain. 
These results are in accordance with observations that the resistant Dd2 contains twice the 
GSH concentration when compared to the sensitive strain (3D7) (Meierjohann et al., 2002). 
Taken together, the fact that MB depletes GSH from the cytosol of P. falciparum thereby 
highlights the significance of the GSH redox system as a drug target. 
PYO is an analog of MB with antiplasmodial activity against asexual blood stage 
parasites as well as young gametocytes (Kasozi et al., 2011). Concentrations of up to 100 µM 
PYO have been detected in the sputa of Pseudomonas aeruginosa - infected cystic fibrosis 
patients (Wilson et al., 1988). Oxidation of hGrx1-roGFP2 by PYO may be explained by fact 
that PYO is a redox cycing agent and exhibits pro-oxidant activity. Like MB, PYO can 
directly accept electrons from reducing agents such as NADH, NADPH, and GSH. Electrons 
are then transferred to oxygen to generate ROS such as H2O2 and singlet oxygen at the 
expense of host antioxidant capacity. 
MNA derivatives as suicide inhibitors of PfGR are lead antimalarial drugs (Bauer et 
al., 2006) that have shown activity on P. yoelii in mice models (Arora and Srivastava, 2005). 
Previously, MNA has been used in roGFP-based studies in HeLa cells (Dooley et al., 2004), 
Arabidopsis (Schwarzländer et al., 2009) and in cardiomyocytes (Loor et al., 2010) to induce 
ROS through redox cycling. Like MB and PYO, MNA also induces oxidative stress by redox 
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cycling. In addition to oxidizing GSH to give GSSG, H2O2 and superoxide (Wendel, 1981; 
Ross et al., 2003), MNA forms a 2-methyl-3- S-glutathionyl-1, 4-naphthoquinone (thiodione) 
conjugate (Akerboom et al., 1988). More importantly, MB exhibited stronger ROS induction 
capacity than MNA. 
ART and its derivatives ATS and ATM are the main stay of antimalarial treatment as 
major partners in ACT (Eastman and Fidock, 2009). ART derivatives are characterized by a 
broad activity across asexual stages including ring, trophozoite and schizont stage as well as 
against young gametocytes (White, 2008). In P. falciparum, using a fluorescent dansyl 
trioxane derivative (Hartwig et al., 2009) and the pH-sensitive probe LysoSensor Blue (del 
Pilar Crespo et al., 2008), ART has been shown to initially accumulate in the food vacuole 
(Figure 4.1). Although the mode of action remains unknown (O’Neill and Posner, 2004), 
current evidence suggests that ART and its derivatives generate carbon centered radicals that 
potentially may alkylate vital target cellular components such as GSH (Mukanganyama et al., 
2001) leading to parasite death (Stocks et al., 2007). Surprisingly, in short term experiments 
(5 min), ART and its derivatives failed to oxidize both the recombinant hGrx1-roGFP2 
protein and P. falciparum expressing hGrx1-roGFP2 even at concentrations up to 100 µM. In 
agreement with these data, ART derivatives have been reported not to act like truly pro-
oxidant drugs (Meschnick and Dobson, 2001). Indeed, pro-oxidant end products have been 
observed at high concentrations (>100 µM) (Meschnick and Dobson, 2001), whereas the drug 
is effective at 10,000-fold lower concentrations (Akoachere et al., 2005). Interestingly, 
following 24 h incubation at a concentration of 4 x IC50, ART derivatives induced the 
strongest oxidation and stronger in the sensitive (3D7) than in the resistant (Dd2) strain. 
Nevertheless, limited changes in EGSH were observed in the Dd2 strain. This result is 
consistent with apparently no changes in the GSSG level despite reduction in GSH levels after 
exposure of P. falciparum to dihydroartemisinin which may be explained by efflux of GSSG 
or adducts of GSH-ART by PfMRP (Raj et al., 2009) (Figure 4.1). Furthermore, the 
susceptibility of sensitive (3D7) and resistant (Dd2) strains against ART and its derivatives 
were comparable (Akoachere et al., 2005) despite reported differences in GSH concentrations 
(Meierjohann et al., 2002). Taken together, our data show that ART and its derivatives exhibit 
significant but delayed effects on GSH metabolism. To explain these results, it is 
hypothesized that ART derivatives (Figure 4.1) probably accumulate and directly act on other 
target(s) both in the cytosol and the food vacuole that lead to the production of ROS which 
ultimately but later significantly affect cytosolic GSH levels. Putative targets of alkylation 
such as the PfATP6 - a SERCA-type Ca2+ – ATPase (Pandey et al., 1999), translationally 
controlled tumor protein (Bhisutthibhan et al., 1998), heme (Kannan et al., 2002), reduced 
GSH (Mukanganyama et al., 2001) and the cysteine proteases (Pandey et al., 1999), proteins 
of the electron transport chain (Li et al., 2005), mitochondrial membrane (del Pilar Crespo et 
al., 2008) have been reported. In addition, ART derivatives have been reported to disrupt the 
redox homeostasis within the malaria parasite, both by oxidizing FADH2 in parasite GR or 
other parasite flavoenzymes, and by initiating autoxidation of the dihydroflavin by oxygen 
with generation of ROS (Haynes et al., 2011). 
Before adoption of ACT, quinoline antimalarial drugs including CQ, AQ, QN, MQ, 
played a key role in antimalarial chemotherapy (Eastman and Fidock, 2009). Currently due to 
high resistance, CQ was abandoned but AQ and MQ play major roles as partner drugs in 
ACT. Furthermore, QN is recommended for severe malaria (Achan et al., 2011). 
Discussion  
 117 
Significantly, mutations mainly in pfcrt (Fidock et al., 2000) and pfmdr1 (Reed et al., 2000) 
differentially influence quinoline drug action and resistance. Nevertheless, an additional role 
for GSH in mode of action and resistance to CQ was suggested (Ginsburg et al., 1998). 
Evidence suggests that quinoline antimalarials inhibit biocrystallization of ferriptoroporphyrin 
IX (FP) into hemozoin in the food vacuole. However, free FP exits from the food vacuole into 
the parasite’s cytosol where it can be degraded by GSH. Yet, FP degradation by GSH is 
reported to be effectively inhibited by CQ and AQ, but not by QN or MQ (Ginsburg et al., 
1998). Furthermore, support for a possible role for CQ-FP induced oxidative stress (Loria et 
al., 1999; Graves et al., 2002) as part of the mechanism of action of CQ has been provided 
however this has been questioned (Monti et al., 2002). Suprisingly, none of the quinoline 
drugs CQ, AQ, QN and MQ caused increases in the fluorescence ratio 405/488 nm of the 
recombinant hGrx1-roGFP2 protein, thereby suggesting that reactive intermediates may be 
responsible for the oxidative effects of quinoline drugs in the parasite P. falciparum. 
Furthermore, unlike MB, none of the quinoline drugs rapidly (within 5 min) caused increases 
in the fluorescence ratio 405/488 nm in short experiments even at concentrations up to 100 
µM. Interestingly, in both 4 and 24 h incubation experiments all drugs caused changes in the 
fluorescence ratio 405/488 nm which was greater in the sensitive (3D7) than the resistant 
(Dd2) strain. Surprisingly, MQ and QN elicited stronger oxidation than CQ or AQ. These data 
are consistent with previous reports suggesting that the primary mode of action of MQ and 
probably QN may be outside the food vacuole (Figure 4.1) probably in the cytosol including 
targeting PfMDR1 (Sanchez et al., 2010). Conceivably, inhibition of GSH-mediated and 
H2O2-mediated FP destruction by quinoline antimalarial drugs leads to a build up of FP and 
H2O2 exacerbating oxidative stress. Although quinolines do not release free radicals, 
presumably FP may exert cytotoxicity via free-radical dependent mechanism. 
Endogenously, H2O2 is formed during the conversion of oxyhemoglobin to 
methemoglobin in the food vacuole (Atamna and Ginsburg, 1993). Indeed it has been 
reported that when an endocytic vesicle containing 20 mM hemoglobin fuses with the food 
vacuole at  pH 5, oxyhemoglobin undergoes spontaneous auto-oxidation leading to production 
of  superoxide anions that dismutate to several millimolar concentrations of H2O2 (Atamna 
and Ginsburg, 1993). Interestingly, data here shows that hGrx1-roGFP2 in P. falciparum 
responded to millimolar concentrations of H2O2 comparable to those achievable within the 
parasite food vacuole. As already shown, H2O2 would diffuse rapidly into the cytosol. 
Alternatively, genetically encoded biosensors including roGFP2-Orp1 (Gutscher et al., 2009) 
and Hyper-2 (Markvicheva et al., 2011) that are sensitive to micromolar concentrations of 
H2O2 would be targeted to the P. falciparum cytosol. 
Finally, previous studies suggest that depletion of GSH is not a prerequisite for 
parasite death (Ittarat et al., 2003). Clearly, this study shows that there was more parasite 
death in the drug sensitive strain (3D7) which has lower GSH levels than the drug resistant 
strain (Dd2) that has higher GSH levels. Nonetheless, the GSH levels in the Dd2 strain were 
also depleted by diamide but without significant parasite death. Collectively, these data 
suggest that depletion of GSH may increase the susceptibility of P. falciparum to death 
caused by antimalarial drugs due to disruption of other vital cellular processes.  
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Figure 4.1:  Model for glutathione redox potential  
Methylene blue (MB), Artemisinin (ART), Artesunate (ATS), Artemether (ATM), Chloroquine (CQ), 
Amodiaquine (AQ), Quinine (QN) and Mefloquine (MQ) as well as compounds including Buthionine 
sulfoximine (BSO) and Pyocyanin (PYO) accumulate in the food vacuole and the cytosol of P. 
falciparum. Following its uptake hemoglobin is digested to heme (FIX) and globin. MB, ART, ATS 
ATM [3], CQ, AQ, QN and MQ inhibit the formation of hemozion (HZ).  Then non-polymerized 
heme exits the food vacuole into the cytosol, were it is degraded by GSH. CQ and AQ but not QN or 
MQ inhibit GSH-mediated degradation of free heme. Inhibition of GSH-FP destruction leads to a 
build up of H2O2 and FP exacerbating oxidative stress MB and PYO are furthermore redox cyclers and 
directly oxidize GSH which may explain their rapid actions on EGSH. Furthermore, transporters 
including PfCRT and PfMDR1 on the food vacuole as well as PfMRP1 in the plasma membrane 
mediate accumulation of drugs between the cytosol and different organelles [8], thereby influencing 
changes in cytosolic glutathione redox potential (EGSH). Mutant PfCRT in Dd2 may transport CQ, AQ, 
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QN and MQ out of the food vacuole where these drugs accumulate [5].  In contrast PfMDR1 may 
pump CQ, QN, MQ, ART into the food vacuole [6].  PfMRP1 may pump GSH, GSH- conjugates, CQ, 
QN, and ART out of the parasite’s cytoplasm [7]. Furthermore, other factors also explain differences 
in EGSH. Glutathione metabolism is differentially regulated in the drug resistant (Dd2) and sensitive 
(3D7) strains mainly by γ-GCS, PfGR and GSSG efflux. The GSH concentration in Dd2 has been 
reported to be twice that in 3D7 while γ-GCS activity was 36 % higher in Dd2 compared to 3D7, but 
in contrast, GR activity was 1.5 fold higher in 3D7 than in Dd2 [16]. Interestingly, only upon drug 
treatment, the GSSG efflux is more reduced in Dd2 (by 20 %) than in 3D7 (by 10 %). 
 
Indeed oxidative and nitrosative stress are known to promote protein-S-
glutathionylation (Townsend, 2007) adversely affecting cellular physiological processes 
including energy metabolism, protein folding, calcium homeostasis, redox regulation and, 
redox and signaling proteins -mainly kinases and phosphatases. Recently, 493 targets of 
protein-S-glutathionylation were identified in P. falciparum (Kehr et al., 2011). Of these, 
enzymes involved especially in energy metabolism including glyceraldehyde 3-phosphate 
dehydrogenase and pyruvate kinase were shown to be reversibly inhibited by S-
glutathionylation.  
In summary, the applicability of a highly specific biosensor hGrx1-roGFP2 for 
measuring the intracellular EGSH, in real time, in P. falciparum has been demonstrated. This 
biosensor should be particularly useful in elucidating the roles of oxidative stress not only in 
the mechanism of action of a wide range of antimalarial drug candidates, but also for 
investigating the effects of immunity, including the oxidative burst in immune cells, which 
plays a major role in destroying parasites/pathogens. 
 
4.2 Uptake of host hPrx2 into P. falciparum 
 Endocytosis has been suggested as an essential macromolecular uptake mechanism 
of host cytosol proteins into P. falciparum (Hoppe et al., 2004). Using electron microscopy, 
Elliott et al. (2008) reported that hemoglobin, the best studied protein, is taken up 
additionally, by the “big gulp”, via cytostomal tubes and phagotrophy. Indeed several 
conflicting models to explain the uptake of proteins have been suggested (Baumeister et al., 
2010). To date, besides hemoglobin, several host erythrocytic proteins (~30, Table 3.3) have 
been reported to be imported into P. falciparum to perform crucial roles in parasite 
physiology (Bonday et al., 2000; Varadharajan et al., 2004; Foth et al., 2011) and antioxidant 
defense (Fairfield and Meshnick, 1983; Koncarevic et al., 2009). Interestingly, some proteins 
have been reported to be imported to different compartments or organelles, in particular, the 
cytosol and food vacuole suggesting that the molecular uptake mechanism may involve novel 
sorting motifs. In this thesis, four endocytosis associated motifs namely: the sorting and 
internalization signal (SIS), tyrosine-based sorting signal (TSS) and clathrin box motif (Clat) 
and the WXXXY|F motif which are differentially distributed in imported erythrocytic proteins 
were identified. Surprisingly, few proteins (7) including hPrx2 contained SIS (154 VDEALRL 
159), TSS (37 YVVL40; 115YGVL118; 126YRGL129) and Clat (129 LFIID133). By evaluation of the 
uptake of SIS, Clat, active site as well as N- and C- terminal deletion mutants of hPrx2, it has 
been shown that the endocytosis associated motifs in hPrx2 may mediate its uptake into 
different compartments in P. falciparum. Similar to host hPrx2, all recombinant hPrx2 
mutants were taken up but hPrx2(C51S), hPrx2(C172S), hPrx2(C51/172S) , hPrx2(Clat129-133), hPrx2(15-
198)
 and hPrx2(1-177) were digested. Nevertheless, these aspects need to be investigated further, 
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to encompass more imported proteins that perform different functions. This data is in 
agreement with that of Bonday et al. (2000) on the uptake of recombinant mutants of δ-
aminolevulinate dehydratase. Although not identified at that time, here it is shown that the 
smallest 93-amino-acid fragment of δ-aminolevulinate dehydratase that was proved to be 
imported into the cytosol of P. falciparum contained SIS (103EAIHLLR108). These data are in 
agreement with the reported abundance profile for hPrx2 where hPrx2 peaks in ring stages (< 
16 h post invasion) followed by decline probably due to degradation by proteases. One 
possible model to explain these results is based on the role of big gulp and endocytic vesicles 
in uptake of erythrocytic proteins (Elliott et al., 2008). The big gulp occurs in the ring stages 
while endocytic vesicles take place throughout the entire life cycle. The big gulp is formed 
through invagination of the parasite vacuole membrane (PVM) and parasite membrane (PM) 
enclosing host proteins giving rise to the food vacuole. Several proteins along with hPrx2 may 
be imported via this route and subsequently some may be digested like hemoglobin (Lazarus 
et al., 2008) and catalase (Clarebout et al., 1998). However, others such as δ-aminolevulinate 
dehydratase (Bonday et al., 2000) may escape degradation by binding to food vacuole 
membrane proteins and using the endocytosis motif to translocate to the cytosol. 
Alternatively, after the big gulp, endocytosis motifs may play a major role in determining 
which proteins are taken up in the endocytic vesicles.  Here it is shown that hPrx2 is imported 
into the food vacuole and digested but presumably some of the fragments may translocate, as 
earlier reported to the cytosol (Koncarevic et al., 2009). Even after the big gulp, hPrx2 may 
continue to be taken up in endocytic vesicles via its identification using endocytosis motifs. 
 Although the 15 kDa and 17 kDa digestion products of hPrx2 were observed in this 
thesis and by Koncarevic et al. (2009), hPrx2 here is reported in the food vacuole in constrast 
to cytosol (Koncarevic et al., 2009). The difference in location of hPrx2 may be explained by 
sample fixation step used in the immunofluorescence methods. Here 4% paraformaldehye and 
0.00075% glutaraldehyde were used as described (Tonkin et al., 2004) while Koncarevic et 
al. (2009) used 5% methanol and 95 % acetone for sample fixation. Sample fixation is a 
crucial step in preservation of cell morphology. Formaldehyde prepared from 
paraformaldehyde is the fixative of choice to examine subcellualar localization as it acts as a 
mild cross linker. By contrast, cold methanol and acetone work by precipitating proteins and 
carbohydrates and hence do not maintain integrity of membranes and organnelles during 
localization (Tonkin et al., 2004). Hence it may be that the presence of hPrx2 in the cytosol 
was due to the rupture of the food vacoule membrane. Similarly, Chu et al. (2011) found that 
PfPV1 localised solely to the parasitophorous vacuole when using the method described by 
Tonkin et al. (2004) in contrast to the parasitophorous vacuole and the Maurer’s clefts when 
using methanol/ acetone methods (Nyalwidhe  and  Lingelbach, 2006). Taken together in this 
thesis further evidence is provided for the use of formaldehyde (Tonkin et al., 2004) as a 
method of choice for subcellular localisation of proteins in P. falciparum by 
immunofluorescence.  
Previous studies suggest that quinoline drugs, ART derivatives (Hoppe et al., 2004), 
actin inhibitors (Smythe et al., 2008) and alkalinizing agents (Hoppe et al., 2004) inhibit 
endocytosis in P. falciparum. By Western blot analysis of P. falciparum following a 24 h 
incubation at a concentration of 4 x IC50, it was found that CQ, MQ, ART, CTD, JAS, DYN, 
BFA, NaN3, MNS, NH4Cl and PQT differentially inhibited not only endocytosis but also 
digestion of hPrx2. Among the tested antimalarial drugs, ART and MQ inhibited both 
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endocytosis and digestion of hPrx2 greater than CQ. Similarly, these data are in agreement 
with reported effects of ART, MQ and CQ on endocytosis. Hoppe et al. (2004) reported that 
MQ and ART inhibited endocytosis of hemoglobin but CQ only disrupted the fusion of 
transport vesicle with food vacuole. Indeed, recently, Klonis et al. (2011) reported that the 
activity of ART against P. falciparum required not only the uptake but also digestion of 
hemoglobin. Indeed treatment of either P. falciparum (Hoppe et al., 2004) or P. berghei 
(Fitch, 2004) with CQ has been shown to lead to the accumulation of transport vesicles in the 
parasite cytoplasm. Consistent with this data, Koncarevic et al. (2009) demonstrated the 
enhanced uptake of host hPrx2 into the cytosol of P. falciparum after treatment with CQ.  
Contradictory effects between the actin inhibitors JAS and CTD were reported on the 
endocytosis of hemoglobin into P. falciparum (Smythe et al., 2008). By constrast, here it is 
also shown that JAS and CTD had similar effects on the uptake of hPrx2. JAS the actin 
stabilization and polymerization agent reduced uptake of hPrx2 significantly greater than 
CTD a depolymerization agent. These data suggest that depolymerization of actin was 
stronger than stabilization and polymerization in inhibiting endocytosis. Additionally, both 
JAS and CTD inhibited digestion of hPrx2. Consistent with hemoglobin (Zhou et al., 2009), 
DYN inhibited endocytosis of hPrx2 highlighting the importance of dynamin in the uptake of 
proteins including hPrx2. 
Compared with CQ, alkalinizing agents such as MNS and NH4Cl have been reported 
to cause the accumulation of transport vesicles suggestive of a blockage in food vacuole-
vesicle fusion (Hoppe et al., 2004). Here it is shown that similar to CQ, MNS and NH4Cl had 
less inhibitory effect on endocytosis of hPrx2 into P. falciparum. Indeed NH4Cl significantly 
enhanced hPrx2 uptake. More importantly it was noted that MNS was highly active against P. 
falciparum (IC50 = 1.0 nM) suggesting that this class of compounds may be good lead 
antimalarial agents. As expected NaN3, an ATP depleting agent, inhibited uptake of hPrx2 
since endocytosis is an energy dependant process. By contrast, BFA did not have any impact 
on the uptake of hPrx2 into P. falciparum. In conclusion, the understanding of the 
mechanisms of uptake of host proteins may yield potential not only drug targets but also lead 
antimalarial candidates. 
 
4.3 In vitro activity of methylene blue against gametocytes of P. falciparum 
 Suitable control, elimination or eradication of malaria will require drugs that not only 
target the blood stages but also transmissible stages the gametocytes (Adjalley et al., 2011). 
Most antimalarial drugs including CQ and QN as well as ART (Benoit-Vical et al., 2007) kill 
immature gametocytes (stages 1-III). However, the young gametocytes (stages I-III) that are 
drug susceptible are sequestered while mature P. falciparum gametocytes are significantly 
more drug resistant and affected only by a few drugs such as 8-aminoquinolines (White, 
2008). Despite being an ancient antimalarial drug of the 1890s (Guttmann and Ehrlich, 1891), 
the in vitro activity of MB on P. falciparum gametocytes had never been shown. In this thesis, 
the in vitro activity of MB on gametocytes was demonstrated. In contrast to CQ and PYO, 
MB was highly active against all stages of gametocytes in the nanomolar range. Notably, the 
IC50 (95% confidence interval) of MB against young (stage II-III) and mature (stage IV-V) 
gametocytes was found to be 33.8 (32.1-35.7) nM and 59.5 (37.3-94.8) nM, respectively 
(Kasozi et al., 2011). These data by Kasozi et al. (2011) were reproduced in a later study by 
Adjalley et al. (2011). Consistent with previous reports (Benoit-Vical et al., 2007), CQ was 
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only active against young (day 9, stages II and III) but not mature gametocytes (day 13, stages 
IV and V). Interestingly, MB was more effective than PYO, which may be due to the fact that 
MB is a stronger inhibitor of PfGR than PYO (Kasozi et al., 2011). In accordance with 
clinical studies, Coulibaly et al. (2009) found strong gametocytocidal effects in trials of MB-
based combination therapy against falciparum malaria. Notably, MB has been shown to have 
prooxidant properties and to interfere with the thioredoxin and GSH system (Buchholz et al., 
2008). As mentioned above, MB in vivo oxidizes GSH with or without the formation of H2O2 
(Kelner and Alexander 1985). In vivo MB can directly accept electrons from reducing agents 
such as NADH, NADPH, and GSH which are then transferred to oxygen to generate ROS 
such as H2O2.  Indeed, knock out of either GR (Panstrana -mena et al., 2010; Buchholz et al., 
2010) or γ-GCS (Vega-Rodrigruez et al., 2009) from P. berghei though not essential for 
asexual stages were critical for sexual stages particularly oocyte development. Furthermore, 
the activity of MB may be explained by the enhanced expression of its target proteins 
including glyoxalases, glutaredoxin, and 2-Cys peroxiredoxin which are involved in 
protection against oxidative stress in mature gametocytes (Le Roch et al., 2003). The fact that 
MB nevertheless retains great potency against mature gametocytes supports its inclusion in 
ACT or the development of MB based combination therapies. 
 The lack of rapid quantitative assays for measuring the gametocytidal activity 
of existing and lead antimalarial drugs has precluded the identification of transmission 
blocking drugs. Most prior data on the in vitro gametocytocidal activity of existing 
antimalarial drugs was obtained by microscopic methods involving counting of gametocytes 
(counts per 10,000 erythrocytes on thin film) which is an extremely time consuming and 
laborious process. Recently, assays utilizing GFPs have been developed (Dixon et al., 2008; 
Buchholz et al., 2011; Adjalley et al., 2011). Assays developed by Dixon et al. (2008) and 
Buchholz et al. (2011) depend on episomally replicating plasmids and as a result selection 
agents mainly WR99210 are continuously added to the gametocytes to maintain fluorescence. 
Additionally Adjalley et al. (2011), developed an assay based on stable integration of GFP – 
luciferase reporter. Serious questions remain as to whether transgenic gametocytes are 
metabolically similar and susceptible as normal gametocytes. Moreover, promoter activity for 
pfs16, pfs48/45 and mal8p1.16 used in these GFP- based methods is so variable during 
gametocyte development. Furthermore, the period of time from transfection to appearance of 
transfectants may take at least 3-4 weeks or even much longer for stable integration. More 
importantly, here the SYBR1 green fluorescence method by Smilkstein et al. (2004) was 
adapted, giving rise to a simple, rapid and inexpensive fluorescence-based technique for 
determining activity of antimalarial drugs against gametocytes. 
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6. APPENDIX 
 
 1 M  A  Q  E  F  V  N  C  K  I  Q  P  G  K  V  V  V  F  I  K   
       1 ATGGCTCAAGAGTTTGTGAACTGCAAAATCCAGCCTGGGAAGGTGGTTGTGTTCATCAAG 
      21 P  T  C  P  Y  C  R  R  A  Q  E  I  L  S  Q  L  P  I  K  Q   
      61 CCCACCTGCCCGTACTGCAGGAGGGCCCAAGAGATCCTCAGTCAATTGCCCATCAAACAA 
      41 G  L  L  E  F  V  D  I  T  A  T  N  H  T  N  E  I  Q  D  Y   
     121 GGGCTTCTGGAATTTGTCGATATCACAGCCACCAACCACACTAACGAGATTCAAGATTAT 
      61 L  Q  Q  L  T  G  A  R  T  V  P  R  V  F  I  G  K  D  C  I   
     181 TTGCAACAGCTCACGGGAGCAAGAACGGTGCCTCGAGTCTTTATTGGTAAAGATTGTATA 
      81 G  G  C  S  D  L  V  S  L  Q  Q  S  G  E  L  L  T  R  L  K   
     241 GGCGGATGCAGTGATCTAGTCTCTTTGCAACAGAGTGGGGAACTGCTGACGCGGCTAAAG 
     101 Q  I  G  A  L  Q  T  S  G  G  S  G  G  G  G  S  G  G  G  G   
     301 CAGATTGGAGCTCTGCAGACTAGTGGTGGTTCAGGTGGTGGTGGTTCAGGTGGTGGTGGT 
     121 S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  G  E  F   
     361 TCAGGTGGAGGAGGATCAGGAGGAGGAGGATCAGGAGGAGGAGGATCAGGAGGAGAATTC 
     141 V  S  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D  G   
     421 GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGC 
     161 D  V  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y  G   
     481 GACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC 
     181 K  L  T  L  K  F  I  S  T  T  G  K  L  P  V  P  W  P  T  L   
     541 AAGCTGACCCTGAAGTTCATCTCCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC 
     201 V  T  T  L  T  Y  G  V  Q  C  F  S  R  Y  P  D  H  M  K  Q   
     601 GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG 
     221 H  D  F  F  K  S  A  M  P  E  G  Y  V  Q  E  R  T  I  F  F   
     661 CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC 
     241 K  D  D  G  N  Y  K  T  R  A  E  V  K  F  E  G  D  T  L  V   
     721 AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG 
     261 N  R  I  E  L  K  G  I  D  F  K  E  D  G  N  I  L  G  H  K   
     781 AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG 
     281 L  E  Y  N  Y  N  C  H  N  V  Y  I  M  A  D  K  Q  K  N  G   
     841 CTGGAGTACAACTACAACTGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGC 
     301 I  K  V  N  F  K  I  R  H  N  I  E  D  G  S  V  Q  L  A  D   
     901 ATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC 
     321 H  Y  Q  Q  N  T  P  I  G  D  G  P  V  L  L  P  D  N  H  Y   
     961 CACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTAC 
     341 L  S  T  C  S  A  L  S  K  D  P  N  E  K  R  D  H  M  V  L   
    1021 CTGAGCACCTGCTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTG 
     361 L  E  F  V  T  A  A  G  I  T  L  G  M  D  E  L  Y  K  *   
    1081 CTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
 
Figure A1: DNA and protein sequence of hGrx1-roGFP2 (40.9 kDa). The human glutaredoxin 
(hGrx1, DNA sequence in black) is fused to the N-terminal end of roGFP2 (DNA sequence in green) 
through a linker (DNA sequence in red) comprising a 30-amino-acid spacer, (Gly-Gly-Ser-Gly-Gly)6. 
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Figure A 2: The pARL-1a+ hGrx1-roGFP2 plasmid.  
The restriction sites in the pARL-1a+ hGrx1-roGFP2 plasmid (kindly provided by Prof. A. Meyer, 
Bonn University) are indicated. 
 
 
 1 M  A  S  G  N  A  R  I  G  K  P  A  P  D  F  K  A  T  A  V   
       1 ATGGCCTCCGGTAACGCGCGCATCGGAAAGCCAGCCCCTGACTTCAAGGCCACAGCGGTG 
      21 V  D  G  A  F  K  E  V  K  L  S  D  Y  K  G  K  Y  V  V  L   
      61 GTTGATGGCGCCTTCAAAGAGGTGAAGCTGTCGGACTACAAAGGGAAGTACGTGGTCCTC 
      41 F  F  Y  P  L  D  F  T  F  V  C  P  T  E  I  I  A  F  S  N   
     121 TTTTTCTACCCTCTGGACTTCACTTTTGTGTGCCCCACCGAGATCATCGCGTTCAGCAAC 
      61 R  A  E  D  F  R  K  L  G  C  E  V  L  G  V  S  V  D  S  Q   
     181 CGTGCAGAGGACTTCCGCAAGCTGGGCTGTGAAGTGCTGGGCGTCTCGGTGGACTCTCAG 
      81 F  T  H  L  A  W  I  N  T  P  R  K  E  G  G  L  G  P  L  N   
     241 TTCACCCACCTGGCTTGGATCAACACCCCCCGGAAAGAGGGAGGCTTGGGCCCCCTGAAC 
     101 I  P  L  L  A  D  V  T  R  R  L  S  E  D  Y  G  V  L  K  T   
     301 ATCCCCCTGCTTGCTGACGTGACCAGACGCTTGTCTGAGGATTACGGCGTGCTGAAAACA 
     121 D  E  G  I  A  Y  R  G  L  F  I  I  D  G  K  G  V  L  R  Q   
     361 GATGAGGGCATTGCCTACAGGGGCCTCTTTATCATCGATGGCAAGGGTGTCCTTCGCCAG 
     141 I  T  V  N  D  L  P  V  G  R  S  V  D  E  A  L  R  L  V  Q   
     421 ATCACTGTTAATGATTTGCCTGTGGGACGCTCCGTGGATGAGGCTCTGCGGCTGGTCCAG 
     161 A  F  Q  Y  T  D  E  H  G  E  V  C  P  A  G  W  K  P  G  S   
     481 GCCTTCCAGTACACAGACGAGCATGGGGAAGTTTGTCCCGCTGGCTGGAAGCCTGGCAGT 
     181 D  T  I  K  P  N  V  D  D  S  K  E  Y  F  S  K  H  N  *   
     541 GACACGATTAAGCCCAACGTGGATGACAGCAAGGAATATTTCTCCAAACACAATTAG 
 
Figure A 3: DNA and protein sequence of hPrx2. The hPrx2 gene is located on chromosome 19 
(NC_000019.9) with 597 nucleotides and 198 amino acids in the protein (P32119.5). 
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Figure A 4: Multiple sequence alignment illustrating differences between the mutants of hPrx2 
as compared to the full length protein. 
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Figure A 5:  pQE vectors for N-terminal 6xHis tag constructs.  
 
PT5: T5 promoter, lac O: lac operator, RBS: ribosome-binding site, ATG: start codon, 6xHis: 6xHis 
tag sequence, MCS: multiple cloning site with restriction sites indicated, Stop Codons: stop codons in 
all three reading frames, Col E1: Col E1origin of replication, Ampicillin: ampicillin resistance gene, 
lacIq, lacIq repressor gene. 
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Table A 1. Results of a eukaryotic linear motif search of hPrx2. These structural and 
functional motifs were identified using the simple modular architecture research tool (SMART, 
http://smart.embl.de/,Letunic et al., 2009) 
 
Elm Name Matched 
Sequence 
Position
s 
Elm 
Description 
Cell 
Compartment 
Pattern 
FRK 65-67 
PRK 90-92 
CLV_NDR_NDR_1  
RRL 109-111 
N-Arg dibasic 
convertase 
cleavage site  
extracellular, 
Golgi apparatus, 
cell surface 
(.RK)| 
(RR[^KR]) 
CLV_PCSK_SKI1_
1  
KGVLR 135-139 subtilisin/kexin 
isozyme-1 
endoplasmic 
reticulum lumen, 
endoplasmic 
reticulum, 
Golgi apparatus 
[RK]. 
[AILMFV] 
[LTKF]. 
LIG_BIR_II_1  MASGN 1-5 motif binds 
specifically to 
type II BIR 
domains 
mitochondrion, 
cytosol, 
cytoplasm 
M{0,1}[AS]... 
LIG_FHA_1  DVTRRL
S 
106-112 phospho-
threonine motif 
nucleus ..(T)..[ILV]. 
LIG_FHA_2  QITVND
L 
140-146 phospho-
threonine motif 
nucleus, 
replication fork 
..(T)..[DE]. 
LIG_MAPK_1  KGKYVV
LFF 
34-42 MAPK-
interacting 
molecules 
nucleus, 
cytosol 
[KR]{0,2}[K
R].{0,2}[KR].
{2,4}[ILVM]. 
LIG_SCF_FBW7_2  INTPRKE 87-93 The TPxxE 
phospho-
dependent 
degron binds 
the FBW7 F 
box proteins of 
the SCF. 
nucleus, 
cytosol 
[LIVMP].{0,2
}(T)P..E 
MOD_CDK_1 WINTPR
K 
86-92 substrate motif 
for 
phosphoryla-
tion by CDK 
cytosol ...([ST])P.[KR
] 
MOD_PIKK_1  SVDSQF
T 
76-82 (ST)Q motif 
phosphorylated 
by PIKK 
family 
members 
nucleus ...([ST])Q.. 
MOD_PKA_1  RRLSED
Y 
109-115 cAMP-
dependent 
protein kinase 
complex 
cytosol, 
nucleus 
[RK][RK].([S
T])[^P].. 
MOD_PLK LDFTFV
C 
45-51 Site 
phosphorylated 
by the polo-like 
kinase 
nucleus, 
cytosol 
.[DE].([ST])[I
LFWMVA].. 
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Table A 2: Results of a eukaryotic linear motif search of hPrx2. List of motifs falling inside 
the SMART/PFAM domains but scoring poorly with the structural filter. 
 
Elm Name Positions Elm Description Cell 
Compartment 
Pattern 
26-30 
127-131 
CLV_PCSK_SKI1_1  
139-143 
subtilisin/kexin 
isozyme-1 
endoplasmic 
reticulum 
lumen, 
endoplasmic 
reticulum, 
Golgi apparatus 
[RK]. 
[AILMFV] 
[LTKF]. 
LIG_Actin_WH2_2 125-141 The WH2 motif is 
of variable length 
(16-19 amino 
acids) binding to 
the hydrophobic 
cleft formed by 
actin's 
subdomains 1 and 
3. 
cytosol [^R].. 
((.[ILMVF])| 
([ILMVF].)) 
[^P][^P][ILV
M]. 
{4,7} 
L(([KR].) 
|(NK)) 
[VATIGS] 
LIG_Clathr_ClatBox_1 129-133 Clathrin box 
motif 
Golgi apparatus, 
cytoskeleton, 
clathrin-coated 
endocytic 
vesicle, 
Golgi trans-face, 
cytosol 
L[IVLMF] 
.[IVLMF][DE] 
LIG_CYCLIN_1  127-131 substrate 
recognition site 
that interacts with 
cyclin 
nucleus, 
cytosol 
[RK].L.{0,1} 
[FYLIVMP] 
16-22 LIG_FHA_1  
51-57 
phospho-
threonine motif 
nucleus ..(T)..[ILV]. 
LIG_SH2_PTP2  37-40 SH-PTP2 and 
phospholipase C-
gamma Src 
homology 2 
(SH2) domains 
binding motif. 
cytosol (Y)[IV].[VILP
] 
37-40 
164-167 
LIG_SH2_STAT5  
193-196 
STAT5 Src 
homology 2 
(SH2) domain 
binding motif 
cytosol (Y)[VLTFIC].
. 
LIG_Sin3_3  17-24 Motif interacts 
with PAH2 
domain. 
nucleus [FA].[LA] 
[LV][LVI] 
..[AM] 
MOD_PKA_2  109-115 PKA-type AGC 
kinase 
phosphorylation 
cytosol, 
nucleus, 
cAMP-
dependent 
protein kinase 
.R.([ST])[^P].. 
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complex 
MOD_TYR_ITIM 124-129 immunoreceptor 
tyrosine-based 
inhibitory motif 
cytosol [ILV].(Y) 
..[ILV] 
TRG_ENDOCYTIC_2  37-40 
 115-118 
 
126-129 
tyrosine-based 
sorting signal 
plasma 
membrane, 
clathrin-coated 
endocytic 
vesicle, 
cytosol 
Y..[LMVIF] 
TRG_LysEnd_APsAcL
L_1  
154-159 sorting and 
internalization 
signal 
cytosol, 
endocytic 
vesicle 
[DER]...L[LVI
]) 
 
